Problems in the treatment and assessment of patients with thyrotoxicosis: A clinical and laboratory study by Bremner, William Fraser
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
PROBLEMS TW THE TREATMELfT AND ASSESSMENT OF 
PATIENTS WITH THYROTOXICOSISs 
A CLINICAL AND LABORATORY STUDY
by
WILLIAM FR A SER B R E M N E R , M . A . ,  B . S c . ( H o n s . ) ,
ChoB., M.R .C.P . (U.K.)
REG ISTR AR;
UNIVERSITY DEPARTMENT OF MEDICAL CAR DIOL OGY, 
ROYAL INFIRMARY, GLASGOW,
FORMERLY,
WELLCOME TRUST RESEARCH A S S ISTA NT,
UNIVERSITY DEPARTMENT OF NUCLEAR MEDICINE, 
ROYAL INFIRMARY,
GLASGOW,
SUBMITTED FOR THE DEGREE Of Ph.D.(FACULTY OF MEDICINE)
UNIVERSITY OF GLASGOW, 1976.
ProQuest Number: 10646942
All rights reserved
INFORMATION TO ALL USERS 
The qua lity  of this reproduction  is d e p e n d e n t upon the qua lity  of the copy subm itted.
In the unlikely e ve n t that the au tho r did not send a co m p le te  m anuscrip t 
and there are missing pages, these will be no ted . Also, if m ateria l had to be rem oved,
a no te  will ind ica te  the de le tion .
uesL
ProQuest 10646942
Published by ProQuest LLO (2017). C opyrigh t of the Dissertation is held by the Author.
All rights reserved.
This work is protected aga inst unauthorized copying under Title 17, United States C o de
M icroform  Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 4 81 06 - 1346

THIS THESIS IS DEDICATED TO MY
DEAR WIFE
AND
OUR DAUGHTER
INTRODUCTION
This thesis originated from three years of personal 
involvement in the clinical assessment of a new radio- 
isotope (iodine-125) therapy for thyrotoxicosis. 1 was 
attracted to this study by Dr, W.R,Oroig who initiated 
this therapeutic approach in 1968.
The somewhat heterogeneous nature of the thesis reflects 
the varied problems that arise in the treatment of 
thyrotoxic patients. Particular problems dealt with in 
this thesis include the difficulties involved in assessing 
such patients after therapy, whether further therapy is 
required, whether and what adjuvant drug therapy to radio- 
iodine should be used, and what is the optimum mode of 
using radio-iodine therapy.
In my opinion, the aspects of this thesis which make 
an original contribution to the therapy of thyrotoxicosis 
include;
1. The results of the Trial of iodine-125 therapy 
which show conclusively that iodine-125 is rioi; 
the answer to the problem of post-radioiodine 
hypothyroidism.
2. The validation of the TRH-thyrotoxic rat model 
as a chosen analogue to the human thyrotoxic 
gland rather than goitrogen-induced hyperplasia,
3o Systolic time intervals and zinc metabolism 
studies in thyroid disease which offer an 
objective measure of assessment of a patient's 
cardiac and metabolic response to hyper- or 
hypothyroidism and may permit detection of 
"at risk" patients(requiring urgent therapy)
and assist in deciding whether (further) therapy 
is required.
The laboratory study of beta-adronoreceptor blocking 
drugs which contributes to the clarification of the 
action of such drugs and supports my critique of the 
current rolo of such drugs in the therapy of 
hyperthyroidism.
The demonstration of abnormalities of lipid 
metabolism in "compensated euthyroidism'% subclinical 
hypothyroidism and frank hypothyroidism that 
underlines tho inadequacy of a purely clinical 
assessment of post-radioiodine patients, emphasises 
the need for full hormonal assessment and supports 
my tentative conclusion that the current usage of 
iodine-131 to produce a euthyroid state is insufficient 
and potentially dangerous to certain patients.
The techniques adopted in this study include;
Measurement of thyroid hormone levels in serum. These 
assays were performed by the staff of the Regional 
Radio-immunoassay Centre and the resulting data was 
marshalled by myself and presented in this thesis,
I did not participate in the actual laboratory 
measurements though I did subsequently spend a 
period at the Centre to learn something about the 
techniques involved.
Tissue culture techniques, I studied and refined
the techniques in a tissue culture laboratory over 
a one year period and performed the experiments
described liera in their entirety. This involved 
a meticulous aseptic technique, use of a Coulter 
counter and cell sizing apparatus, microscopy and 
the handling and counting of radio-isotopes®
3o systolic time interval measurement« This was
a collaborative study performed with Dr.liJ. S. Hillis 
who made the measurement in the study of hypo-, 
hyper-, and euthyroid groups without prior knowledge 
of their thyroid status. J performed the 
sequential systolic time interval measurements 
in patients with "compensated euthyroidism" and 
"T“3 toxicosis".
4o Laboratory studies of lipid metabolism involved
ultracentrifugal separation of plasma lipoprotein 
fractions, cholesterol and triglyceride assays 
and spectrophotometric assay of the light-scattering 
index of sera in the intralipid Tolerance Test,
I performed these studies in their entirety,
5. Autoradiography and staining of thyroid sections.
Those preparations were done by Dr,5,Kennedy,
Consultant Pathologist. I was responsible for the 
administration of isotopes and TRH Lo the rats 
studied, for the dissection of the thyroid, tissue 
preparation and preservation, and for blood sampling 
by cardiac puncture.
This thesis crosses the boundary between the two specialties
of endocrinology and cardiology and, in rny opinion, is the
richer for this as the two specialties have deepened and 
widened my understanding of the problems of thyroid 
disease.
This thesis is the result of three years of intense 
study, of clinical and of laboratory work, that have led 
to the mastering of new techniques and to a modest 
contribution or two to the current understanding of 
thyroid disease.
In my opinion, the work described in tliia thesis and 
the techniques acquired in the process of completing 
these studies, satisfy the requirements laid down 
in the University regulations for the degree of doctor 
of philosophy.
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SUMMARY
This thesis falls logically into 5 sections.
SECTION A outlines the present understanding of the 
tletiology of thyrotoxicosis and discusses presently available 
tests of thyroid function regarding their relevance to the 
Trial of Iodine-125 therapy* This is important as accuracy 
of assessment of thyroid status has markedly improved since 
tho inception of the Trial in 1968. The currently available 
treatments for thyrotoxicosis are discussed with particular 
attention paid to their drawbacks. Ti'ie problem of post- 
therapy hypothyroidism is emphasised,
SECTIONJ3 outlines the experimental and theoretical basis 
for the iodine-125 trial and describes, in detail, the design 
and results of the trial in 3GÜ patients.
Reasons for the fallure of this isotope to reduce the 
incidence of post-therapy hypothyroidism are discussed and 
further experimental evidence (from the author) is adduced. 
The validation of a TRH-induced thyrotoxicosis model in the 
rat as an approach to the human condition is described,
SECTION C describes experimental tissue culture studies 
of jP^adrenoreceptor blocking drugs which have rapidly 
attained the status of a major adjuvant therapy in treating 
thyrotoxicos i s *
^.CrriOi|_D This section discusses the need for a tsst or 
tests of body response to thyroid hyper-or bypofunction 
and describes a new test of thyroid status; systolic time 
interval measurements. Zinc losses in hyperthyroidism are
deacribüd and tha potential value of such measurements 
discussed.
SCCTICjN E concentrates on the cardiac complication of 
hypo- and hyperthyroidism with investigations of lipid 
abnormalities in hypothyroid patients and electronmicroscopic 
studies of hyperthyroid rat hearts.
ABBREVIATIONS
LVET LEFT VENTRICULAR [SECTION TIME
PROTEIN-BOUND IODINE-127
PEP PRE-EDECTION PERIOD
.^ 2 TOTAL ELECTROMECHANICAL SYSTOLE
STI SYSTOLIC TIME INTERVAL
T^ THYROXINE
TRH THYROTROPIN-RELEASING HORMONE
TSH THYROID STIMULATING HORMONE
Tg TRIIODOTHYRONINE
UNITS; ALL UNITS ARE S.I. UNITS UNLESS OTHERWISE STATED
S E C T I O N  A
INTRODUCTION
Thyrotoxicosis as a recognisable entity first appears 
in the literature in the ijiritings of Parry as recently as 
1825® Graves subsequently related the ocular complications 
to the disease (1835) and von Basedow made further 
contributions to defining the disease entity in 1840, The 
absence of any mention of the disease from literature prior 
to 1825 has fostered the belief that thyrotoxicosis is a 
modern disease but this is pure speculation* Certainly, 
that most obvious of thyroid disorders, diffuse goitre, was 
described circa 1215 by Marco polo in his travels in 
Yarkand (306),
Thyrotoxicosis (or hyperthyroidism) is due to excessive 
secretion of thyroid hormones (thyroxine and/or tri­
iodothyronine) with a sustained rise in plasma levels*
With this excessive output, the unoccupied binding sites on 
the thyroid hormone-carrying proteins of plasma decrease 
in number, and the free or unbound hormone fractions 
increase, with consequent over-stimulation of tissues 
responsive to thyroid hormones. In many aspects, the disease 
is simulated by thyrotoxicosis factitiae (excessive ingestion 
of thyroid hormone).
Graves’ disease is characterised by a diffusely enlarged 
overactive thyroid gland with an onset usually in younger 
adults (20 - 40 years), frequently with co-existing ocular 
and skin pathology, whereas toxic nodular goitre presents 
as an unevenly enlarged, overactive, nodular gland in older
patients, with less prominent ocular and skin involvement* 
Whether these conditions are distinct entitles or an age- 
dependant variation of the same disorder is disputed,, for 
the purposes of the iodine-125 trial no distinction was 
made between these conditions, all such patients being 
regarded as "thyrotoxic" for the purposes of the Trial «
Toxic adenoma is a term used to distinguish a single 
hyperactive nodule from the commoner diffusely overact.ive 
or multinodular glands,. Patients with thyrotoxicosis due 
to this cause are uncommon (,<2 5/ of patients with 
thyrotoxicosis) and were not included in the Trial*
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PART 1
A E T I O L O G Y  GF T H Y R O T O X I C O S I S
’’lühat song the syrens sang, or what
name Achilles assumed when he hid
himself' among women, though puzzling 
questions, are not beyond all 
conjecture*' HYDRIDTAPHIfl V,
There arc many pointers to suggest that thyrotoxicosis has 
an immunological basis» At the clinical level,there is the 
association of thyrotoxicosis with recognised auto-immune 
disorders (2, 7, 67, 159, 150, 288-291) and the occasional 
finding of lymphoid and thymic hyperplasia » Hashimoto's 
thyroiditis occurs frequently in relatives of thyrotoxic 
patients and occasionally in the same patient (70,260,
261, 291). The presence of thyroid antibodies and the
discovery of thyroid stimulating immunoglobulins in thyrotoxic
sera (2, 69, 153, 211) coupled with abnormalities of cellular 
immunity (as evidenced by the lymphocyte migration inhibition 
test (291) and by in vitro stimulation of thyroid cells by 
lymphocytes from thyrotoxic patients(73) )led to the hypothesis 
proposed by Volpe et al. (291) and shown diagramatically 
opposite. According to Volpe*s theory, "forbidden** clones 
of lymphocytes arise through a defect in immunological 
surveillance and act directly on thyroid follicle cells 
(cellular immunity) producing thyrotoxicosis. They also 
stimulate "bursa dependent" lymphocytes capable of directly 
affecting follicle cells, through the anaphylactic reaction 
pathway by way of IgE, or by secretion of thyroid-stimulating 
immunoglobulins.
One major drawback to this concept is the lack of conclusive 
evidence for this hypothesis but it serves as a useful 
working hypothesis,
Studies by Kriss (153) have linked opthalmopothy to 
formation of thyroid antigon-antibody complexes on extra- 
ocular muscle membrane; the complexes arising by way of the 
lymph transfer that has been shown to occur from thyroid to 
orbital tissues.
Such idoas have been a major influence upon the author's approach 
to thyrotoxicosis»
PART 2» TESTS Of THYROI D rUNCTI ON
(only tests relevant to tho Trial are discussed)
In the absence of simple tests of secretion rates of thyroid 
hormones, reliance is placed on measurements of plasma hormone 
levels and of gland avidity for iodine (114). The use of the 
TRH test is a recent and useful innovation»
1) Protein-bound Iodine (PBI-127)
This is an automated, chemically determined assay 
which was the only routinely available measure of plasma 
thyroxine level at the commencement of the Trial. The 
normal range is 315-630 nmol/t. If circulating iodo- 
proteins are present in excessive amounts (as in 
Hashimoto's thyroiditis, or immediately following 
radio-iodine therapy), the butanol-extractable iodine 
is a more reliable measure of circulating hormone levels. 
Misleadingly high values for the PBI-127 occur if the 
patient has ingested organic iodine compounds(especially 
radiographic media.) False values also arise if a 
sample containing an excessively high PBI-127 is 
processed before the patient's serum as inter-sample 
contamination occurs in these circumstances. Studies
of the extent of cryptic iodine contaminction(l) have 
shown this to be a considerable problem ( among
hospital aut-patients(214)), mitigating against the 
value of PEjI-127 as a reliable test of thyroid status» 
For this reason, routine assay of serum thyroxine 
was adopted in 1972 as the best test of thyroid status.
2 ) ^s^ay
Serum thyroxine, or T_^ ç is assayed by non-chomical 
protoin-binding techniques and the assay is readily 
available as a standard pock (Thyopac-4, Radiochemical 
Centre, Amersham). The normal range for the Glasgow 
area is 55-144 nmol/t.
This assay is unaffected by iodine contamination 
and is valid if the binding capacity of the carrier 
proteins is normal, Pronounced elevations of thyroid- 
binding globulins may occur in pregnancy or with 
ingestion of oestrogens while decreases occur in 
patients on steroid therapy or with nephrotic syndrome. 
These alterations may be detected by measuring the 
unoccupied sites on thyroid hormone binding proteins 
by means of labelled T^. This measure is routinely 
available as the Thyopac-3 (Radioamersham),
3) The ratio Thyopac-4/Thyopac-3 x 100 is the Free 
Thyroxine index and gives a measure that is proportional 
to the free thyroxine concentration as measured by 
equilibrium dialysis or gel filtration. This measure
is less subject to distortion by iodine contamination 
or alterations in carrier proteins.
4) Tri-iodothyronino assay
This radio-immunoassay method gives a measure of 
total circulating T.^  in serum and became available in 
the Glasgow region in late 1973, It is of prime value 
in detecting patients with "T^-toxiccsis" (where serum 
thyroxine and PQÏ-127 measurements are normal). Use of 
this assay permitted characterisation of a group of 
patients with biochemical T^ toxicosis following 
iodine-125 therapy. The clinical course of those 
patients is described later. The normal range for T^  ^
levels is 0 , 6  - 2 , 2  nmol/t»
To allow continuity in patient assessment over the 
7 years of the Trial, T,^ assays were not used in 
reaching a decision regarding further therapy, reliance 
being placed on thyroxine assays,
5) Tli y r o i d - s mutating hormone (TSH)assay
This radio-immunoassay became available in 1971 and 
permitted detection of patients with biochemical 
"compensated euthyroidism", (T^ in normal range but
elevated TSH). The normal range is 0 to 8 mu/t» This 
test was not used in assessing patients as hypothyroid 
to allow continuity of assessment.
6 ) TRH Test
The measurement of the plasma TSH increment after 
2 0 0 yjg. of intravenously administered thyrotropin- 
releasing hormone is of value in distinguishing primary 
from secondary hypothyroidism. The lack of response 
may be used to confirm hyperthyroidism though euthyroid 
relatives of patients with Graves' disease and patients
euthyroid after treatment for Graves* disease may 
show no response (49), This tost tuas used to 
characterise patients with "compensated euthyroidism"
7) Thyroid olarid uptake of luadio-indigne
The 24 hour uptake of a tracer dose of .iodine-131 
offers a measure of gland avidity for iodine. In 
conjunction with an elevated PBI-127, an uptake in 
the thyrotoxic range ( 50'/c) w&ts used to conf .i.rm the
clinical diagnosis of thyrotoxicosis in patients 
entering the Trial, This procedure was continued 
to include all 360 patients in the Trial, Routine 
scintiscans using initially iodine-131 but, more 
recently, technetium-99, were performed to exclude 
patients with solitary hyperfunctioning nodules,
PART 3
THERAPIES AVAILABLE FOR THYROTOXICOSIS, 
lo NON-INTERVENTION
From a study of hospital records from around 1900 to 1940 
'when no therapy was available, Wilson (217) deduced that 
two thirds of thyrotoxic patients failed to recover with, 
perhaps, up to one half of these dying^ the remainder 
eventually became euthyroid. This, however, was in the
days when the only diagnosis was clinical; consequently 
miloer cases may have escaped attention arid the mortality 
estimation may be excessive. Nevertheless, the morbidity 
and mortality is such that therapy is indicated. Also, 
a proportion of patients becoming spontaneously euthyroid 
eventually become hypothyroid (114), possibly due to the 
presence of Hashimoto's Thyroditis (109, 186, 317),
2» IMMUNOSUPPRESSIVE THERAPY
Since thyrotoxicosis (excluding toxic solitary adenoma) 
may be an autoimmune disorder, the use cf immunosuppressive 
therapy is theoretically attractive. The results are 
difficult to evaluate as the disorder is of variable 
severity. Large doses of Prednisone were given to 5 patients 
by Werner et al, (305) with induction of a remission in all, 
permanent in 2» Steroids, however, have multiple actions 
and may affect the hypothaimo-pituitary axis directly (309). 
The main contra-indications to steroid therapy are the 
frequency and severity of sido effects. Other forms of 
immunosuppression are subject to the severe limitations of 
toxic side effects.
The three modes of therapy in curront use are all 
directed against the thyroid gland rather than the basic 
pathology»
3. SURGERY
prior to the advent of antithyroid drug therapy and 
radio-iodine therapy, surgery was the only effective therapy. 
With modern anaesthesia and pre-operative control of thyroid 
overactivity 5 surgery is less heroic and much safer. However, 
there is still a significant morbidity and mortality attendant 
upon thyroidectomy. Also, the widespread use of radio- 
iodine and drug therapy has resulted .in a marked decline 
in the number of patients being referred for surgery with 
potentially deleterious effects on the standards of thyroid 
surgery. "The occasional thyroidectomist" has been soundly 
condemned (152).
The results of the surgical approach are perhaps typified 
by the report of Green and Wilson (107)» They reported a 
rate of 07/ for euthyroidism, 5/ for hypothyroidism, and 
8 / for persistence or recurrence of thyrotoxicosis. Subsequent 
experience f rom the same group demonstrated an inverse 
correlation between the incidence of hypothyroidism and 
recurrence, and extent of the thyroidectomy, with a 
combined morbidity of some 30/ four years post-operatively, 
McNeill and Thomson (191) reviewed 123 patients who underwent 
thyroidectomy more than 5 years earlier and found 81/ 
euthyroidj 12/ toxic and 7/ hypothyroid. In contrast, a 
review of 146 patients at a mean period of 9 years post- 
thyroidectomy by Medley et al, (133) found 36; hypothyroid. 
Other reports(114, 195) are in keeping with the last report.
The overall incidence of hypothyroidism post-thyroidectomy 
appears to reach 35/ to 49/,
The lower incidences are based on retrospective studies 
which tend to be incomplete and lack the more recent hormonal 
assays necessary for accurate assessment.
The risk of hypo thy r old ismi has been correlated with the 
extent of the thyroidectomy, the presence of thyroid 
autoantibodies in the circulation and the extent of plasma 
cell infiltration and number of lymphoid follicles with 
germinal centres at operation (36, 105),
The various studies of thyroidectomised patients suggest 
the incidence of hypothyroidism mainly reflects the amount 
of thyroid tissue resected while, in patients with an 
active immune process in progress damaging thyroid tissue, 
the autoimmune process may be contributory.
The other drawbacks to surgery relate mainly to the 
risks of anaesthesia and operation. The mortality rate 
is low but probably around 0.2/ (191). The major 
complications include laryngeal palsy (0 .6 / if nerve 
identified at operation, 2/ if not (235)), phonation 
disturbances, parathyroid insufficiency, bad cosmetic 
result, as well as the risks of haemorrhage, embolism 
and atelectasis consequent upon any operation under 
anaesthetic (191, 235).
The present indications for surgery are probably limited 
to patients with pressure symptoms, young women wanting 
to start a family, patients who relapse after an adequate 
period of drug therapy and who are under 40 years of age, 
and perhaps to patients who intend to work as missionaries 
etc, far from any follow-up centre (114). This last 
indication is open to argument in the light of tlie high 
incidence of post-operative hypothyroidism noted above.
Repeat thyroidectomy is contra-indicated as there is a 
high risk of recurrent laryngeal nerve palsy and of 
recurrence of thyrotoxicosis (189),
Treatment of older patients with iodine-131 has improved 
the peri-operative surgical morbidity figures by removing 
many at risk patients from the surgical lists.
4. ANTITHYROID DRUGS
Antithyroid drugs, such as carbimazole and propylthiouracil, 
are usually efficacious in controlling thyrotoxicosis: the
exceptions are the occasional very resistant patient and
patients with large goitres w h o m  c.uch large doses are 
required that toxic side effects supervene. Drugs are 
the treatment of choice in young mildly toxic patients with 
small goitres j, and in such patients where rapid control is 
essential. Therapy is efficient, safe, and carries none 
of the potonrial risks of damage to adjacent structures 
incurred by surgery.
The main drawback to drug therapy is the high relapse 
rate which after a course of one to two years is at 
least 50/. By 10 years at least two-thirds of patients 
have relapsed which is close to tho spontaneous remission 
rate. Wilson suggests that antithyroid drugs control gland 
overactivity until normal thyroid function recurs 
spontaneously (217), It would appear that antithyroid 
medication does not influence the basic course and pathogenesis 
of the thyrotoxic process. Beck, however, claims that 
carbimazole acts not only on thyroid gland organification 
but also on the thymus gland directly, influencing tfiymic 
lymphocytes (personal communication based on thymic biopsy 
studies in patients undergoing thyroidectomy),
problems with drug therapy relate to the difficulty of 
predicting which patients will have a remission and to 
the optimum duration of therapy. At the clinical level, 
rapid initial control of symptoms and reduction in goitre 
size are rough oointers to a favourable outcome, with 
delayed cent rol or increasing goitre size (despite cutting 
off TSH stimulation by concomitant T^ thyroxine administration) 
mitigating against a remission. Alexander et al (34) have 
used the T,, suppression test to predict which patients are in
3 «
remission while on drug therapy on tho basis thsL patients 
who do suppress are moro likely to respond to drug therapy 
with a prolonged remission. This approach is not generally 
accepted despite its initial promise - for example, while 
Harden (129) found the presence of LATS to correlate with 
non-suppressibility, Sellers et al. (254) did not. patients 
have had recurrences after suppression has become normal (126) 
and some authorities feci the test to have little practical 
value (I21)o Also relapse may be obscured by on iodine- 
deficiency state induced by antithyroid drugs (128),
Side effects of drug therapy, apart from relapse or 
failure to induce a remission, include a maculo-papuiar rash 
and occasional granulocytopaenia or frank agranulocytosis.
Anot lier risk affects the pregnant patient where placental 
passage of drug may induce a foetal goitre with dystocia 
at delivery or frank hypothyroidism.
Relapse after a second course of antithyroid drugs is very 
common,
5. Radiation Therapy
The use of external irradiation of the thyroid has gained 
little support because of the very real risk of post-cricoid and 
nasopharyngeal carcinoma (114), This was reinforced by findings 
of up to 30/ incidence of nodules and 3/ of carcinoma in children 
given raoiation therapy for enlarged thymus or tuberculous 
glands (134). A proposal for combination therapy with x-rays 
and iodinO"131 was put forward and applied by Trotter and 
Willoughby but, for the above reasons, has not found general 
acceptance (277), Children's thyroid are particularly
susceptible to neoplastic change induced by radiation.
The thyroid cells treat radioactive iodine as normal iodine 
and concentrate it in tho gland colloid: consequently isotopes
of iodine can be used to destroy thyroid tissue with minimal 
irradiation of contiguous structures. In January 1941, the 
first thyrotoxic patient Wus treated with an isotopo of iodine-127 
(iodine-130, half life 12,5 hours) and two preliminary reports 
on this therapeutic approach appeared in 1942 (127,136),
Iodine-131 witli its longer half-life ( 8 days) superseded iodine-130 
and by I960 was the therapy of choice for the majority of 
thyrotoxic patients.
Ad van t a neji _o f/_ I odi ne-131 Thera py
Tho characteristics of this form of thcra:;y that make it the 
most frequently adopted treatment are its ease of administration - 
it is taken orally and takes only a fow minutes on an out-patient 
basis •“ it is inexpensive and it eventually always controls the 
thyrotoxicosis (115), There is, moreover, only very rarely 
overt evidence of serious extra-thyroidal damage.
The aim of iodine-131 therapy is the maximum possible cure rate 
with one therapy dose. 50 per cent of patients respond to one 
therapy of average size (22,28,216) with some two-thirds of 
resistant patients responding to each subsequent therapy dose.
3 months minimum have to elapse between doses; if this delay is 
extended to 6 months, a further 15 per cent of patients became 
euthyroid witiiout further therapy (46). Conventional doses of 
iodine-131 leave 50 per cent of patients thyrotoxic 3 months later 
and a minority require frequent therapies or, in the rare very 
resistant patient, massive therapy doses.
3 ?
D i sa ü V an t an, es of Iodins-131 Therapy
lo CARLY COMPLICATIONS.
(a) Radiation Thyroiditis,
This occurs in a minority of patients, may cause 
localised discomfort and gland swelling, but subsides 
spontaneously(46)o This potential complication,
however, excludes patients with pressure symptoms from 
radio-iodine therapy.
(b) Exacerbation of thyrotoxicosis and thyroid crisis,
Exacerbation of thyrotoxicosis occurs in most reported 
sories of 131-treafced patients but thyroid crisis has 
been reported infrequently (158,204,209,246,255,287) 
and has been absent from some large series (44). Thyro- 
cardiacs are at risk of deterioration or death if they 
suffer an exacerbation of their hyperthyroidism and 
should be treated with entithyroid drugs prior to or 
as a "holding measure" after iodine-131 therapy.
Radiation Sialitis.
This may be painful but is uncommon at the levels 
of dosage used to treat thyrotoxicosis, being more 
common with cancericidal doses (102). The parotid 
is most commonly affected because of its high saliva : 
serum iodine ratio (34, 41). This complication usually 
subsides spontaneously.
2. LATf C O M P L I C A T I O N S .
(a) Neoplastic change.
1. THYROID.
Epidemiological surveys hcve demonstrated an increased
incidence of thyroidal carcinoma in children following 
external rcdiation (52,134). Using three data sources,
Hempelinann derived a linear relationship between the 
incidence of thyroid nodules and estimated cumulative 
radiation dose to the thyroid (134). An association 
between external irradiation and thyroid neoplasia has 
also been found in adults (103,313,318). Further 
epidemiological evidence relating thyroid irradiation to 
thyroid carcinoma comes from the increased incidonco of 
thyroid carcinoma and benign nodules found among atomic 
bomb survivors in Hiroshima and Nagasaki (141) and ainong 
the Marshallese islanders accidentally exposed to nuclear 
test fallout (51,52). In the latter group of 67 islanders 
four cases of thyroid carcinoma and 15 benign nodules were 
found. These people received an estimated exposure of 
160 Rads from several iodine isotopes (1-131, -132-133,-135) 
and 175 Rads from gamma rays»
Some of the claims relating to the effects of low 
levels of radiation of thyroid can be disputed as control 
populations are often lacking. The frequency of thyroid 
nodules fi'.ay seem unduly high because they may go unnoticed 
in normal populations unless scecifically sought. A study 
of children exposed to fallout in America with control 
groups found no significant difference in benign nodules 
nor carcinoma (228) and noted an unexpeoterlly high 
incidence of unsuspected thyroid disease in the control 
groups.
It is still a matter for argument whether iodine-131 
therapy for thyrotoxicosis results in tnyroid neoplasia. 
Studies using rats have shown that iodine-131 can produce
35
thyroid neoplacms particulorly in glands rendered 
hyperplastic u.ith o goitous challenge (67,101).
Iodine-131 therapy has been administored to 
some children, particularly in the United States, 
and occasional reports of neoplasm lisvo limited its 
use to older patients, c i thar over 2 b years of age 
(some Clinics in the U.S.A.) or over 40 years (more 
generally) (134,141).
An extensive survey by the Cooperative Thyrotoxicosis 
Therapy Follow-Up Study (63) offers the most definitive 
statement on tho possible association between iodine-131 
therapy and induction of neoplasia.
A 96/ follow-up of 36,050 patients treated by iodine-131, 
thyroidectomy, antithyroid drugs, x-roys or a combination 
of these therapies between 1946 and 1958, has been 
achieved. 8 6  malignant neoplasms of tliyroid were found,
9 occurring in 21,714 pr tients treated with iodino-131 
within one year of therapy and 19 occurring one year or 
more after iodine-131 therapy. 50 malignant lesions 
were found within one year after therapy in 11,732 
patients undergoing thyroidectomy, with 4 further lesions 
occurring one year or more after thyroidectomy. If it is 
accepted that the malignant lesions in patients treated 
by tliyroidectomy are incidental, then the risk of 
malignancy from iodine-131 therapy is not significant.
The average follow-up time for patients treated with 
iodine-iSj. was 8 years which compares with 1 2 | years 
for patients treated with thyroidectomy. It must be 
remembered that the latent interval between irradiation 
and the detection of carcinoma of thyroid is long -
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Fîaventos and Uinship (232) suggested a mean interval of 
10o9 yoarsj while Dolphin (65) calculated the mean 
latent period to be 20 years minimum. In the Marshallese 
islanders, the first nodule was not found until 9 years 
after exposure and the first card noma not until the 
1 1 th year»
Of 438 patients who were given x-ray therapy, 2 were 
subsequently found to have malignant lesions and 19 
benign adenomas »
F'ew conclusions could be drawn as to frequency of 
benign adenomas in patients treated with iodine-131 or 
thyroidectomy due to bias in selection for therapy in 
the light of the presence of nodular lesions,
A statistically significant increased incidence of 
adenomata was fVund in patients under 2 0  years treated 
with iodine-131 and it is suggecteo that young adults 
treated with iodine-131 for thyrotoxicosis without 
causing hyp_otnyroidism are more susceptible to the 
development of adenomata than older adults. The diagram 
(fig.2 ) opposite relates the occurrence of neoplasia to 
age at time of therapy. The incidence of malignancy was 
not statistically significant vis a vis mode of therapy 
but total numbers of patients under 2 0  years of age 
were small»
Study of the appearance of malignancy'in relation to 
time since therapy demonstrated that, for iodino-131 
treated patients, ttie number of malignant neoplasms 
found per year is approximately proportional to the 
numbf-.r of patients at risk up to the 10th year. The
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latent period for appearance of malignant neoplasm 
is thought to be several years and so bhe majority 
of tliosB tumours wore probably present at the time 
of therapy. After the lüth year, no new malignant 
lesions waj'u discovered in the iodine-131~traated 
group even with 22,700 pationt-years at risk after 
the 10th year, 1903 iodine-*131~treated patients 
have been followed for 15 years, and 115 for 20 years. 
This data suggests the development of lesions with 
time that occurred and is still occurring in the 
Marshallese islanders is n£_t developing in patients 
treated with radio-iodine. The figure (Fig,3) 
opposite relates occurrence of neoplasm to time 
following rodio-iodine therapy and thyroidectomy.
It may be concluded, with the proviso that a 
longer period of follow-up is desirable,that 
iodine-131 therapy carries little increased risk of 
thyroid neoplasia,
2. LEUKAEMIA.
Radiation increases the incidence of leukaemia 
as evidenced by the frequency in survivors of atomic 
bomb explosions (31), in patients treated for ankylosing 
spondylitis with x-rays (53) and in children of mothers 
who had diagnostic x-rays during pregnancy (270), It 
is calculated that 1 mCi of iodine-131 irradiates blood 
and marrow by 1,7 Rads, so that a thyrotoxic patient 
receiving an average therapy doss receives between 1 0  
and 20 Rads to the marrow (106),
A personal communication from Professor Dobyns 
informs me tliot onu of the MershallesG islanders who 
was operated on for thyroid cancer has subsequently 
developed and died of leukaemia, A further islander 
has developed an as yet incompletely characterised 
ha eina tological no op la srn,
A reoort frof.-i the Cooperative Therapy Follow-Up 
Study found no significant d.ifference in leukaemia 
incidence between patients treated with iodine-131 
and with thyroidectomy though the age-corrected 
incidence in all patients was 50 per cent above the 
expected average for the general population (249).
However, this tends to confirm the findings of several 
earlier studies that radio-iodine therapy does not 
increase the risk of ieukaemogenesis (181,226,304),
CHROMOSOMAL A B N O R M A L I T I E S .
Chromosomal abnormalities have been demonstrated 
following iodine-131 therapy. They are most obvious 
following massive doses for thyroid carcinoma (28,208). 
Gross, readily detectable abnormalities are not 
apparently e prodromal phase of leukaemia. Subtler 
abnormalities produced by small therapy doses may be 
moro significant than those produced by cancericidal doses,
DAMAGE TO EXTRATHYRQIDAL TISSUES.
The maximum range o f r a y s  emitted by Iodine-131 
is 2 0 0 0  microns making hypoparathyroidism unlikely 
unless all the parathyroid glands are intra-thyroidal. 
Several cases have been recorded (27,74,94,150,273,275)
39
and none of these patients received an excessive 
dose and none was hypothyroid when hypocalcaemic.
A proportion of patients when stressed with [.D.T.A, 
manifest a degree of parathyroid insufficiency (16).
The risk of hypoparathyroidism is thereforo present, 
but small. The potential hazards of subclinical 
hypoparathyroidism aro unknown.
5. FERTILITY AND RISKS TO THE FOETUS,
(a) Thyrotoxicosis decreases libido and fertility* 
cure in female patients is often followed by pregnancy. 
There is evidence of amenorrhoea after cancericidal 
therapy doses of iodine-131 but not oftor the amounts 
used to treat thyrotoxicosis? tho amenorrhoea may 
have been duo to high uptake of neighbouring métastasés 
though testicular atrophy has been reported after 553 mCi 
(165).
(b) Foetal hypothyroidism is rare when radio-iodine 
has been given in error to pregnant women, probably 
because the maternal thyroid soaks up most of the radio- 
iodine; at least 6 cases of foetal hypothyroidism have 
been recorded (89,126,220,233,247). Radio-iodine is 
contra-indicated during pregnancy.
(c) There is a risk of genetic damage to children
born to mothers after radio-iodine tharaoy. The doubling 
dose (the Rad dose that eventually doubles the number 
of gene mutations) is estimated to bo between 15 and 
30 Rads (169). The number and type of abnormalities 
in children born to iodine-131-treated mothers does not 
differ from the guui ra1 population (46).
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6 . HYPOTHYROIDISM F O L L O W I N G  I O D I N E - 1 3 1  THERAPY,
ludine-iSl exerts its effect by destroying thyroid follicular 
colls and from the earliest days of its use, it was expected 
that a proportion of patients would be rendered hypothyroid » 
This was soon confirmed with sevoral reports suggesting an 
incidence of perhaps 10% (15,246^257,264,294),
Much more disquieting was the gradual awareness that 
euthyroid patients were at risk of eventually becoming 
hypothyroid(33,72,107,110,121,185,209) and a flurry of 
reports from the mid-1960's demonstrated a cumulative 
incidence of post-therapy hypothyroidism, reaching 7CJT 
1 0  years post-therapy in two reports (19,209) with no 
evidence of a levelling-off in the annual accrual rate.
The figures opposite(figs 4,5) illustrate the problems 
the number of patients at risk is cumulative and produces 
a massive clinical-load in terms of follow-up*
The use of small doses of iodine-131 merely delays the 
onset of hypothyroidism and at the cost of a prolonged 
period of toxicosis (45,177).
Several trials of low dosage schedules with concurrent 
use of inorganic iodine (1 2 0 ), anti thyroid drugs (182), or 
beta-adrenoreceptor blocking drugs (118,171) have failed to 
reduce t^ e^ climbing incidence of hypothyroidism.
Hypothyroidism, after radio-iodine therapy, is frequently 
of insidious onset and patients may not perceive its onset. 
Delay in diagnosis is serious because of the dangers of 
accelerated atherosclerosis, cardiac failure, coma and death 
(224,225,245). This makes routine follow-up essential.
The size of the problem has led to computerisation of follow- 
up (2 2 1 ).
The CausG of jpost-lodine-^ 131 Hypothyroidism.
The therapeutic effect of iodine-131 is exerted by its/-’ ray 
emission which is absorbed over a path length of 400 to 2000 
microns. The 15" emission i s largely unabsorbed by the thyroid.
TheP» wave path length is sufficient to irradiate follicle cell 
cytoplasm, cell nucleus and vascular stroma. Hypothyroidism 
is considered to result primarily from nuclear irradiation with 
damage to the cell's divisional, integrity and subsequent cell 
death (61,62,109). Vascular damage is thought to be of only 
minor significance in the development of gland fibrosis and 
atrophy that ensues (58,121,146) though some authorities 
consider this view too extreme (55).
There is, of course, the eventual onset of hypothyroidism 
that will ensue in a proportion of survivors of thyrotoxicosis 
treated or untreated (see page 7 ). This will add to the 
radiation-induced hypothyroidism, the incidence of which is 
too great to be explained in terms of spontaneous hypothyroidism. 
High LATS titres persist in the majority of treated thyrotoxics 
which tends to support a low incidence of spontaneous "cure”.
, Irradiation-induced auto-immune thyroiditis has been proposed 
as the cause of hypothyroidism (18) but, despite the transient 
increase in triyroid antibodies in serum of some patients after 
radio-iodine therapy, titres do not correlate with eventual status 
(37) and this hypothesis is not widely held,
SUMMARY or SECTIPN A.
This section has reviewed the present, partly speculative., 
knowledge of the aetiology of thyrotoxicosis. Present therapies 
are directed against thyroid gland rather than against the 
primary cause.
J "
Tests of' tfiyroid function relevant to the iodino-125 Trial 
(section B) have been briefly outlined to emphasise the dogrE-je 
of continuity in defining patients' tfiyroid status over 7 years.
Therapies available for thyrotoxicosis have been discussed 
and attention focussed on the advantages of radio-iodine 
therapy. The risks of neoplasia and the genetic hazards have 
been reviewed ; there is no good evidence of an increased risk 
of carcinoma of thyroid in adults; risks to younger patients 
have led to restrictions on the age at which radio-iodine therapy 
may be given, and pregnant patients are not given radio-iodine.
The major problems appear to be related to the inevitable 
rise in post-therapy hypothyroidism which necessitates follow- 
up for patient (until hypothyroid and on replacement therapy,or 
dead) and places a considerable clinical load on thyroid centres.
One way to deal wi.th these problems is deliberately to render 
patients hypothyroid with large doses (82,125,161) and give 
them thyroxine. This guarantees control of the thyrotoxicosis 
but leaves the patient on medication (which he or she may not 
have required for years with ordinary therapy doses). Also, 
the risks of large therapy doses may bo significant, though 
Dobyns's data suggest that hypothyroidism protects against thyroid 
neoplasia (at least in children).
As an alternative to iodine-131 therapy and its associated 
problems, the use of another isotope, icdine-125, was oroposed. 
Section S deals with the theoretical and experimental basis for 
this proposal and with a trial of iodine-125 therapy in 360 patients
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T H E O R E T I CAL BASTS F[:H THE U S E OF ICDINE-125.
Iocline'".l25j discovered in 194G, is one cf' the 24 radio­
nuclides uf iodine. Its decay is complex (112,259) occurring
by electron capture, emission and internal conversion with
production of soft x-rays and low energyparticles. The 
majority of the Iguj energy x and V  rays pass through the thyroid 
without dissipating energy. Most of the energy deposited in 
the thyroid is due to the low energy particles. It hc-s been 
calculated (99,112) that few electrons travel further than 
15 microns from a point source and the maximum range is 26 microns 
From a spherical source of iodino-12 5 there is a marked fall in 
dose rate across the sphere boundary. Changing sphere size 
from 55 to 70 microns (selected for similarity to proportions of 
colloid in rat follicles^the ret thyroid being the model for the 
human disorder) makes little difference. The figure opposite 
illustrates these points (Fig. 6 ),
Iodine-125 has, of course, to cross the follicle cell to be 
incorporated into thyroglobulin and it traverses the cell again 
when the colloid is rescrbed and thyroid hormone released and 
secreted. However, the intracellular content of iodine-125 is 
less than 1 0  per cent of the total thyroid gland content and may 
be much lower than this upper limit (202,321); 90 per cent plus 
of iodine-125 will, therefore, be in the colloid.
This permits an important comparison to be made between the 
emissions of iodine-131 and iodine-125 (Fig. 7). Iodine-125 
will subject the cell apex - the site of hormonogenesis - to a 
much higher dose rate than the nucleus - the site of reproductive 
integrity. The doso rate across the cell does not reach zero by
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virtue of photon omissions, but the Rad dose at the colloid 
interface will be 3 to 4 times that at the nucleus 10 microns 
from tlie colloid (112,306). . To convert Rads to rems a quality 
factor has to be introduced g the factor is greater than unity 
for the low energy electrons which travel 0,05 to 5 microns and 
irradiate tlie apical segment. The quality factor is uniry at 
nuclear level as the low energy electrons do not travel that 
distance. This factor raises the colloid interface dose to 
5 times the nuclear dose (168).
Iodine-131 emits and rays. The rays have an average 
energy of 187 Ke\/ and are absorbed over a path length of 400 to 
2000 microns. The rays pass through the thyroid largely 
unabsorbed. The radiation field of iodine-131 is great in
comparison to follicle cell height (15 microns) or follicle
diameter (300 microns) and so adjacent follicles will irradiate 
one another, producing a uniform irradiation of cell cytoplasm
and nucleus. Only a narrow rim of peripheral follicles will
escape this uniform irradiation (10).
By contrast with iodine-125 the path length of the iodine-131 
emissions is such as to irradiate cell apex and cell nucleus more 
or less equally with consequent cell death and eventual 
hypothyroidism (fig.8).
The figures 6,7,8 illustrate the actions of iodine-125, its 
potential benefit residing in its capacity to preferentially 
reduce hormone production.
Figure B illustrates the differential irradiation across 
the thyroid gland : colloid-cell interface receives proportionately
more irradiation m a n  cell nucleus with iodine-125. 1 he question 
to bo answered is the following i is this difference sufficient to 
permit preferential suppression of hormonogenesis leaving an
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adequate reserve of ceJ.lu.lor replicative capacity to 
reduce the eventual hypothyroidism that is inevitable with 
iorilnc-ldl?. Figure 9 illustr^ites the effects of iodine-125
and iodine-131 on thyroid cellsç the hypothesis on which the 
therapeutic Triel is based holds that, with iodine-125 therapy, 
cells grouped as C are increased in number compared with 
iodine-131 and provide a therapeijtic advantage as regards eventual 
hypothyr o idism.
EXPERlhlbTAL BASIS FDR THF USF OF IODIME-125.
There is no laboratory animal equivalont of thyrotoxicosis 
though Settlor (251) describes a thyrotoxic mare that was cured 
by a subtotal thyroidectomy. There is, however, a useful 
alternative, for assessing the effects of radiotion^in the growth 
response of the rat thyroid to a goitrogenic stimulus (66),
Gross et al. (115) found that increasing doses of iodine-131 
progressively diminished the growth response whereas equivalent 
doses of iodine-125 did not interfere with the response. Iodine- 
125 treated rats grew less well than iodine-131-treated rats 
and this was attributed to a greater differential destruction of 
thyroid hormone synthesis in the former group. The pituitary 
glands from the iodine-125-treaLed rats wero heavier than those 
of control or 131~irradiated rats; this was taken to indicate 
increased secretion of TSH in response to the reduced thyroid 
hormone production. The DNA content of 125-1-treated rat 
thyroids was found to be increased, indicating the cells still 
retained the capacity to respond to TSH,
Greig et al (113) compared rat thyroid survivals after 
irradiation with x-rays, iodine-131, and iodine-125. Euthyroid 
glands have a very low rate of cellular replication and a 
goitrogenic stimulus has to be used to increase replication rate
to permit measurement to be mode. The Do voLues for x-rays, 
iodinG-131, and iodine-125 were 450 rads, 5,500 rads and 
9,400 rods. The difference in Do value for the isotopes was 
explained by the inhomogencous absorption of radiation ocross 
tho follicular cells in the iodine-125 treated rats which 
protected the nucleus. The cell apex, which is concerned in 
hormonogenosis, receives a greater degree of irradiation but 
this does not appear to offect cell viability and replication* 
Irradiation of cell cytoplasm has been shown to have little 
effect on cell viability (200) and erythrocytes require irradiation 
doses several orders of magnitude higher than nucloatcd cells 
for destruction (253). Vickery and williams (289) confirm 
Gross's conclusions. They also demonstrated that the effect 
of iodinB-131 was increased by prior feeding of an iodine- 
deficient diet to increase uptake of iodine-131. lodjno-125 
produced less diminution in goitrogenic response and less thyroid 
destruction in animals on normal diet. prior feeding of an
iodine-deficient diet produced even less inhibition of goitrogenic 
response or thyroid destruction, Iodine-deficiency causes 
follicle cells to elongate and the nuclei are further from the 
colloid thus resembling thyrotoxic glands. The ratio of destructive 
efficiency of iodine-131 to iodine-125 was IB to 1 on normal 
diets, but this ratio rose to 60 to 1 on iodine-deficient diets. 
Iodine-125 produced less cell destruction in iodine-deficient 
glands than in normal glands.
Other reports (177,288) have shown iodine-131 to cause eventual 
fibrous replacement of rat thyroid whereas large doses of iodine-125 
left gland architecture intact.
Lcwitus and Shakam (168) noted an increase in thyroid 
size from a week after administration of iodine-125; this increase 
persisted for 3 months (without administration of a goitrogen) 
and, in the light of low serum hormone levels, was thought to 
be TSH'-induced. Konecny (151) reported an increase after 
iüdine-125 but the increase was not detectable until 35 days 
post-therapy. Ho confirmed that iodine-125 caused less 
structural damage than iodine-131.
These studies all tend to confirm the basic premise that 
the effects of iodine-125 are a reduction in hormonogenesis with 
less structural damage to the gland.
Not all studies, however, aro in accord with this view, 
dongejan ana von button (144) administered iodino-131 and 
iodiiiB-125 to rats and mice on low-iodine diet and, 4 months 
later, measured iodine uptake (a function of the basal part of 
the cell), thyroxine levels in serum as a measure of apical 
hormonogenesis and cell death and structural alterations as a 
measure of nuclear damage. They found iodine-131 to be more 
effective than iodine-125 by a factor of 20 in reducing circulating 
thyroxine, by a factor of 16 in causing nuclear damage and by a 
factor of 20 in suppressing iodide uptake. These authors, being 
unable to demonstrate any gross difference in radiation effects 
of iodine-125 across the cell, concluded that iodine-125 has n£ 
significant extranuclear effect.
On the postulate that iodine-125 might reduce the incidence of 
hypothyroidism attendant upon iodine-131 therapy for thyrotoxicosis, 
the Medical Research Council was approached and permission obtained 
for a therapeutic trial of iodine-125 in humans.
THE TRIAL
The first question to be answered was whether iodine-125 
would actually be effective as a therapy for thyrotoxicosis.
With iodine-131 tiiorapy, some 50 per cent of patients are no 
longer thyrotoxic by three months at a dose of 10,000 rads* It 
was decided to begin with a pilot study of equivalent doses of 
iOQina-125 tliat would deposit this amount of radiation at a 
distance of 10 microns from the source (i.e. the nucleus-colloid 
distance in the elongated thyrotoxic cell)* The nuclear dose 
is reduceo by some G0>; with iodine-125 and so the doses ocrninistcred 
were 4 times the standard iodine-131 doses.
10 patients, all over 60 years, formed the patient material 
for the pilot study. The average administered dose was 38*2 mCi.
Two patients received 56 and 57 mCi, respectively. The mean 
recovery time was 8.5 weeks and all 10 were euthyroid by 20 weeks 
(111). This was encouraging as one would have exoected at
least 3 patients to require re-treatment with iodine-131. The 
patients receiving the largest doses were clinically euthyroid 
at 40 weeks. The numbers treated, however, were small.
This initial group has been increased by a further 8 patients 
(given large doses to control severe thyrotoxicosis). One patient 
has required a repeat therapy dose and a further patient three 
therapy doses of this order tor control. Mean initial theracy 
dose for the IB patients was 27.6 mCi.
One potiont has since died (of congestive cardiac failure 
and atrial fibrillation), three have been lost to follow up (one 
has emigrated). Of the remaining 14 patients, after a mean 
follow-up period of 5.4 years, 9 (64^ ') are hypothyroid. The 
rest arc euthyroid.
This high incidence of hypothyroidism is predictable 
after such high doses. The study did, however, confirm that 
iodino-125 is efficacious though the need for further therapy 
doses at this level suggested that efficacy might be less than ideal
D ESIGN o r T H E TRI AL
1) S E L ECTION Cr P A T I E N T S
As knowledge regarding the efficacy of iodine-125 at 
smaller doses was lacking, patients were considered to 
require frequent review initially. Also, as titere was 
a possibility of side effects and, particularly a 
potential risk of neoplasm, review had to be life-long.
For these reasons, patients wero selected if they lived 
within roughly a 30 mile radius of the Royal Infirmary.
It subsequently proved difficult to recall a 
proportion of patients living some distance away, 
particularly as they were also attending for review 
at their "parent” hospital* Such patients, when 
euthyroid or hypothyroid for a year, who fell into this 
category, were then released to the care of the initial 
referring consultant.
Admission to the Trial was restricted to patients 
aged around 40 years or older. Only 13 were under 40 
years when treated, the youngest was 37 years of age,
2) P R E-THERAPY PIAGPCSI S OF T H Y R O T O X I C O S I S .
Patients referred for iodine-125 therapy usually had 
already been diagnosed os thyrotoxic with confirmatory 
laboratory investigations.
<> J' Vji
In the early stages of the Trial, each patient 
required an elevated PBI-127 and a 24 hour thyroidal 
uptake of a tracer dose (5ylci) of iodine-131 in the 
thyrotoxic range to confirm the diagnosis. Thyroid 
scans initially using iodine-131, latterly, technetium-99, 
wore also performod to exclude patients with toxic 
adenomata *
From the end of 1972, serum thyroxine assays became 
routinely available and were complimented, from late 
1973 onwards, by serum triiodothyronine and thyroid 
stimulating hormone assays. Thyrotropin releasing 
hormone (TRH, Roche) was available in 1973 and TRH tests 
wore used to further clarify thyroid status in selected 
patients.
3) EXPLANATION TO THF PATIENT.
Each patient was seen individually before therapy 
and at each review. The reasons for using the new 
isotope were explained and the necessity for frequent 
review emphasised. Patients wero grateful as their 
thyrotoxicosis became under control and early reviews 
were well attended. After several years, however, 
they were less enthusiastic (particularly as they felt 
"well"), and default became more frequent. There was a 
particular tendency for patients in the Glasgow city area 
to move house (as part of an extensive rebuilding programme) 
and to fail to inform the thyroid clinic of the now 
addi'uss.
All patients still fertile were advised to use 
contraceptive precautions from the first therapy dose up 
to one year after the last dose.
5  '
4) A D M I N I S T R A T I O N  OF T H E R APY D O SE S '
Indiv/iclual doses were calculated as described below 
and wero ordered from the Radiochemical Centre Arnersham. 
Doses were administered on a Friday cr a i-.onday orally 
on an out-patient basis. Patients were advised to 
avoid contact with cnildren for a fortnight. Patients 
were advised to be careful with their urine during tiie 
first week and to avoid contamination by splashing. The 
risk of irradiating other individuals is less than with 
iodine-131. Van Fiiddlesworth has pointed out that 
contamination of the environment with icdine-125 (half 
life 60 days) would bo prolonged but his radiation levels 
data shows the environmental hazard to be insignificant 
(285),
5) R E V I E W  DF PATIENTS
At tiie commencBfrient of the Trial, review was at 
fortnightly intervals but with increasing experience, it 
was considered safe to reduce the frequency to a first 
review one month after therapy, then tujo three-montnly 
reviews and subsequently six monthly reviews. This basic 
pattern was altered according to the patient's condition at 
review.
Patients were assessed clinically end had, initially, 
routine PBI-127's performed; after 1972, serum thyroxines 
were performed routinely and other hornional assays 
subsequently,
The primary ^m_ of this Trial was to reduce the 
incidence of late hypothyrcidism inevitable with iodi ne-131 
therapy. To tr.is end, patients were assessed clinically
and biochemically. if the serum thyroxine (initially 
the PB I-127) was in the hypothyroid range, the assay 
was repeated three weeks later and yet again after a 
further throe weeks. Thus the patient was given a 
period of six weeks* grace before being considered 
hypothyroid, and replacement tlierapy instituted. Ttiu 
point at wiiich hypothyroidism woo considered to be 
present was defined as the presence of one or two 
clinical indications with a serum thyroxine (initialjy 
the PBI-127) persistently in the hypothyroid range.
The reasons for clianging to thyroxine assays are 
detailed in Part 2, 1.
The USB of a biochemical standard as pert of the 
diagnosis of hypothyroidism was considered essential 
in view of the incipient, often unpcrceivcd, progression 
of hypotnyroidism after rsdio-iudinu therapy* The 
serum thyroxine assay was considered the best end }joint 
of the titration at which hypotfsyroidism occurred « 
both in regard to continuity of patient asscssrfient over 
7 years of the Trial and in regard to patient safety,
6) S E L E C T I O N  OF T H E R A P Y  D O S E .
For iodine-131, gland irradiation is fairly uniform
and the mean gland dose (the therapy dose) is an
accurate measure of the irraoiation of the whole gland.
With iodine-12S, the major therapeutic emission consists
.of low energy electrons with ranges less than 1 micron
and nuclear dose is mly a fraction of the apical dose,
even allowing for photon irradiation and up to 10 per
cent of the iodine-125 in the cell cytoplasm (see the
first part of Section B). From the calculations of
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D o se  r a t e  ( l l a d s )  f r o m  I m C i  i o d i n e - 125 p e r  day in  
t h y r o i d  g la n d s  of m a s s e s  f r o m  20 g r a m s  to  100 g r a m s
A .  D o s o  r a t e  at c o l l o i d  c e l l  i n t e r f a c e
B .  D o se  r a t e  at 1 m i c r o n  f r o m  a p i c a l  m a r g i n  o f  c e l l
C . D ose  r a t e  at 10 m ic i ' o n s  f r o m  a p ic a l  m a r g i n ,  the
p r e s u m e d  s i t e  o f  th e  c e l l  n u c le u s .
of Gillespie et al (99), graphs may be derived giving the 
dose rate per mCi iodine-125 per day at different distances 
from the colloid in glands of different masses. Figure 10 
opposite si lows the effect of 1 rnCi at colloid-cell interface 
and at one and ten microns from the apical membrane assuming 
90 per cent of the dose is in the colloid and 10 per cent in 
the cell itself, with the colloid fraction being 15/, The 
graph permits calculation of the total rad dose at any point 
in the cell for each patient from the formula.
Rad Dose - R x Therapy Dose (mCi) x per cent thyroid uptake
 of dose X TB  ___
100
where R is the reading from the graph and Te the effective half- 
life of iodine-125 in the colloid. The percentage thyroid uptake 
of iodine-125 is difficult to measure and so the 24 hour uptake 
of the diagnostic tracer dose of iodine-131 is used as a rough 
equivalent. T^ is subject to great individual variation and 
an effective half-life value of 15 days was rather arbitrarily 
chosen.
This value was obtained from the relationship;
T . -
where Tg ~ Biological half-life (on average 20 cays in a 
thyrotoxic patient) and T^ is the physical half-life of 60 days,
Tg is subject to considerable error in adopting the value of 
20 days; experimental measurements have ranged in value up to 
double this value (^.83),
Thus calculation of rad dose to various levels along the
5.^
foIJiclG cell involves several assumptions which, it is 
hoped ; will be valid wllen applied to large numbers of 
patients,
7 ) I h DI C A T f [ k'J a FhR FUR T H EM TH L. R A F Y
All patientiî were left for a full three months before 
rec:oiving further therapy, A proportion of severely 
thyrotoxic or frail, elderly "at risk" patients wore 
given adjuvant therap’y (carbimazole/proqiranolol) as a 
10 1 r; p o r or y ho 1 d ing m o a s ure.
patients were given further therapy (a repeat of tho 
initial dose) if still severely clinically and biochemically 
thyrotoxic. Patients mildly thyrotoxic, clinically or 
biochemicallyJ were not rotroeted in tho oxpactation 
that serum hormone levels would fall gradually with passage 
of time. No patient was retreated without biochemical 
evidence of thyrotoxicosis. Thus the therapy policy was
designed to protect patients frum (unnecessary) hypothyroidism.
8) THE NFID FCR Ah OBJECTIVE MEASURE CF HYPOTHYROIDISM
Following radio-iodine therapy, patients can be placed 
in one of 5 groups, viz.
1. Clinically and biochemically thyrotoxic.
2. Biochemically toxic (clinical status misleading)
3. Euthyroid (T^, TSH in normal ranges)
A. Compensated euthyroid (TSH elevated but T-A normal)
5. Biochemically hypothyroid (clinical status misleading)
G. Clinically and biochemically hypothyroid.
The. author considers, in agreement with Wenzel et al (303) ? 
that these groups merge imperceptibly into one another,
making it essential to have a well-defined concept 
of hypothyroidism* Patients with compensated euthyroidism 
are not considered hypothyroid by virtue of the adopted 
definition*
PATJt-lNTb TREATED w'lTH TOPI HE-12 5
1) SEX Pi STRI RUT ICN
308 are female (85,5/) and 52 male (14.4/); this is 
similar to tho sox ratio for patients attending for 
iodine-131 therapy (185), suggesting no significant bias 
in patient selection.
2) AGE DISTRIBUTION
The ago range at initial therapy is 37 to 76 years 
with only 13 patients under 40 years of age. 78/ of 
patients are aged 40 to 59 years, only 1/ are 75 years 
or older,
3) THYROID GLAND PASS PRIOR TO THERAPY
Thyroid gland moss was estimated by palpation tc the 
nearest 5 grams by one of three physicians (W.R.Greig,
I.R.McDougall, W.F.Bremner). impalpable glands wore 
empirically accorded a weight of 25 grams; this was the 
lowest weight. The largest gland size was 80 grams.
75 per cent of the glands weighed 40 grams.
It is generally realised that assessment of thyroid size 
is a major source of inaccuracy in attempting to tailor a 
therapy dose to gland size. Soley et al.(264) fcunc that 
only 25 oer cent of clinical estimates of gland size, 
measured by palpation, prior to thyrcidectomy fell within 
10 per cent of tne actual weight. In the remainder, errors 
of up to 40 per cent occurred. similarly, Myhill at al,(2Dl)
found that, for small glands, estimates of sizo by 
palpation carried a standard deviation of about 10 grams 
while, for larger glands, tlie standard deviation rose 
to 45 grams, smaller glands are more accurately 
estimated but the degree of accuracy in either case 
is poor *
Myhill con,pared estimates using radio-isotope scans 
and showed them to be no more accurate than palpatioOn 
Himanka at al. reached similar conclusions (157).
Accordingly, palpation was used in this trial to assess 
thyroid size and adequate numbers of patients treated to 
minimise this source of error. 1ntcr-observer variation
was limited by restricting assessment to three physicians.
4) patients were given a preselected therapy dose of
iodine-125 per estimated gram of tliyroid. The total dose 
administered was calculated from the formula;
Administered dose (mCi) = Desired dose (;uCi/gram)
X Thyroid mass (grams)
1,000
Initially, patients were divided into 7 groups but the 
autl'ior later reclassified patients into 5 groups as it was 
felt that the greater number of patients per group reduced 
the possibility of bias due to small numbers per group.
The initial group of patients received large therapy doses, 
other groups were treated with progressively smaller doses. 
Most of the patients receivingjC 200 /jCi/gram were created 
most recently. The initial therapy dose varied from 57 
to 5 mCi. 76 per cent of patients received less than 20 mCi 
as tlm first therapy dose.
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RESULTS
By late 1973; 360 patients had been treated with iodine-125 
and sufficient data had accrued for the findings to be documented 
with a fair degree of reliability*
1. Patient Assessment; Clinical j^ioch^niicsi^ (Hormonal)
Correlations.
The two tables opposite detail the degree of agreement 
between clinical and biochemical status for 197 post- 
therapy patients assessed by the Wayne indices (56,294) 
modified in the light of the following remarks.
Correlations for euthyroid and thyrotoxic states is 
reasonable when one remembers the difficulties inherent .in 
assessing post-therapy patients who may have conflicting 
signs. As patients treated tend to improve with therapy 
and to be less obviously thyrotoxic on the full Wayne index, 
clinical classification tends to concentrate on the amelioration 
of the more prominent signs and symptoms in each individual 
patient. Also, in the (relatively) elderly patients who 
form the subjects of this Trial, the constellation of signs 
and symptoms that comprise the Wayne index is less frequent 
and patient assessment by reference to a few stigmata possessed 
by individual patients is necessary. In the light of these 
comments, correlations of clinical and biochemical status is 
reasonable in the euthyroid and thyrotoxic groups.
The correlation as regards hypothyroid patients is less 
satisfactory: 43 per cent of patients biochemically hypothyroid 
(T^i persistently in hypothyroid range) were classified as 
clinically euthyroid while 57 par cent of patients classified 
as clinically hypothyroid were, in fact, biochemically eutnyroid.
C O
This emphasises the need for adequate hormonal assessment 
of patients to confirm clinical classification,
2. Outcome in Whole ilitiont Group (November 1973 - Oanuary 1974
(Follow-up data available for 303 patients)
Patients who are euthyroid (including these mildly 
thyrotoxic) form 59*5 per cent of the total* 31,5 per­
cent are hypothyroid while 9 per cant reniain thyrotoxic*
The patients who are still thyrotoxic are either a,nong the 
most recent entrants to the trial or have refused further 
therapy for irrational reasons,
3. Relatjon of Bex to Present Status.
62 per cent of the males are euthyroid compared to 
60 per cent of the females, while the percentages hypo­
thyroid are 24 and 32 respectively, 8 per cent of the 
female patients are still thyrotoxic compared to 15 per 
cent of the males. The follow-up periods are similar end 
the higher male incidence of persistent thyrotoxicosis may 
indicate a greater degree of resistance to therapy. The 
number of treated male patients is, however, small*.
4. Age and Response to Theraoy,
The highest incidence cf hypothyroidism is in the 
older patients but patients for the pilot. stLidy of large 
doses were all elderly and this produces bias. Omitting 
this group, t!ie percentages of patients eutiiyroid and 
hypothyroid in the age range 45 tu 49 years - 61 end 30 
respectively are comparable to the equivalent figures 
for the age range 60 to 54 years ~ 63 and 29 respectively.
The findings suggest that age at time of therapy has little 
effect on outcome (for a mean follow-up of 34 months).
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! : i i , CUMULATIVE INCIDENCE OF 
HYPOTHYROIDISM IN  THE
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5. Gland Size -nr' Response to Therapyo
Comparison of tlie outcome at tho 1974-75 rowisi.j bo two en 
impalpable glands and glands weighing 45 grams arid over 
showed similar results (57 and 28 per cent euthyroid and 
hypothyroid compared to figures of 62 and 27 respectively).
This would appear to indice.to that gland size per se ha.s 
little of foe t on final outcome though, of course, large 
grands will require a proportionately larger the ropy dose 
to give equivalence in terms of pZi per gram of thyroid,
6, Variation -U }_T h yr o^ijj _ 5 ensi t i \/ j, t y to I rrad y -1 i o n.
Table 3 contrasts the outcome in two patients and 
emphasises that there is a marked variation in thyroid 
sensitivity to iodine-125: this variation is not predictable
and confounds atroinpts to predict individual outcome.
GenerallyJ however, cure of toxicosis increases and occurs 
more rapidly with increasing therapy dose and concurrently 
the rote of hypothyroidism increases,
7 , Ou tc omc re 3. eted to initial The rap y D o ^ .
Table 4 and figure 11 detail the relevant points about the 
five therapy groups. This is a general rise in the rate of 
hypothyroidism with increase in initial therapy dose. Use of 
small therapy doses (groups 1 and 2) leaves an unacceptably 
high residue of thyrotoxicosis end repeat therapy (or therapies) 
is required. Even in the largest initial therapy dose groups, 
26 per cent (group 4) and 7 per cent (group 5) required 
further therapy,
8. Outcome re la t^d tu o u r a tion o f fell ou'-U o ,
The figure opposite shows the cumulative incidence of 
hypothyroidism with the passage of time for the 5 groups.
Irrespective of the administered dose of iodine-125 
there is a progressive rise in the number of patients 
effected; the som;. rise in hypothyroidism is evident 
for the total 302 patients,
It should be emphasised that there is no marked 
decline in the incidence of late hypothyroidism,
9, Ad juvant Drug Therajiy t'tor Todine-125 Thsropy ,
14 per cent (42) of the patients required drug 
therapy as a holding measure after iodine-125, 60 per 
cent of these patients werG given csrbimazole and 
40 per cent propranolol, 5 patients were given 
combination therapy. One was given potassium 
perchlorate because of a skin rash due to prior carbimazole. 
Patients were taken off drugs for at least two months 
before a final decision as to thyroid status.
10, Further _ [ h ^ apy Doses.
79 patients required 2 theracy doses, 24 patients 
3 doses, 6 patients 4 doses, 4 patients 5 doses and 
3 patients 6 doses, out of the 303 patients reviewed.
11, P£tients lost to Follow-Up.
57 * patients were not available for this review, 9 have 
died (4 of bronchial carcinoma, 2 of ischaemic heart 
disease, 1 of systemic lupus erythematosis and 2 of unknown 
causes). The remainder were either lost to foilow-up 
or were attending othsr hospitals and information as to 
thyroid status was not obtained or was incomplete.
A1
21 patients wore subsequently traced ; 17 were euthyroid, 
one thyrotoxic and 3 hypothyroid (2 not on thorapy). If 
these ratios hold for the remaining 27 patients not 
reviewed, then the overall incidence of late hypothyroidism 
is around 28%^ (by ”lete'' is meant at least one year after 
the last therapy dose).
12, C oncl us ion t o Revi u i j_ a f 3 D3 Patj.G n t s,
Tabla 4 and figure 11 give information about the 303
] 25
patients treated the doses of I prescribed, the 
percentage of patients racjuiring further thcrnpy/cherapies, 
the length of follow-up and the outcome.
With increasing doses, the percentage of patients 
requiring further therapy/thtrapies fell (from 56;f for 
Group 1 to 7t' for Group 5) and the opposite trend is noted 
for hypothyroidism.
In Group 1 where the smallest therapy doses were 
prescribed ( A  200 ;jCi/g) 24^ (13 out of 55) are hypothyroid. 
Of the 22 patients in this group who required only one 
dose, 7 (32y) became hypothyroio, 3 within 4 months of 
therapy and one each after 5,5,11 and 30 months. Thus, 
even this small dose is associated with a high incidence 
of hypothyroidism and the need to retreat 56>f of the 
patients.
Group 3 who were given a mean dose of 410 yuCi/gm,thyroid 
show the best outcome with only 18;'{ hypothyroid and 11% 
euthyroid after a mean follow-up of 36 months.
With doses over 500 ^Ci/gm,thyroid, there is a marked 
rise in the incidence of hypotnyroidism (561? and 6Of for 
Groups 4 and 5 respectively) but persistent hyperthyroidism 
becomes rare.
The essential conclusion to the Trial resides in figure 11 
irrespective cf the administered dose of thsre is a
progressive rise in the number of patients being affected 
by hypothyroidism; the same rise in hypothyroidism is 
noted for the total cf 303 patients, and there is no obvious 
marked levelling off in accrual rate.
Comparison with TorJirmi-J- ^
The groupof patients showing the best results 
in terms of the lowest incidence of hypothyroidism 
was Croup 3, Tliis group was selected tor comparison 
with iodine-131, Also, this uni.tormity of the 
dose administered mokes for e truer indication of 
the efficacy of iodino-125 which :night be obscured 
by the inhoniogeneity of the whole patient group.
A graph of percentage of patients euthyroid after 
1,2,3,4 and 5 therapy doses (log scale) was plotted 
against number of doses (linear scale) and the 
slope of this lino gave the rate; constant ( A  )*
The fraction of patients remaining thyrotoxic 
is relatively constant from therapy doss to therapy 
dose. Consequently, the number of patients
not cured is expressed by the exponential equation;
N = No \  D
where
iM is the number of patients still 
thyrotoxic.
Mo is the original number of patients,
D is the number of therapy doses
\ the rate constant 
A
IhrsQ sets of data arc availed]Jo (100,209,259) which 
give values o f f o r  iodino-0.31 for three separate dose 
regimes. The rate constant for the iodine-125 group 
selected for comparison was 0.510 whicli is similar to the 
rate constant for a dose regime designed to deliver 80 yjCi 
of iodine-131 to each gram of thyroid tissue (0,676),
This indicates than an administered dose of 410 yjCi/iodino»125 
gram of thyroid is roughly as effective as GO yjci of iodine-131
A second approach to defining the rate of response to 
radio-iodine uses the number of doses par patient required 
to effect a 50 per cent cure. For the iodine-125 group 
receiving a mean of 410 ^ jCi/gram this figure is 0.6 which 
is less than the figure of 1.03 required for an iodine-131 
therapy dose of 80 jjci/gram of thyroid tissue.
Yet a third concept is that of average number of doses
prescribed per patient in the entire group. For this
particular group, the figure is 1,41 which is similar to 
the number prescribed by Nofal but less than the number 
prescribed by Maynard and Silver,
This data suggests that iodino-125 is only about one 
fifth as effective as iodine-131 on an equivalent dose 
basis but is more efficient in terms of cure rate.
14< Side Fffeets of Iodine-125 Therapy
No cases of leukaemia nor thyroid carcinoma have
been noted, 3 patients have had surgery for carcinoma 
of breast, suosequent to radio-iodine therapy. 4 women 
patients have died of. bronchial carcinoma - all were heavy 
smokers. One patient developed systemic lupus erytheniatosis
/ f  IT
U'
and diedo None of theso conditions appear related to 
radio-iodine therapy.
Seven years after the start of tho Trial there is no 
evidence that iodine-125 is less safe than iodine-131, 
but the follow-up in terms of patient-yeara, is 
comparatively short.
TAB LE 5,
C l a s s i f i c a t i o n  of P a t i e n t s  R e v i e w e d  1 9 7 1 - 1 9 7 3 / 7 4  (n-104)
G R O U P No.
I 11 p a t i e n t s  e u t h y r o i d  in 1971 and s u b s e q u e n t l y
h y p o t h y r o i d  in 1973.
6 w i t h  n o r mal TSH l e v els "I , ^
5 w i t h  e l e v a t e d  TSH levels
II 10 p a t i e n t s  e u t h y r o i d  in 1971 and b e c o m i n g
h y p o t h y r o i d  p r i or to 1973,
6 w i t h  n o r m a l  TSH l e v e l s  . .
4 w i t h  e l e v a t e d  TSH levels ^
ill 40 P a t i e n t s  e u t h y r o i d  in 1971 and sti ll so in 1973
32 w i t h  n o r mal TSH l e v e l s  in 1971 (6 now h av e 
e l e v a t e d  TSH levels)
8 wit h e l e v a t e d  TSH l e v e l s  in 1971
IV 15 P a t i e n t s  m i l d l y  t h y r o t o x i c  in 1971 but well
and r e c e i v i n g  no f u r t h e r  therapy,
9 p a t i e n t s  s e e m i n g  well and still b i o c h e m i c a l l y  
m i l d l y  t h y r o t o x i c
6 p a t i e n t s  now c o m p l e t e l y  e u t h y r o i d
V 28 T h y r o t o x i c  p a t i e n t s  in 1971 r e c e i v i n g  f u r t h e r  the r a p y
13 are now e u t h y r o i d  (4 w i t h  e l e v a t e d  TSH)
9 are h y p o t h y r o i d
3 r e m a i n  t h y r o t o x i c
3 are wel l but b i o c h e m i c a l l y  tox ic
HORMONAL STATUS ANU SUBGROUPS OF PATIENTS
■1 971/73/74 Comparison
A review with measurement of all hormonal parameters 
was performed in selected patients in 1971 by Dr.J.R. 
McDougello The opportunity was taken to review these 
patients again in 19'lZ/lA with a view to discovering if 
it was possible to predict which patients would become 
hypothyroid.
Samples from patients reviewed in 1971 were sont by 
rail to Newcastle anci hormone assays performed by 
arrangement with Professor R, Hall, Measurements in 
1973/74 were performed by arrangement with D r . R a t c l i f f e  
in the Regional Radioimmunoassay Centre, Stobhill Hospital.
Table 5 classifies the patients reviewed according to 
thyroid status. Patients were classified as euthyroid on 
the basis of amelioration of symptoms and in the light of 
their thyroxine assay; these patients were subdivided on 
the basis of their TSH levels in 1971. Patients uiere 
designated hypothyroid on the basis of one or two clinical 
pointers and a scrum thyroxine persistently in the hypothyroid 
range.
Minor differences in the normal ranges for T3H between 
Newcastle and Glasgow made valid comparison of changes of 
TSH over the 2/3 year period rather dubious except in so far 
as there were marked alterations in TSH levels.
RESULTS All DISCUSS IGN
Table 5 illustrates tho sub-classes of patients availaale
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for re-review in 1973. Qf 104 patients 40 wore euthyroid 
in 1971 and remained so in 1973. 24 patients had normal
TSH levels in 1971, 16 elevated TSH levels. 30 patients 
have become hypothyroid and they are classified in 3 groups 
(1), (2) and part of Croup 5. The other sub-classes are 
as shown.
Table 6 illustrates the hormonal data on these patients.
Of 11 patients who were euthyroid in 1971 and who subsequently 
became hypothyroid in 1973, 6 had originally normal TSH 
levels while 5 had elevated levels. Two y.^ars later these 
patients were clinically and biochemically hypothyroid, the 
mean times to hypothyroidism from the initial therapy being 
36 and 32 months on avcra go respectively. Whilst these two 
groups of patients had a similar clinical course the proportion 
of patients with elevated T3H levels in 1971 is smaller than 
those with normal TSH levels suggesting that patients with 
elevated TSH levels may run a greater risk of hypothyroidism 
then patients who had normal TSH levels. This compares with 
the position after 1-131 therapy where patients with raised 
plasma TSH levels develop hypothyroidism at the rate cf 
per annum. As many as 58/ of patients euthyroid after 1-131 
therapy are reputed to have elevated TSH levels (Toft et al.
1974 (274), and Tunbridge et al. 1974 (280) who found 46:.' 
of euthyroid patients to have elev.ted TSH levels.) However, 
these data are tauen from review of patients treated with 1-131, 
at least 6 years after therapy, i.e. they ware further on 
following therapy than the patients reviewed hero. It is 
possiole that the 125-1 patients will gradually develop a 
rising titra of TSH levels with time. In fact, the oatients 
with still normal TSH levels in 1973 show a slight but 
significant rise; in TSH levels with a coincidental reduction
68
in T4 lovais. Also, six poLiants with normal TsH 
levels in 1971 liave now developed elovu tod TSH levels 
though refi.aining clinically euthyroid witli thyroxine level 
in the low normal range.
From Toble 6 it can be seen tliat the post therapy 
patient presents a spectrum of tliyroid status rangirm 
from frankly hypotiiyroiri to frankly thyrotoxic. Division 
of these patients into subgroui s on a clinical basis is 
difficult, if not impossible, and measurement of hormonal 
parameters is essential, for correct cl assi flection of 
patients following radio-iodine therapy. In late 1974 
(Septembcr-October) review, o detailed study of clinical 
and hormonal status was undertaken and the results are 
detailed as follows.
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THERAPY G KO IIP
F! G  13 Tjj ) P P I,  T „  AND TSII LEVELS IN  TJIE
C L IN IC A LL Y  EUTHYROID PATIENTS RET^VTED TO 
TJIEPMPi GROUP, THE DOSE OP IO D IN E  125 
GIVEN INCREASES PRON THERAPY GROUP I  TO
GROUP 5-
HEMIEZ [if PATIENTS TRF8TCD WITH 1-125 THFRAPY 1974.
Tabla 7 dutails tho patiunts reviewed in each therapy 
group. Table 8 gives the biochemical status of the
125 patients found to be clinically euthyroid.
Figure 12 relates clinical status to dose. As expected 
ths percentage incidence of clinically apparent hypo­
thyroidism increased snd that of persistent thyrotoxicosis 
decreased with increasing dose.
For the euthyroid patients, all the mean TA and FTI 
levels were in the normal range but there was a progressive 
drop in these means and a concomitant rise in maan T5H 
with increasing therapy duse (Table 7), Figure 13,
By applying Students' t-test, the mean TA and FTI of 
Groups 2 and 4 were shown to be significantly lower than 
the corresponding Group I values (p<L0,05), also the means 
of Group 4 were significantly lower than those of Group 2 
(p<4,0,l) ; TSH levels remained in the normal range for 
Groups 1 to 3 but were significantly raised above the normal 
range in Groups 4 and 5 (p ^ 0.005).
These findings suggest that,with increasing dose, there is 
a progressive trend towards suboptimal thyroid hormone 
concentrations with reduced T4/ t3 ratios, leading to 
elevation of TSH levels.
Only 93 of the clinically euthyroid patients were 
biochemically euthyroid on the basis of 1'4 values and 
12 of these had elevated TSH levels*
10 patients, who had normal 14 levels, had elevated T3 
levels while 4 patients who were clinically eutnyroid 
had elev:tad T4 levels- A further 6 patients had both
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elevated TA and T3 levels i u e » luarc: biochemically toxic. 
Another group of 10 patients ui.,ro clinically euthyroid but 
were biochemically hypothyroid.
The 20 patients who wore biochemically thyrotoxic but 
classified as clinically uutnyroid were^ at most, minimally 
thyrotoxic and did nut require further therapy. At a 
further review one ye,'r later in 3 975, 11 of these patients 
were clinically and biochemically euthyroid.
Of the 12 patients with 14 values in the cutlryroid 
range but with elevated levels of TON (Table 9) 7 were 
recalled 7 months after initial review and reassessed by 
the TRH test and 10 of the group were recalled 12 months 
after the initial review,
Ac the figure opposite shows, all patients studied 
had an exaggerated response to TRH? uihen compared to a control 
group composed of laboratory personnel and hospitalised 
patients with no history of thyroid disease,(Fig® 14 jTable 11)
The 12 month follow-up review showed that 3 of the ten 
patients were showing clinical signs of hypothyroidism and 
the T4 level in 8 patients was lower than at the initial 
review (Table 9).
This condition has been described as "comoensated 
Guthyroidism” or "subclinical hypothyroidism"(83).
All patients in this group showed an exaggerated res, cnse 
to TRH, This agrees w_ th the results of Tunbridge e-t al. 
1974 (159), who investigated' the thyroid status of 39 1-131 
treated patients in tfiis category. The mean 1'4 level of 
these patients was shown to oe significantly lower than in
patients with normal JSHs in agreement with the results 
of Tof't et al, 1974(158), wh,o found the some rosu.it in a 
group of post-I-131 patients.,
Tunbridge et al, thought sucii patients were no n'ore likely 
to develop hyoothyroidism thon euthyroid patients with 
normal TSH, although Toft et al, thought the subc1inically 
hyr.iothyroid group were most at risk and should bo reviewed 
more regularly.
This study showed that 3 of these patients founc: to be 
clinically euthyroid at the initial review had become 
clinically hypothyroid t)y the third review ono year Istor and 
a further patient had developed e hypothyroid T4 level 
although still judged clinically euthyroid. This represents 
an annual incidence of hypothyroidism of 25-35 par cent which 
I S  significantly higher than the annual incidence in patients 
with normal TSH levels which is of the order of 5 per cent.
It should perhaps be Emphasised that this was a prospective 
study free of the potential bias that may distort retrospective 
studies.
It should also be remembered that this particular group of 
patients was treated with iodine-125 and the rapidity of onset 
of hypothyroidism may possibly bo accelerated by use of this 
particular isotope.
Patients with "compense tad eutnyruidism" after iodine-125 
therapy form an "at risk" group wl^ io require close follow-up, 
However, there is still an incidence of 5 per cent per annum 
of euthyroid patients who become hypotnyroid and who cannot 
be identified by hormone studies.
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Doubt exists as to the hormonal status of such patients - 
hence thi. two tenns, compensated euthyroidiam end subclinical 
hypothyroidism. It is disputed whether such patients should 
receive thyroxine replacement therapy,
Tunbridge (280) investigated this problem by comparing 
cholesterol and electrocardiographic appearances before and 
one mon til ciftcr replacement therapy with 0.2 mg, thyroxine 
per day. bo changes were observed.
The author measured cholesterol and triglyceride levels 
and lipoprotein fractions in 12 patients at each review.
The samples were fasting samples and permitted comparison 
with normal values for individuals of the same ages as the 
patient (ranges taken from Fredrickson et al.(y2)). Groups 
of patients of the same ages as the compensated euthyroid 
patients wore selected randomly from patients euthyroid with 
normal TSH levels for further comparison.
Table 10 details the findings. The patients with 
elevated TSH levels had values in the normal range except 
for 2 cholesterol and 2 triglyceride values in the frankly 
hyperlipicaemic range; there latter 4 results persisted in 
the hyperlipidaemic range when repeated one month later. 
However, the mean values of both parameters in the compensated 
euthyroid group were nob significantly different from those 
in the control patients nor from tTse normal range of values 
obtained from Fredrickson.
The 3 patients with the abnormal parameters were recalled 
in the fasting state and full lipoprotein typing carried out 
by beta quantification and electrophoresis. One patient was
7
confirmed as having a.Type lïa abnormality, one as h; wing 
a Type IV abnormality and the third patient as having a n b  
abnormality (Fredrickson classification). None of these 
patients had clinical stigmate of a lipoprotein abnormality.
In tho light of these findings, these three patients were 
commenced upon Thyroxine therapy and 3 months later, when 
they were each on 0.2 mgm. par day, full lipoprotein 
phenotyping was performed. The patient with the Ilb abnormality 
and the patient with H a  abnormality now showed normal 
lipoprotein phenotype values in the normal range. The 
patient with the Type IV abnormality was known to be e 
heavy drinker and her lipoprotein abnormality persisted. She 
was taken off thyroxine replacement therapy and her lipoprotein 
disorder clerrod with control of her drinking.
Thi.s data suggests, though in view of the small numbers 
of patients involved, does not prove, that patients with 
compensated euthyroidism may be at risk of accelerated 
atherosclerosis and coronary artery disease, as elevated 
lipoprotein levels in the LDL and VLDL classes are 
significant risk factors for ischaemic heart disease.
Two of this group of patients have since died of 
myocardial infarction compared with only one patient in the 
control group. The patient (who had elevated cholesterol 
and triglyceride levels suggestive of a Type lib abnormality) 
now has an ECG showing inferior ischsemia and frequent sino­
atrial block which is causing dizzy spells and will probably 
necessitate a permanent cardiac pacemaker.
These findings are again, of course, not conclusive but do 
suggest that replacement therapy should be considered in this 
group of patients.
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S Y S T O L I C  TIPiC I N TERVAL KCA5UREMENTS IM COMPENSATED E U T H Y R O I D ISM,
In an attempt to measure the dynamic response of the 
body to thu;x. hormonal alterations, tlio function of the 
heart was measured using the non-invasive technique of 
systolic time interval mGasurcments(sea Section d ).
Eight patients with compensated euthyroidism wore so 
studied and the results compared with the results from a 
control group of ten patients with no evidence of thyroid 
nor of cardiovascular disease. These control patients 
had normal TSH values, wore of the same age and sex as the 
ten patients studieo and none of the patients studied had 
overt nor ECG evidence of cardiovascular disease. All were 
normotensivG.
RESULTS
The intervals for 5 of the 8 patients studied fell 
within the normal range of the control group. The other 
three patients had parameters outwith normal (Table 12). 
Comparison of the moan values of these 8 patients with the 
means of the 10 control patients showed no statistically 
significant difference,
SOME FURTHER LIPID STUDIES 1C PATIENTS wITH 
CDMHELSATEC EüTF.YRClbïSM .
1, L. ip id Ç] e ■' ring C acacity
Investigation of the clearance rates of triglyceride were 
measured in six patients with compensated euthyroidism 
using the intravenous intrelipid tolerance test (23,24,25),
Patients and hethod_.
Patients were studied in the fasting state.
0.1 ml/kg.body weight of a 10 per cent solution
75
en
IxJ
ra
<x
s:
OD
Q
O
CC
'.>■
X
I—
ZJ
a
Lü
I—■ce
C/D
Z
LJ
Q.
a
LJ
UD
IjJ
X
■_J
a :
33
(N
se
•H
o O  OrH to Sf o
1 o O
E
o °  V
.{. j -}■ 1 CL
00 ■—1
en en UD
CM
se CM UD
X QJ
'H ex
O c
•H A CD
CD >. A
Q S X
w  X A -4-3 QJ
O  UD O 3 IX
X  K- X  C 0) UD CD
t— X  o
Z  D. X  \ D- X  C 11 OJ
W  X 1— kJ II Z  UD "-I Et-i o X  ^ O  }" ■—1 C CD
1“  r r Lü c X  -w u UD
cC LD
(X 4 >r-
üf Intralj; it.: (a soyabea n extract availablü coa,nuirc j ally 
f rOÎT1 A. C. \/ i-1rt.im , Swoden ) i r_, clmi n.i.s t l r ed as an intra­
venous bolus and vonoscinples obta.'nad at 10 rninuto 
intervals over tite subsiamont hour from a Uonflon cannula 
in tho opposito arm, kept patent by a non-Iiepr riniscri 
slow solin.i flush. The samples (taken into EDTA" 
anticoagulatoo tubes) arc plticod in ice and rapidly 
ctuitrifugcid, Plasma aliquots arc taken and the decree 
of light absorption at 350 A  measured on a Bookmarm
spectrophotometer ( to give a measure of the number of
remaining fat particles). A one in 2000 dilution of 
ttic original Intralipiu solution is made and the absorption 
measured in triplicate. The absorption of fasting plasma 
is subtracted from ttrot of the samples obtained after the 
bolus and tho subsequent values are expressed as a percentage 
of tho absorption of tho injected Intralipid. A semi-log 
plot of )f- absorption remaining in plasma against time 
gives a straignt line, tlie gradient of which, |<2 ( P" / rnin), 
is the required parameter.
The parameter K2 is a measure of the body's cacacity to 
remove chylcnicra from plasma, i.e. is a measure of lipid 
clearing capacity. The K2 parameters are detailed in
the table opposite eno oemonstrate a reduced ability to
clear triglyccrioes from tho plasma in these oaticnts 
compared to normal values obtained from a group of out­
put i cnt controls (Table 13).
This again, is suggestive evidence tnct such individuals 
have subtle abnormalities of metabolism and may be at risk 
if "compensated eutu.yrcidisrn" is prolonged and replacement 
therapy not instituted.
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Lipoprotein lip;u,o activity ho.s assayed in 7 
patients ui th "componooted cutl .yrc.idism" .
Method*
Fasting plasma samples were taken and 100Ü units 
of heparin edininistorcd intravenously and Further 
plasma samples obtained exactly 15 minutes after 
heparin administrât i on, plasrrici samples were obtained 
by immédiate centrifugation at 5000 r.p.m« for 3 
minutes of F.D.T.A. anticoagulated blood. The samples 
wore frozen directly and assayed with control 
samples from 10 norrnolipaemic, 6 Type IV hyper- 
triglyceridaemic end 6 Type II hypcrcholesterolaemic 
patients. substrate was produced by mixing equal 
volumes of normal serum and 10 per cent Intralipid.
9 ml. of substrate was incubated with 1 ml. of test 
plasma, after thawing, for 15 minutes at 37°C. (298). 
The incubation mixtures were immediately assayed in 
triplicate by extraction with Dole reagent (64) and 
measurement of total free fatty acid levels by micro- 
titration with 0.02 M sodium hydroxide.
Activity was expressed as microequivalents of 
free (unesterified) fatty acid released per minute 
per 100 ml, of plasma.
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RESULTS
Table 14 details the findings.
As expected,there is no significant differences between 
normals and Type 11 individuals. Type TV subjects show 
a high prc-heparin lipase activity that rises to normal 
levels foliuwing heparin. This has been reported 
before (91, 298). It is postulated tinhc the high 
pre-heparin level in tho Type IV abnormality is 
insufficient to counterbalance the hypertriglycoridacm?a 
witii the result that elevated plasma triglyceride values 
persist.
Interestingly, the patients with "compensated 
euthyroidism" are close to the Type IV group in terms 
of their fasting lipase(pre-heparin lipase)activity.
This is further suggestive evidence that metabolism 
is subnormal in this pa lient group.
DISCUSS Icn
Thu studies described here sugge/t that patients with 
"compansaued eutoyroidism" may oe metaoolically "embarrassed" 
in terms of lipid metabolism anti cardiovascular function.
This finding suggests that such patients should be given 
replacement thcraoy when their TSH levels start to rise.
The mean T3 levels were net significantly different between 
the "compensated euthyroid" patients and the control group. 
This finding has seen noted by others (274,280,303).
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There appears to be two possible explanations for this 
finding cr Firstly, it may be that, as the stimulus duo
to thyroid stimulating immunoglobulins and lymphocytes 
wanes (as part of the natural course of the disease), 
hormonal levels fall and TSH is secreted to increase tliyroid 
hormone output. Tho TSH levels do not rise to the maximum
level attainable due to regulation et hypothoJamo-pituitary 
levol by T3 levels in the circulation.
Alternatively, the thyroid gland may be failing due to 
radiation, ano TSH production is stimulated to increase 
hormonal levels of T-4 and T-3. The TSH level does not 
reach maximal levels necessary to maintain T-4 levels 
because of n preferential effect at hypothalamo-pituitcry 
level by circulating T-S. The T-3 levels are preferentially 
sustained by an alteration in the T-3/f"4 secretion ratio 
by a damaged, failing thyroid gland.
Unfortunately, studies of gland secretion ratios of T-4 
and T-3 were not performed to prove or disprove the latter 
possibility.
In an attempt to evaluate the possible role of relative 
iodine deficiency in perhaps causing preferential gland 
production of T-3, 4 patients were given physiological iodide 
(120 }.)g/day) orally for 4 weeks and re-assessed at 5 and 
16 weeks. The findings are detailed in Table 15*
There was a significant rise in T4 and fall in TSH levels 
in all patients with a small fall in mean To levels in this 
group at 6 weeks. By 16 weeks, T4 levels had fallen and 
TSH levels had risen with a small rise in T3 levels.
This small study suggests a role fur iodine deficiency 
in patients with compensated euthyroidism by causing 
preferential production of T3 in the failing gland. It is 
possible that patiente with elevated TSH levels may bncome 
completely euthyroid without hormonal replacement therapy, 
if given physiological iodine replacement. It is also 
possible that eventual hypotnyroidicm may be staved off by 
this manoeuvre (though not prevented). It should be noted 
that physiological and not pharmacological doses of iodine 
were given to these patients. It has been recorded that 
pharmacological doses of iodine may induce overt hypo­
thyroidism (230)o
patients _w h f leva ted T - 3_1„ e v o Is r " T-3 T o x i cos ixi ' ’.
An elevated T™3 level without a concomitant rise in T-4, 
producing clinical thyrotoxicosis, was first described by 
Moclagan et al%(17b) in 1957. Frequent reports have appeared 
subsequently, in particular, one from Hollander et al (140) 
describing 40 cases. Further studies, by the letter group 
suggested tti. t elevated T3 levels were frequently an early form 
of frank thyrotoxicosis where both hormones are elevated (139).
The reasons for selectively high elevation of T-3 levels 
are unclear; its occurrence in autonomous hyperfunctioning 
thyroid nodules suggests that L.A.T.S. or TSH stimulation is 
not the cause. Some cases may result from a relative iodine 
deficiency (198) with preferential secretion of T-3.
During hormonal studies on post-125 patients, 20 patients 
were noted to have elevated T-3 levels. 10 were selected for 
prospective review at frequent intervals. These patients wore 
euthyroid or minimally tnyrotoxic on clinical assessment.
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Tho table opposite (Tobio 15) lists ttio relouant data 
for the 10 patients reujeireo over one year. At the second 
review the T-2 levels remained elevated, 1"-4 levels remained 
in the normal range except for 2 patients who had elevated 
T-A levels.
TRH tests performed at this point showed that these two 
patients together with six cf the r^ nat of the group, had 
no response to TRH^
Two patients, however, si towed an exaggerated response 
to TRH although both these patients had normal basal TSH 
levais »
[Vine of the group were further revicued 12 months after 
the initial review. At this review, the T«3 and T-4 of 
the two patients who showed classical thyrotoxicosis (bioch£"iic;al) 
at the previous review, returned to values similar or slightly 
below those found initially, although T-3 levels wore still 
elevated (Table 16).
Of the other 7 patienl.s, five now had normal T-3 levels, 
that is ; they had become biochemically euthyroid and the T-4 
of all but one of these patients had decreased significantly 
(an amount greater than could result from inter-assay variation).
The other two patients still had toxic T3 levels, although 
slightly less than initially, in addition, both patients had 
significantly reduced T-4 levels.
These finding^, indicate that in tTio context of radio-iodine 
therapy ; (particularly 1-125 tnarapy), the raised T-3 is 
probably a transitory state and not necessarily indicative of 
impending tnyrotoxicosis♦
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In an attemut to evaluate the passible significance of 
iadidB-deficicncy in the aetiology of T-o tox i c o s i s ,  (i.e. 
biochemical T-3 t o x icos is, as 6 of those patients were 
clinically euthyroid end the rest at most minimally 
thyrotoxic) five patients with T-3 toxicosis were given 
physiological iodine (120 ^jg/dey for 4 weeks) and reviewed 
at 6 and 16 weeks subsequent to tho commencement of the 
oral iodine.
The table opposite (Table 17) details the hormonal changes, 
Three of the 5 patients devoloped classical biochemical 
thyrotoxicosis at the 6-uocks review. There was little
clinical change. The other two patients had slight further 
elevations of To lovelsj. By 16 weeks, of the 3 patients 
who had developed raised T-3 and T-4 levels, one had reverted 
to t 3 toxicosis and tho levels in another had declined.
The tliird patient had become biochemically euthyroid. The 
two patients with T-3 toxicosis and elevation at 6 weeks 
showed falls at 16 weeks.
This study suggests that relative iodide deficiency may 
regulate the relative secretions of T-4 and T-3 by the 
irraciated thyroid glend.
"T-4 Toxicosis''
During the hormonal studies, a small group of patients 
were noted to have elevated T-4 levels with normal T-3 levels. 
This finding is termed "T-4 toxicosis".
Doubt has been expressec; es to the existence of such an 
entity (32), Turner et al (281) have suggested this entity 
may result -di e to the presence oF concurrent severe non- 
thyroidal illness which is known to lowcr T-3 levels (198),
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It has also boon oug estorJ that T-4 toxicosis is a 
relatively common finding in FJlderly patients with thyroid 
di.sease (32,38) but this in disputed^
Tho seven patients in this study found to have T-4 toxicosis 
were free of obvious extra-ttiyroidal illness. Four wore 
clinically mildly thyrotoxic, throe clinically outhyrcid.
The seven were reviewed rogulorly and, in 5 cases, hormonal 
parameters were repeated to confirm the findings two to six 
weeks later. Hormonal revic;j; at 6 months showed 6 patients 
to be clinically euthyroid* 2 continuée to ssnou T-4 toxicosis 
but three had classical biochemical toxicosis and one was 
euthyroid, Cne patient failed to attend, Reviews between 
12 and 16 months showc..d that of tne 6 patients attending, all 
were clinically euthyroid, five were now biochemically 
euthyroid and one was biochemically thyrotoxic,
T3 and free thyroxine index values for the 20 T-3 
toxic and 7 T~4 toxic os well as for 11 compensated euthyroid 
patients were plotted on a log-log scatter graph (261) along 
with 28 classically thyrotoxic and 48 euthyroid patients^ 
parameters for comparison (Figure 15). The population 
distributions appear to be discrete and to confirm the existence 
of 14 toxicosis as an entity following 1-123 tfiwrepy.
U O
THF T.R.H.TEST TN THE EVALUATICN OF TFFATED
Th yr 0 iTx 7c ‘"p aT T'ht T
This test has been used to characterise patients with
I
T-3 toxicosis and compensated euthyroidism following 125 =•» 
therapy. Its use in the more ocneral situation whore post- 
therapy patients are being assessed is of interest.
The test would appear to be on extremely sensitive 
measure of thyroid function - Saber i and Utiger (248) 
have shown that the T„ 5, Ht responce is augmented by sn'.all 
decreases in circulating hormone levels whereas Fukuoa 
ot al. (95a) have demonstrated inhibition of T.S.H. response 
to T.R,H, by small increases in circulating hormone levels. 
Wenzel et al. (303) have demonstrated that both and T^ 
inhibit the T.SaH* response to T.R.H. and interpret the 
delay in onset of action of T^  ^ as indicating that the intra- 
pituitary inhibition is due to T^? time being required for 
de-iodination of T^ to Biochemical studies, however,
indicate high affinity specific T^ receptors in pituitary, 
but also, in some species, low affinity specific T^ receptors 
(259,271). In regard to this point, it is of interest that 
the two T.R.Ho tests performed on patients in the Trial with 
biochemical "T^ -* toxicosis" showed no response.
The value of the T.R.H. test following radio-iodine
therapy is disputed. Clifton-Bligh et ai. (49) found a lack
of response in patients biochemically and clinically euthyroid 
131
following I therapy and a lack of response in some 
individuals with euthyroid Graves' disease where the subjects 
had never been (overtly) thyrotoxic.
Twenty-four T.R.H. tescs were performed on patients
J 25
clinically and biochemically euthyroid following '' I therapy.
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prior to T.R.H. injection (200 jjg* intravenously in 
the morning) full hormonal measurements were performed 
(T^, ToS.fl»), Patients were divided into 3 groups
according to the change in T.S.H. levels 20 minutes after 
injection * (1) no response (n 7), (2) inadequate
response (n “ 10), (3) normal response (n =■■ 7). The
table opposite details the pertinent data.
Grouped in this fashion, the data suggests that tf'is 
response to T.R.H. depends on circulating hormone levols, 
even with values in the euthyroid rangs, as diminution 
in ToB.H. response occurs with rising T^ and T^ levels.
When the responses to T.R.H. ( T.S.H.) was graphed 
against time since last therapy (it was not possible to 
define accuratelythe onset of thyrotoxicosis in this 
group), therewas no obvious relationship (for a linear 
relationship, r = 0.42).
It was not possible to demonstrate that recovery of the 
capacity to respond to T.R.H. by the pituitary depends 
on the passage of a period of time sufficient to permit 
"resetting" of pituitary responsiveness to the altered 
circulating hormonal levels - i.e. it is possible that 
prolonged elevation of T^  ^ and/or T.^  levels may produce 
pituitary thyrotroph suppression and they may not recover 
for some time when T^ / T^ levels are made normale
The relationship between circulating thyroid hormonal 
levels and response to T.R.H. strongly suygests that 
pituitary responsiveness is related to levels of circulating 
hormoneso Further evidence comes from further T.R.H.
test data performed on 3 members of Group 1 some nine 
months later, when an improvement in response coincided 
with a fall in T, and T., levels.
8 ' 5  '
WHY D I D  THF T R IAL FAIL ?
"But facts arc chills that 
UJinne diny, cn' canne bu 
disputed"(Cujns).
To dote, tne Trial has failed in its prime purpose s 
that is indisputable. The theoretical and experimental 
basis of tii2 Tr.ial has to be reassessed in the liplvl of 
this finding.
The autfior has engaged in sLudies aimed at improving 
experimental studies of irradiation therapy for thyrotoxicosis.
A Nth AHll'IAL MODFi FF THYFFTOXiChSIS
The studies of thyrotoxicosis and of theraoios for 
thyrotoxicosis have been hindered by the lack of a suitable 
animal model. It has not proved possible to date to : roouce 
a thyrotoxic animal. In particular, us>:. of TSH is associated 
with transitory stimulation but this effect disappears 
apparently cue to antibody formation and annulment of the 
effects of TSH^ Also TSH has ti' be given by injection.
The closest aoprocch to an animal model has been to use 
rats or mice subjected to goitrogen stimulus to induce gland 
hypertrophy. Tho response of the gland to the goitrogen 
has been studied subsequent to radio-iodine thera.y and indeed 
was the basic rnooel used for this trial.
Recontly, tayrotrcpin-releasing hormone (TRH) became 
available from Rocho Lcboratcries. This material, a non- 
antigen ic tri-pc.p tide , ic absorbed orally anu of f ored, an 
opportunity of producing an animal equivalent of thyrotoxicosis.
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The lit era tint' date is rather confusing, there be i ng 
some reports sugge-.,tinq that TRH may induce thyrotoxicosis 
while otfier studies have been unrowardino.
127
Sakoda ct al» (250) noted el ova ted PB" ' I and TSH levels
in the sera of rets given oral TRH (100 or 1000 jjg/rg. for
32 days); while Chonre et al. (48) claimed to havo induced
hyperthyroidism in mice by 2 hourly injections for 10 days
,131
of 10 joq TRH— tliyraid ' 'I uptake, gland size and serum
thyroxine levels were all increased. Researchers in
Hoechst, however j, found little effect of TRH given to rats
and dogs over 14 days, on thyroid weight. There was,
however, a slight increase .In weight and "some morphological
changes inciCotive of thyroid activation" (personal
ccmmunicatiun from Dr.O.Oarrod, Roche Laboratories). Haigler
et al. (122) found that repetitive doses of TRH given to
humans did not increase T.SH levels, though inappropriate TRH, secretion
has been found to Ou a rare cause of hyperthyroidism (7C).
Rebello et al. (227) found repetitive administratiLO of TRH 
to humans did elevcte TSH levels but the response was limited.
The author studied the effect of chronic oral administration
,of TRH in drinking water administered to rats over a three
month pariocj. 43 male Ulster rots were given 2 me,
crystalline TRH per oay for up to three months and sacrificed
by ether anaesthaesia in hatches at one, two, four eight and
twelve wee-.s. Diet consisted of Puri no chow of normal iodide
content. Thyroid status was assessed by increase in thyroid
weight, by histological evidence of increased colloid rescrotion
in tissue sections of thyroid stained with hacmatoxylin and
127
eosin, ana by changes in serum PB I. The results are derailed 
in Table 20-.
FIGURE 17
HISTOLOGY OF THYROID IN RATS GIVEN 
TRH FOR THREE MONTHS.
(A) GENERAL VIEW OF HYPERACTIVE THYROID 
(H. and E. x 22g) .
ACTIVE COLLOID RESORPTION IS EVIDENT
(B) VIEW OF CONTROL GLAND.
(H. and E. x.56o)
(c) ANOTHER VIEW OF HYPERACTIVE RAT THYROID. 
(H. and E. y560 ).
Findings of glandular hyperactivity were detected at
two months and persisted until month throe by which time
gland weight was 30a more than control values, 4 control
rats sacrificed at three months showed no cliangs in the
thyroid parameters studied. The histological appearances
in treated rots consisted of increased follicular resorption
131
suggestive of a hyperthyroidism. The '' 'I uptake in 5 
treated rats at threes months was 24.2^ 3,1 (mean ISD)
compered to an uptake of 6Op + 2,0 in 3 control rats(over 24 hours) 
Figure 17 illustra ten, the histological appearance at thr^e 
months,
This evidence suggests fairly decisively that TRH given 
chronically at this level for 12 weeks produces a hyperactive 
gland. This may serve as a model for the thyrotoxic human 
gland,
RADTATIbl] STtPIFF OF THi: lFFFCTS tF IQDINC-125 USING THE 
TRH-TOXIC RfT ilGOCLî COFPARIfCIj ' PITH lODIfiC-ÎSl'i
The author felt that the "TRH-toxic" rat model offered a more 
accurate model of the hufnan thyrotoxic gland and its response to 
radiation therapy. The goitrogen-induced hyperplasia model has 
usually involved aoministraticn of radio-iodine to a normal 
thyroid followed by studies of goitrogen induced hyperplasia, 
preliminary use of goitrogen to render the gland hyperplastic 
and more akin to a toxic gland requires cessation of goitrogen 
therapy to permit uptake of radio-iodine with the possibility 
that cells may return to a resting state in the interim and 
so be protected against taking up much radio-iodiriG (unlike a 
continuously stimulated toxic cell).
With TRH administration, it is possible t;.. continue gland 
stimulation boforc. during radio-iodine adfiii n.i s tratiun, and 
oftcruiards - an experimental situation much more analogous to 
human thyrotoxicosis. Also, the relotiv/ely mild thyrotoxicosis 
induced may bo closer to the avorruje pcti ent of today, who is 
detected relatively early in the course of th,u disease and whose 
thyroid is less hypertrc.diiod than th- 2-3 fold enlargoinent 
usually induced in onime Is by goi trogen administration,
iff TH DPS
40 male Ulster rot.- worn fed oral TRH ( 2mg./bn y ) i.n their 
drinking water end maintained on normal Purina cliou; diet for 
ton weeks when groded dosec of iodinc-125 or iodine-131 wore 
administered intraperjtoneally on the samo day to groups of the 
animals*
The doses administered wore 2,5, ID, 40 and 160 ^ uCi iodine-125 
and ID, 40, 100 jJCi iodine-131. Animals from each group 
were sacrificed 24 hours after administration and on days five, 
nine and sixteen after therapy. The animals were killed by 
ether anaesthesia, the thyroids rapidly dissected out, iMoighed 
and transferred to formal saline preservative. Microtome 
sections of thyroid were taken for histology (hacmatcxylln end 
eosin preparations) and outorcdicgraphy (using Ilford coarse 
and fine grain nuclear emulsion),
Slides wore studied for evidence of histological damage 
and scored in terms of the presence or absence of frank 
follicular damage, Askanazy change (ceil cytoplasmic structural 
citanqe) and extravasation of follicular colloid into the 
intravascular space.
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A u t o r a d i ü g r a p h .1 c p r t L. y n s uj . r e r. 1 n s f : J f i e d a s r a d i a 1 u i t h
f-j V j dence or' no 3 1 o :i. d 1 a a !< ' g c; bot w son f □ 1J i c u i a r c o .11 s o r
annular wlinn nolloid 1er: ta go produced an annular linage around 
t In u F o 1.1 j. c ]. ù c X10 r n o J. ,l y.
P a r t i c u .i. ;.r .et t e n t i o n i ; o a p a i d i: o t !n o s. o ear 1 y a u t o r a d i o g r a p h i c: 
appcc.’.ranLw.. t.f c'anago u.'itin extravasation of colloid.
REnuITS
Com p.-'ri s i.u i _rj f of f c c ir of_ R acli o - i rni i jn u cl idc s,
No si gni f .i Cf. nt change in thyroid L-oight was noted until
12 n
Day b when a small fall was noted in rats given 160 yjCi I 
and this fall was groetor by Day 16. Rats given shewed
a small fall by Day 9 witli 100 and a more dramatic fall
by Day 14.
127
PBÏ 1 measurement on pooled sera from cardiac puncture 
(all of each group pooled) showed no significant chances except 
at th'. higher doses of both nuclides with a rise by Day 5 in
190 1 n]
rats receiving 160 ^ C l '  I or 100 jjCi i.
Table 21 lists the relevant findings with particular regard
to the histological and autoradiographic appearances, A general
pattern is apparent. 24 hours after isotope administrer ion,
changes are minimal though there is clear evidence of extra-
125
follicular colloid in the "l~treoted group at a oosc of 
160 yuCi (annular autoradiographic pattern). There is no
unequivocal evidence of rcuration damage in terms of Askanazy 
change nor disruption of follicular architecture at this time.
By Day 5, the evidence of colloid leakage and frank follicular
1X1
breakdown is apparent at lOC^jCi  ^ 1 with no frenk structural or
131 125
autoradiographic cnangas at 40 yjCi I, The I-treatcd group
9
FI G URE .18
A P P E A R A N C E S  OF I R R A D I A T E D  G L A N D S  IN RATS 
GIV EN T.R.H.
m
a
(A ) F RA NK F O L L I C U L A R  D A M AGE (UPPER HALF OF FIELD) 
DAY 16 DOSE - 1 6 0 yjc 125;
(H. and E. x 225)
4(B) A S K A N A Z Y  CHANGE. THE T H Y R O I D  E P I T H E L I A L  C E L L S  ARE LAR GER THAN
NORMAL, C U B ICAL , HAVE A G R A N U L A R  C Y T O P L A S M  W H I C H  IS EOS INOPHILIC. 
D AY 16 DOSE 160 yjc 125% H. and E. x 560.
(c) Tcc.iDiciivAni shov/t::t c c n s t d c r a b l s loss c e u e s l l e d  c c l l c i d
FEC:: FCLLICLFH I:'TO FFAI FOIL ICUL/JÎ TISSU-
DAY 9 DOSE 160 u C  'I. Ilford 45 X 225.
V  f ' /
(D) A U T O R A D I O G R A P H  S H O W I N G  R A D I A L  AND A N N U L A R  P A T T E R N S  DE L A B E L L E D  C O L L O I D  LE,
I lford 44 X 560. . ^ ,
DAY 9 D O S E  160 p c  I.
H. a n d  E . H A E M A T O X Y L I N  AND E O S I N  STAIN.
show little changeÎ autoradiographic appearances are 
equivocal but probably show an early radial pattern of 
labelled colloid,
Dy Day 9, frank follicular breakdown and continuing
12 5
colloid leakage is quite unequivocal at 160 ^jCi " I and
autoradiographic follicular change is more obvious at 
] 33
40 yjCi I,
125By Day 16, radiation change is unequivocal at 160 juCi I 
.131
and 40 .^iCi I with follicular disruption and colloid loss 
clearly seen.
No frank histological changes are seen at dose levels of 
125
up to 40 jjCi 1 (borderline changes only at Day 16) or
1 31
10 /UCi I.
Fig* 18 illustrates typical appearances of irradiated glands,
DISCUSSION
The model of iRM-induced thyrotoxicosis was used to
J 31 125
compare the irradiation effects of ' J end ' I on rat
125 3 31
thyroid. Up to 10 ^Ci I and 10 i^Ci " I gave no frank
125
follicular damage, whereas at 40 ^Ci end, more so, at
125
160 jjCi I, evidence of follicular damage was apparent. The
125
changes due to 160 yuCi I appeared as early as Day I and
125
persisted for the 16 days of study. The 40 ^Ci ' I dose 
produced less clearcut evidence of damage with no Askanazy 
change nor frank follicular disruption but with some auto­
radiographic evidence of colloid extravasation. By comparison,
131
40 and JDO^jCI I produced frank follicular damage. There
195
was a tendency for “ I-induced damage to occur earlier at a
131
dose level of 160 /jCI in ccmp.'i'ison to 40 ^jCi I.
The results suggest a threshold level for observable radiation 
damage over 16 days, of a minimum of 10 and 10-40 yjCi'^^’^j ,
125
with higher doses of “ I producing an effect earlier than 
131
I. The dose ratio for similar effect would apinj-.r to be 
125 131
of the oriicr of 4%1 I : I. There in no demonstrable
125
sparing effect of ' I in terms of preservation of follicular 
architecture or increase in thyroid weight duo to retention of 
cellular canacity to proliferate.
This finding is in accord witti the results of ttie clinical 
125
trial of '" I in 360 thyrotoxic patients, where there is no
demonstrable reduction in the rate of hypothyroidi&in at three
125 j 25
years after ' " % therapy and where the dose ratio of ' 1
] 31
to I for optimum control of symptoms with minimal evidence 
of hypothyroidism was approximately 4 to 1,
The present study has to bo cnnsidored in regard to other
relevant experiments, Greig et al, (113) studied the response
125 131
of rat thyroid irradiated with I or I to goitrogen, 
found a difference in DNA values of roughly 2 to 1 and considered 
this to indicate a relative sparing of nuclear replicative 
capacity for the same reduction in hormonoyenesis by the shorter 
radiations of icdine-125 - i.e. there was held to be a 
differential effect across the follicle cell with the afjical 
cytoplasm (the site of hormonogenasis) being more highly 
irradiated by iodine-125 emissions (coming largely from the 
colloid store), than the more distant nucleus.
Vickery & Williams (289) also found a qualitive difference 
in effect of iodine-125 compared to iodine-131 with greater 
dainage to hormone production than to growth (goitrogen- 
induced). This effect was exaggerated by feeding a low iodide 
diec prior to isotope administr:tion with conséquent elongation 
of the ceils.
92
Ttiret! C].-'il ici;.,ms me y be ro.lscri regarding these studies.
Firstly, the glands produced by goitrogen administrât j on in
thooe stutiiG:S are large [y 2 X normal size) with el ongated cells
and bear less structural similarity to the relatively mild
cases of thyrotoxicosis tro,ated nowadays (duo to curly detection)
Secondly, administix tion to resting thyr-oid of radio-iodine may
p r Ü du CO spec i o u s- d i f f urni i c e s w .i. th subsogu e n t g o i. t r o g o n
1 ?5
administrât ion. The ths,ra;)eutic irradiation from " I is of
low energy end so its effect will he confined to follicles
whore it is takonup - i.e. non-stimulatcd follicles will he 
J 31
protected. I, on the other hand, has a, much longer path-
length in time and so wi. 1 1 irradiate adjacent follicles with
more uniform effect. Prior aoministrati on of a low iodide
12 5
diet will elongate cells .and so cross-irradiation by I (or 
extravasated colloid) will also be reduced. Thirdly, the 
differential radiation concept is dependent on follicular 
integrity. There is evidence in the pressent work of early 
colloid leakage between the cells of appa ently intact follicles.
The hypothyroidism that appears to be an inevitable 
131
accompaniment of I therapy has eon shown to ce due to 
a damaged capacity of follicular cells to replicate (5).
Konecny (151) observed a striking increase in gland weight 
125
in rats after '“I treatment (detected after Day 30 and peaking
at Dey 60) and interpreted this effect as due to a nuclear
I 25
sparing action of ' I anc retained capacity to respond to
TSH; this, however, is explicable in terms of the lowish dose
of 125^ administered (50 pCi). Damage was not apparent on
histological examination until Day 15 - in accord with the
125
findings demonstrated here for 40 ^ j[i I.
Tl’te prBuünt findings agree wit'n those of ponge j an and
von Pucten (144) who fc;d rats o low iodine ; :ir t for 2-3 weeks
and g^ve urodod doses of both nuclide?;. Tudi.clo up toko (a basal
function of tf\c cell), scrum levels (an apii iîl funotion) and
histological evidence of cell cooth 1ÛU days after ias;tope
administration show m  evidence for o diffcruritial action of 
125
Ï on hormonogc3nesis. Also, in mice, u’ocrt; the nucleus ic 
not basally sited, comparable risuits were obtained. These 
d a ta refe r t o t !i o e r c s u 11 s j n i r r a o ,i. a t g r.J i; r ; y roids but 
accord with these moru acute findino?;,described here.,
Fig'ou 9 outlines the potential actions of and ^ I.
The evidence for a thcrcncutj c advantage of ovor'^'^I will
131
dep' nd on C being largo enough in comparison to ' '"'I action to
produce a differential effect*
Neither tho data prcurented here, nor the results of
.125
the clinical trial of "" I in humans support the claims for
a differential effect with I.
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CONCLUSION TO THE TR IAL
Briefly, this Trial has failed to show any therapeutic 
superiority of iudino-125 in comparison to iodine«13i.
In particular, the same unncceptahly high incidence of 
hypothyroidism is found and, 7 years after the commencement 
of the Trial, there i.o no evidence of a decline in the accrual 
rate. Data from other trials of iodine-125 io detailed 
opposite (Table 19)  ^ the slightly better résulte are 
explained in terms of small numbers of patients treated and 
the short period of follow-up. The patient's variability 
in response to thorsipy is obvious on loulcing at tho two 
groups B and C treated by Weidinoor whore doubling the dose is 
associated with a decreased incidence of hypothyroidism^
Review end prospective studies of patients using horimonal 
measurements has defined 3 groups of particular interest and 
they have been dealt with in some detail. ijaticnts with 
"compensated cuthyroidism" are probably hypothyroid in 
their intermediary metabolism and do not have "normal" 
biochemical status and should have replacement therapy; T3 
toxicosis cost-radio-iodine theraoy is a transitory state, 
and T-4 toxicosis does appear to exist as a biochemical 
entity.
9 5
SECTÏCN C
/5 “ADRENÜi-ÎLCEr'ÏDR BLOCKING DRUGS : A CRITIOUE DE THEIR 
USE IN THYROTOXICOSIS AND A LABOR. TORY STUDY DE THEIR 
MODE or A C T R L  ON TUT HEART.
INTRODUCTION
Many of' the features of thyrotoxicosis - the tachycardia, 
tremor, stare, sweating - bear a striking similarity to the 
features ci‘ sympathetic activity amJ several reports have 
claimed that sympathetic blockers such as reserpine or 
Quanethidino have an ameliorating effect in thyrotoxicosis 
(30,43). Schafer (252) consioersd that tissues were rendered 
more sensitive to the actions of adrenaline in thyrotoxicosis 
(this, in 1916) and this belief forms the basis for using 
sympathetic antagonists in thyrotoxicosis. The specific
- adrenoroceptor blocking agents introduced recently huave 
gained wide acceptance as adjuvant therapy for thyrotoxicosis.
However, Levey et al (8Ü, 154) have criticised the concept 
of increased sensitivity to catecholamines in hyperthyroidism 
on the grounds that the investigations were unscientific and 
biased and, in particular, did not look at dose-response 
relationship and placebo effect. Levey's studies suggest 
thet there is no_ increased sensitivity of heart to catecholamines 
end he found that ^ -adrenoreceptor blocking drugs are incapable 
of reducing the resting heart rate in the thyrotoxic state to 
normal. The relationship between thyrotoxicosis and palpitation 
first recorded in 1825 by Parry (216) is possibly explained by 
the finding of an increase in free adrenaline in the heart of 
rats rendered thyror.oxic (322). Levey's group have also 
demonstr;teo the existence of two discrete adenyl cyclase systems 
in heart, one stimulated by thyroid hormon:s (and glucagon).
the othor by catecliolamines. Also the similarity to syinprthotic 
stiniuletion is only partial - for example, vasoconstriction is 
conspi cuously absent.
The exp?riments noscribed in this section arose from the
above considerations nno from the follow!no clinical incident ?
o male p-ationt aged 6b years biitif no history of ischaemic fie art
disease presented witli fnyrotoxicosts and f large goitre. He
was averse to surgery and abiatis-n tdioropy with radio-iodine 
131
(30 m C i ' I ) w a s sol a c t g r! ;, s an a 11 •: : i;- native. His rest i n f j h e a r t 
was 96/inin. pri.or to tnorapy. Ha was commenced upon Propranolol 
40 mg. t.i.b. orally ns a. holding ■mae.s.ure to protect i'lim from 
tho anticipated suedoc rciease uf thyroid hormones from the 
goitre into the biood sr.r e am. S i x ci a y s 1 a t e r lin r e t u r n e d i n 
gros?; cardiac failure with a weight gain of ten pounds, 'iis 
cardiac rata was 58/minute, His failure cler’reo uiith diuretic 
therapy end withdrawal of propranolol. He is now eutnyroid 
(on thyroxine replacement therapy) and has no failure*
This observation suggested that the potency of propranolol 
was more than sufficient to outweigh the positive inotropic 
effects of thyroid hormones* It emphasisod the need for 
caution in administration of/^“blocking drugs to thyrotoxic 
patients end suggested that a more critical evaluation of the 
action of -sdrenoreceptor blocking agents was required. 
Obviously, if there is an element of adrenergic overactivity 
in hyperthyroidism then a /o-blocker would b„ of potential 
value in alleviating symptomatology but, if the myocardial 
depressant effect (quinidine-like action) of the orug is such 
as to induce failure in a cro^orticn of patients tfien selection 
of another -blocker witfi less cnrdio-daprossant action might 
be sw.fer and yet as beneficial in controlling symptoms.
Tho action of catecholamines upon the cardicc action 
potential(in purkinjo and ventricular muscle fibres) has 
bean shown by Carmeliet et al (43a) to be exerted upon 
the inward calcium current which :is largely responsible 
for the action potential plateau. It has been demonstrated 
that, in sodium-free Tyrode solution (containing choline 
chloride as substitute for sodium chloride), the rapid 
inward sodium current disappears, leciVing an action potential 
due solely to inward calcium and outward potassium currents.
This has the appearance shown in the figure opposite*
Addition of adrenaline augments the plateau height The 
increased intracellular calcium concentration enhances 
myocardial contractility by promoting actin - myosin 
interaction.
It has not been possible to demonstrate an effect of 
yS ^sdrenoreceptor blocking drugs on the inward calcium 
current that is independent of their action in blocking 
catecholamine action® This suggests that any postulated 
negative inotropic action of such drugs on cardiac tissue 
in a basal state (i.e, rm sympathomimetic stimulation) is 
not exerted at this site but at some other locus, if indeed 
such an action is produced by such drugs.
This study was designed to study the action of several 
such drugs on sodium and potassium fluxes as these functions 
of the cardiac cell membrane would seem an obvious site for 
a postulated direct depressant effect of -adrenoreceptor 
drugs.
Moreover, cardiac glycosides are known to inhibit the 
5 K," ATP-ase dependent ionic pump with changes in 
cellular concentrations and membrane fluxes of these ions (17a),
It IE g e n e r a l l y  held, in the light of a large body of experimental
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evidence (17a) that ttie positive inotropic of Feet of 
glycosides on cardiac tissue is due to tho increased 
intracellular sodium levels displacing sarcolemmal 
calcium, increasing intracellular Free calcium levels^and 
so enhancing myocardial contractility. The efficacy of 
P  -«adrenoreceptor blocking drugs in opposing the toxic, 
arrhythmogenic actions of glycosides (276) could be 
due to an action on glycoside-mediated Na, K, ATP-ase 
dependent pump inhibition and, if such on effect was 
demonstrated, would support the contention that such 
drugs exert a direct depressant effect at cardiac cell 
membrane level.
Failure to demonstrate such an effect would suggest 
another locus for the anti-arrhythmogenic action of
-blocking drugs and, indeed, there is evidence that 
sympathetic blockade reduces the incidence and threshold 
of glycoside-induced dysrhythmias*
A NOTE ON CATECHOLAMINE ACTION ON CARDIAC 
TISSUE
Present understanding of the action of catecholamines on 
cardiac tissue is in a state of flux (207a) but a unified 
analysis may be attempted as follows. Such an analysis 
is obviously relevant to an understanding of the function 
of -adrenoreceptor blocking drugs*
Firstly, the inward calcium currant is increased (by 
adrenaline) and this effect is responsible for the increased 
height of the action potential, for (in part, at least) the 
positive inotropic action, and for the increased pacemaker 
rate in sino-atrial and atrial tissue.
Secondly, the activation curve for the outward pacemaker
y y
DIAiiK/Rf OF THF POSTULATED INTERRELATIONSHIPS BETWEEN ACTION 
POTENTIAL UORATION, CONTRACTION AND INTERNAL CALCIUMl
CLYCOSIDES
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An increase in intra-cellular calcium augments myocardial contract 
loy stimulating sarcolemmal calcium uptake and release." Intra-cel 
calcium is increased in turn Ry direct inflow of calcium (slow cal 
current) sliown here as part of the Na~Ca exchange, which in turn i 
stimulated hy cyclic AMP produced hy catecholamine action at the 
B-adrenoreceptor site, Intra-cellular calcium is increased indire 
hy a rise in intra-cellular sodium which displaces hound calcium, , 
Cardiac glycosides have this effect hy inhihiting the sodium pump.
Tho increased intra-collular calcium increases the background outw 
potassiu/ii current (shown here as a function of memhrane potential
and time), thorchy shortening the action potential duration, redu 
the hifi ow of calcium ions and thus preventing decoupling of ce 11 ^
potassium current in purkinje fibres is shifted in a 
depolarizing direction, so accelerating Purkinje pacemaker 
activity (207a)* The outward potassium current is 
increased in amplitude and, in some studes, its activation 
threshold is lowered, so shortoning the action potential 
and, in sino-atrial and atrial tissue increasing the 
maximum negative potential in diastole.
Thirdly, adrenaline increases the activity of -
K'*" exchange pump and this may be the cause of the increased 
moximum negative potential in diastole in Purkinje fibres (207s)
Studies by McGuigan ( 10a) and others on mammal Ian
ventricular fibres suggest that tho inward calcium current 
regulates the outward potassium current and thattiiis regulation 
controls the action potential duration. Moreover, it is 
suggested that the calcium current in turn is regulated by 
cyclic amp levels which in turn are regulated by catecholamine 
levels. The overall postulated scheme is diagrammed opposite. 
Such a synthesis of currently available data may apply to 
cardiac tissues in general*
Thus it may be perceived that/9-adrenoreceptor blocking 
drugs may have many actions which are, however, indirect 
and exerted via the adrenoreceptor site*
To évalua to the apparent cardiu-deprosoant action of)6“'blockor 
drugs, r? culturu-d cardiac coll prcpcrctiun woe used ?,ud tho 
effects of A p-blocJ--.ev drugs on transmembrane ion fluxes were 
measured. The drugs cfiosen fur study were propranolol, which 
is now widely used in tnyrotoxicosis (26,104), prqctulol which 
is a cardio-selccti VC be ta-blocker, has suire intrinsic 
sympbthornimotic activity^ and which has some: benefit clinically 
in toxic pa.tients (30,205)^ oxprcnolai which h.as some intrinsic 
sympjihoinime tic action and is of little i ; u 11 fit clinically in 
hypcrtnyrci dism (222, 262) and new drug, tolamoloJ, wiiich has
no intrinsic sympottiornimetic activity. This latter drug has 
recently been reported to cause tumours in animals end its 
general release has net been pcrc.ittod.
In this study, particular attention was paid to l.hc drug 
concentrations used as .some of the actions of y^-blockorc are 
demonstrable only at levels for beyond clinically attainable 
concentrations *
The study was extended to the. action of propranolol on 
the effect of a cardiac glycoside (ouaboina) on ionic fluxes 
as it has been suggested that the action of blocking drugs 
,in protecting against glycoside-induced dysrhytnmias is exerted 
at cell membrane level (173, 174,265). Also /3 -blockeae is of ocnofit 
in thyroccrdiec patients in potentiating the slowing affect of 
digoxin on impulse conduction through the A-V node in atrial 
fibrillation, may slow sinus tachycardia^ and it is of interest 
to study the interaction of these drugs at cellular level (262,312),
IMPhCUfhehT TC A TI55U5 CULTUili tAht'H TthY
The laboratory used for tho tissue culture experiment was 
located in a small portakabin which presented various structural 
difficulties to adequate organisation and sterility can-ider.tions.
Tho following improuernonto were made ;
(1) The laboratory woe enptied of all non tisoue culture 
(e.g, flame photometer for ion assays, bench centrifuge) 
to reduce tho risks of contamination and to give 
ariequdLe roorno
(2) Techniques for transferring solutions irere re-dosigned„ 
Long steol needles with wide bore were used to suck up 
cells to break up clumps with minimal carnage to the 
cells, A wide bora gloss filter funnel was fashioned 
to fit the necks of bottles of media and the rubber 
tube of n Cornwall syringe weighted with a perforated 
steel hollow ball that slipped down the funnel into 
the bottle and permitted transfer of media sceptically,
(3) Cell counting procedures were automated using a Coulter 
counter. The instrument was calibrated using latex 
beads of accurately defined diameter and set to the 
diameter of Girerdi cells in suspension. A PZ64 cell 
size plotter was addsi. to the counter to permit cell 
sizing and detection of any volume changes (which would 
alter intracellular ionic concentration significantly. 
Automation of cell counting (in place of the uss of
a haamocytometei)permitted processing of large numbers 
of plates (up to 40 per experiment) with increased 
accuracy and reliability of results.
(4) By trial and error, tnc constant clogging of the Coulter 
counter orifice by scrum (used to ctop trypsinisaticn
of cell layers) was circumvented by the usa of a 
specific trypsin inhibitor^ met-.ylphenylsulphonyi fluoride,
(5) Rigid standarcisition of experimental protocol was 
adopted so that cell numbers per plate lay within 
a narrow ranee and the same correct.i or. factor for
persisting clumping of cells could be used»
(5) Emphasis on meticulous aseptic procedure which obviated 
the use of antibodies» This included repeated checking 
of media, soak solutions and plates for contaminating 
bacteria (bacteriological culture on agar plates) and/or 
the presence of pyrogens (animal studies).
GENERAL THEORY pF INN i XL! ! ANGE I r ' NRLr^rNT Î f- I I  SLUES USTf.'G
ITa 01 ü’^ üfôV-T'-'rXi tÿy
INT R D D U C T I N N
Exchangee of ions between colic and ti'icir surroundings 
arc best cxprecsBd in absolute units, without prejudice e£>
9
to the mechanism involvod. The cunt,ion unit used is molos/cm" sec,
y
in practict, the result is exproscud in units of p-mole/cm sec.
Under atordy state connitione, the quantity of the ion 
going into tas cell (the influx) is equal to that leaving the 
cell (the efflux) in unit time, so that it is only necessary 
to measure one of those and the inlorneil concentration if the 
ion does not ch.snge with time. Cone rally, iiowsver, most 
isolated tissues are not in a steady state on i will eventually 
reach a similar composition to th/jt of the environment. This 
means that t!'ic influx and the efflux arc not tho same one so 
both must bo measured and also that the intenml concentration 
is changing with time.
The Flux Equations
Tho model chosen for deriving these equations is that of a 
cell consisting of a bag of fluid separated from the surrounding 
medium by a thin membrane of high resistance to the movement of 
the ion, but with a low csuficily for the storage of thfi ion.
Let such a cell of area A and volume V , 
and with an internal concentrât! un of 
/ be suspended in a solution containing the
same ic m  a t  a c o n c e n t r a t i o n  C , F o r
exp•rimuntai purposes some of the external
In our
ions art replaced by tho labelled ions .
 ^ 0
Ths specific activity of the bathing fluid 
is tlien C / U . After a sufficiently long time tho internal
ions will bo lobollod in the samo r--t.:o. Let tho fluxes of
this ion acru:s the mofiihr i no be f '. and h for tho influx
 ^ ou b
and the efflux respoctivoly. The l;.bolled fiuxos of the
ion a m  thon M . ^ and n , rcs.nmt j vely »
in out ^
In unit tlinu the amount of .ion in tho cel 1 changes by
n. A " M ,A therefore the concentration chcnoes by 
in out ^
M . a/V - M ,A/V in unit time, 
in  ^ out '
i, e, d/C. ) dt ™ n . Wjw " M' 1' in ' our / ' ^
Using this basic equation both the inf j ux and tho efflux can
be measured by suitable £-dJu:-;tmcnt of the experimental condition
INFLUX
If the cell is placed in a solutiufi containing the labelled 
ion tlisn for a short time therra is an influx of the labelled 
ion, with only o small efflux of the labelled ion (for there 
are only very few of the labelled ions in the cell at this ti me) 
Therefore, aquation (1) bocumesz-
d(Cj)/ot “ Fir A/'J ooo,.*s.«o,oc>eooo«’,ot(2)
Rearranging M ^  ~ d(Cj)/dt«\//A ooeo»oooco«-»oo,c*o(3)
M . is: then obtained by multiplying M . ^ by C /C^
in in o' o
EFFLUX
If the cell is allowed to accumulate seme radioactivity, ano 
is then washed in a solution containing no radioactive ions, 
ttien the influx term fp ^  ^a/V in equation (1) becomes very 
small (theoretically zero), and so
U/C^/Z^t —■ A / V OCOt(.».«n®BOt0.t*o(4^
At this staoc it is necessary to assume some relationship
between the flux and the internal concentration of the ion. 
That usually assumed is to suppose that the flux is 
proportional to the concentration (a physical model of 
tills would be. tj'iat of Brc;unian movement causing the ions to 
impinge in random way on one side of a thin membrane 
witiI holes in it).
Thus is proportional to (C^ )
where Kp is a constant.
Therefore from equation 4;-
d(C^)/dt ~ -A/V.Kg'CC^)   .......... (6)
A/V.Kg can conveniently be replaced by k giving,
d(C^)/dt = -k,(C*) .......... . (7)
or, ■(Cj) =  ( C j ) . e x p o “ k t , f . . . . . . . . . . . (B)
t-o
where (C^) is the activity left in the cell after time t,
where (C^ ) was the original activity at time zero. 
t“D
A more convenient form of this equation is obtained by talking 
the log. when In. (C^) = In.(C^) kt   (9)
lOQjO (c)) = lOQio^c)) - kt.log^o...(9a)
t=0
Experimentally one obtains (C^) at various times and so a
plot of log (Uj) against time gives a straight line of intercept
log (Ch) and slope proportional to ko 
t--=o
k in thosû equations is a rate constant (or an exchange constant 
in this particular case), anc is the
so that it has the dimensions of l/time (i.e. miOo etc.)
I n  ^I
a 1 of a time constant;
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Tilt! \/aluo oT k t l i U 3  fuunrj frufn the experimental reauJts is 
equally applicable to the total ion in the cell. Frcjin the abov/c
it is also equal to so from équation 5
k = Mout/c,.A/v nri-i
Rearranging = kn u/ a . (Cj ) ,...*(11)
POINTS
1) This equation can ba used in non-stoady state conditions ; 
prov/idod that the rate of change of ttie total ion in the 
cell is smell compared with the rates at which the tracers 
are being exchanged. If not then some expression for the 
change of the total ion must- be incorporated in equation 11.
2) Since k.T-, = In.. 2 (i.e. 0.693), where T i is the half time
V T:
of the exponential process^ equation 11 bccomess-
^ o u t  " ln.2/T^. V / A .(C^ ) . . . . . . . . . ......(11a)
The halftime is found by noting the time that the initial 
activity in the ceil takes to fall to half its value.
2
3) In equations 11 and 11a the flux is in moles/cm  ^ scc.t
if the half time is in seconds, thy internal concentration 
3
is in moles/cm end the volume to surface ratio is in cm,
EXPERIMENTAL PROTOCOL
Figures 20 and 21 illustrate the flow plan for measurement of 
intracellular concentration influx and efflux of sodium and 
potassium in the presence of t, ,e beta-adrenoreceptor blocking 
drugs studieo. Feasursments were made over a range of drug 
concentra11 on varying from levels therapeutically obtainable 
to levels well outwith the therapeutic range.
Measurements were made in the presence of d-1 Propranolol, 
Dxprenolol, Procbolol end Tolnmolol, in concentretions from
001 uprii/m 1 « to 10Ü ugm/ml. Tho effect of Propranolol on 
Qua bai no-induced ionic cnariges wore men. su red in the presence 
of Qua ha i no with or without 5 ugm/nil, propranolol.
METHODS
proper a t. i o n o C u ]_t^ r a plat o s.
Girerdi cells, an established cell line derived from 
human r.iqht atrium, were snppl.i ed as a trypsinised .suspension 
of 10^ cells/ml. (Cibco-Biocult Ltd.). The cells wore 
thoroughly pipetted to dissociate clumps and were transferred 
to growth medium composed of basal medium Earle (containing
2 gm. sodium bicarbonate/litre), 10% foetal calf scrum and 
1% Glutamine to give a cell concentration of ancut
2 . 5  X 10' cells/ml.
Four ml« aliquots of cells and medium were plated out in 
35 mm, vented Petri oishes and the dishes stacked in a sealed 
container, which was gassed with 95% CO^ î ST’CO^ to maintain pH.
In the studies of the effect of beta-adrenorGce;;ter blocking 
drugs on ionic parameters, the medium was poursd off plates 
four cays later and replaced with fresh medium contairing * 
isotope and drug at the appropriate concentration, four 
hourslater, this growth medium was replaced with Earle's buffer 
salt solution containing isotope and drug (soak solution). After 
four hours in this solution, wi,en the cells were in a non-dividing 
state, they wore used for the experiment. Final cell concentration 
was a confluent layer of about lO''’ cells/platc.
In the experiment to study trie effect of propranolol on
Cuabaine-induced ionic cnanges, plates were incubateo for four
riccys anci then tho medium was replaced with growth medium 
where aonrnnri^ifo « ü »
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containing glycoside and propranolol in the combinations 
and for tho times shown in Table 22.
Count l_ng of Ctslj^o
Medium was aspirated from the cell Isyor which was washed 
with ice-ccld isotonic sodium-and-potassi um-f ree Krcb's 
solution to remove external isotope. The cell layer was thon 
covurec; ui tli 0,5 ml. of 0.25%. [u/\l Trypsin solution and the 
plates viowod under an inverted phase microscope until, with 
repea tod shaking, the cell layer became detached. The 
trypsinisation procedure was then stopcod immediately using 
the trypsin inhibitor, methylplienylsulphony1 fluoride (85)^ 
and 1 ml. Isoton eddsd subsequently. An inhibitor concentration 
of 10 molar was sufficient to stop the process of oigestinn,
Tho ce.ils wore pipetted up and down six times to break up 
clumps, using a wide bore steel needle anu syringe. Tho cells 
were transferred to a 25 ml. measuring cylinder using on isoton 
wash, which was used to make up the final volume to the 25 ml. mark. 
Cells were counted ancjelso sized using a Coulter counter (model 
Z with PG4 size plotter), calibrateo in the usual fashion using 
latex beads. Six plates were dealt with at one time and every 
plate war counteo in duplicate at least.
Countijicj of Iso^Goe
Immediately after ceil counting, 5 ml. of' the final solution 
of cells arid isoton were taysn into counting vials. Counting 
was performed on the Packard Tricerb instrument, No,3375. The 
isotopes studied were and Rb^^ (which behaves as but
is more convenient to tiandle oy virtue of its lunger naif-life (17C)]. 
Concontrot_ans of isotope in the growth and soak media were, 
for 1 uc/ml, anc for 5 uc/ml. Activities were
sufficient to allow ccuntino without addition of sc.i nt i 1 ianto
M eesur eimin t of ion c one c ntrat ions.
Concentration of sodium and potassium ions in tho soak 
solutions itiero measured in an EEL flamo photometer, each 
assay being porformod in duplicate.
Calc u Ib ti o IIS
1o hBasurement of col1 volume,
The diameters of 50 single cells wore measured and
averaged using a micrometer eye-piece, calibrated against
a slide engraved with linos 10 cm (10 yj) apart. Since
trypsinioed cells are spherical in shape, the volume may
bo calculated from cell volume, V , = r3 where r is
3'
the moasurori cell'radius (cm.) This is an approximate 
measure of cell volurno, but Burrows & Lamb (40) and 
MacKinnon (188) have demonstrated that, whereas surface 
area changes markedly with cell shepe (e.g. spherical 
to flat and elongate) tiiore is no significant change in 
cell volume and that tnis is a satisfactory estimate of 
cell volume*
2 . ficas urc:'- e nt of cell surf a ce area .
Direct measurement of cell surfe_e area was performed 
as described by MacKinnon,1959 (163)^from measurements of 
cell depth, perimeter, and surface area facing tne solution. 
The latter two measurements were obtained using a drawing 
tube attachment to the microscope, treeing the cell outlines 
on graph paper and measuring the area and perimeter against 
a standard obtained from s calibrated slide. The surface 
aroa facing into the solution was doubled to a count for 
the area facing the bottom of oetri dish (Burrows & Lsmb (4U))
iNnJMi^ KU IN MONOLAYER CULTURES OF GIRYRUI CELLS
4
O
io "ROUNDED" CELLS IN CULTURE.
OBSERVED MEAN CELL VOLUME - TRYPSINISED CELLS.
CALCULATED MEAN CELL VOLUME FROM CELLS AS
OBLATE SPHEROIDS.
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THE CELLS AS OBL/VTE SPHEROIDS, COMPARED TO MEASURED 
MEAN CELL VOLUME OVER A RANGE'OF CELL POPUUITIONS.
A total of 5Ü colls from a tAiickly populated i.ionoloyer were 
so inoasurod, 50 colls from a tninly propula tod monolayer 
were similarly measured and a figure for the near cell surface 
area for monolayers of different population densities was 
obtainedj knowing tlie percentages of rounded and flattened 
cells in the monolayers.
Volume to surf r ce area / f\) ratios were calculated and 
graphed as shokin opposite (Figc22 ). The regul red value for 
each plate was taken from this graph. do allowance was made 
for possiLle small SL/rfaca projections and therefore the v/a 
ratio is probably an over-estimete.
3 0 De to r i n in a t i o n_ of _j: ntra_cj^  1_1 u J. a r jrU e r.
The moan diameter of 10^ colls equilibrated as a suspension 
in Kreb's solution for one huur was calculated from measured 
diameters of AO colis. 2G0m [■] excess KCl was then added end 
cell volume shrank. After one hour, the mean diameter was 
calculated from measured diamotcrs of 40 cells.
Calculat i^T.
The dry weight, D, of the cells ; tcys constant. If the cell 
behaves as an osmometer, then x -■ 0^^ ^ (equ. 1)
where 0^ and W arc the cell water and osmetic pressures in
Kreb (suffix I) and hyperosmolar Krebs(suffix 2). On transfer,
the cells lose water (U^ ~ ).
D + = \J^ - volume in solution 1
D -F ^2 ^2 " in solution 2
IjJ , -- k' ~  1/, -
« Î 1 2 1 2
and from this, is substituted in equ.l and the volume of cell
occupied by u;atcr is given by --
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R E S U L T S
Table 23 lisLs the results obtained for the action of the 
beLa-adrenoruceptor blocking d r u g s , Propranolol, Practolol, 
OxpranolDl and Tolaniolol on sodiuin and pctoso.ium conccntrati 
and fluxes. Over the therapeutically obiainable Icwcls of 
these four drugs, intraccllulci potass.: urn concentration and 
sodiuiri concentration re ma.: nad unchanged at around 160 and 
26 mbq/litre of cell water. Giruilarly, there is no change in 
ion influx and ion off lux parorrnterso
At drug concentration levels of 50 and 100 ug/ml, an apparent 
effect on those parameters is seen. Tliis, however, is 
associated with reduction in cell numbers (to less than 75^ 3 
of control plate values), with marked staining of colls with 
trypan blue, indicating loss of viability or membrane leakage, 
with increase in cell size when the cells are sized and with 
the presence of cell debris.
Table 24 snows that the ionic changes produced by two 
concentrations of Ouabaine (10  ^ and 5 x 10  ^ molar) in contact 
with the cells for 24 hours wers unaffected by the a dition of 
5 ug/ml of Propranolol for the last 12 hours of the incubation, 
i\tor was there any effect over a shorter period of incubation 
with Propranolol (30 minutes). Similarly, when the cells were 
incubated with Propranolol first and then with Ouabaine plus 
Propranolol, giving an exposure time to Proivranolcl of 24 hours 
and to Ouabaine of 12 hours, there was yet again no effect.
D I S C U S S I O N
Studies designed to demonstrate a depressant effect ov 
myocardial c f j I I s  by beta-adrenoreceutor blocking drugs havo 
largely utilised isolaced cardiac papillary muscle préparai onsw
Using such a preparation, Naylar et al, (203) and Levy 
et al. (163) have claimed that Propranolol apparently 
depresses the twitch response of isolated cardiac muscle 
préparations. However, these results have been criticised 
on ttie grounds that the dioineter of' tho musclo strips used 
was such th;-it central hypoxia must have occurred cvid the 
apparent decline in Switch response with time in ttic presence 
of propranolol was, in fact, the result of increasing hypoxia, 
as the tissue was repeatedly stimulated (Harry et el. 1976, 
(131), Blinks et al. 1963, (20)). Several workers - Harry 
et al. (131), Blinks (21), and Meier (193) have, in fact, 
producea data from this self-same experimental approach to 
support the thesis that bcta-adrenorecci)tor blocking drugs 
do not depress isolated cardiac muscle function when used 
i. n clinics 1 ^ y at ta ina ble concent ry; j: i on
Recently, in s series of carefully controlled experiments 
using thin papillary muscle preparations, end skeletal muscle 
preparations as a control, Hsrry ct a1(131) have shown no 
depression of twitch resoonse by d-1 propranolol, Dxprenolol 
and Prrctolol at therapeutic concentrations.
The experiments described here have failed to show any 
effect of the four orugs studied, propranolol, Practolol, 
Dxprenolol anc Tolamolol, on intracellular ionic concentrations, 
ionic effluxes and influxes at therapeutic levels of drugs.
At very high levels, an apparent effect is seen with a fall 
in intracellular potassium and a rise in intracellular 
sodium end increases in influx and efflux rates. However, 
thi£5 is almost certainly a toxic effect as cviderii eu by the 
points mentioned in the Results Section®
It is possible that many of the oxperimontol claims 
for a direct depressant effect of beta-blockers on 
papillary muscle preparations are dui to tfc: presence of 
catecholamines in these preparations and acparent 
depressant effects are the results of beta-adrcnoreceptor 
blockade. Indeed, Choi ot ai. (47) hove demonstrated that 
pre-treatment of a papillary muscle preparation by rescrpine 
(which does not per se alter transmembrane sodium and 
potassium exchanges, but depletes adrenergic terminals of 
catecholcmines) markedly reduces the ability of Propranolol 
to reduce potassium efflux in those preparations, suggesting 
that this drug may be functioning as a pure beteblocker.
The experiments described hero demonstrato that beta- 
adrenoreceptor blocking drugs do not affect transmembrane 
sodium and potassium ion exchanges in this cell preparation, 
which is entirely free of catecholamine influence. Though 
these cells are an established cell ine (i.e. are dedifferentiated 
dividing cells) they are still useful for studying transmembrane 
ion exchanges. In particular, they are sensitive to the 
action of cardiac glycosides with changes in intracellular 
'ionic concentrations and fluxes that bear a proportional 
relationship to increasing glycoside concentratJons Lamb et al.
(155, 157).
The studies described here demonstrate that addition of
Propranolol does not affect the ionic changes produced by two
different concentrations cf Ouabaine in contact with Girardi
cells. do erfect has been demonstrated despite incubation
with Propranolol over 12 hours nor has any effect been demonstrated
with a shorter incubation of 30 minutes, tending to suggest
that propranolol docs not have a transitory action on
Ouabaine-induced ionic alterations. When cells wore inculiated
1
ujvth propranolol firsr and then with Duabaino plus 
Propranolol; thoro was yet again no effect, excluding 
the possibility that Ouabaine might become membrane- 
bound and so resistant to the action of Propranolol.
The leek of effect of propranolol on this effect of 
cardiac glycosides indicates that the protective action in 
safe-guarding against glycoside-induced riycrPythmias is 
not exerted at tho Pa,K-ATPcsc level. Tso and Han (27G) 
havo demonstrated that the effect of Ouabaine on incrcaslnn 
Purkinje fibre automaticity is greatly augmented by the 
presence of adrenaline wnils Roberts et al (238) have 
shown that reserpinc reduces the car a city of glycosides to 
induce extracystoles in canine hearts. The experimental 
results dctailod lierc would also tend to suggest that the 
action of digoxin in producing oysrhytnmia may be in large 
measure due to coincidental presence of catecholamines, 
and the protective action of bota-adrenoreceptor blocking 
drugs is, in fact, being exerted at this single site. Against 
this suggestion must ba set the fj.nding that d-propranolol is 
less effective against catecholamine-inouccd tachyarrhythmias 
compared to 1-Propranolol while d-propranolol is as effective 
as d"l propranolol in preventing puabaine-induccd dysrhythmia 
in experimental animals; this appears to indicate a double 
site of action of d-1 Propranolol (parmley et al. (215)).
The lack of effect of propranolol on sodium and potassium 
flexes contrasts sharply with the marked effect of this drug 
on human erythrocytes u/herc major change;; in fiuxos occur with, 
as the drug concentration is raised, eventual rupture of the 
cells (Ekrnan et al. (75)). This might suggest that beta- 
adro/ioroceptor blocking drugs exhibit a docroc of tissue 
specificity and ttvt their action, for example, on Purkinjo
fibres may be quite different from their action on c-rdioc 
musclo fibres, Howovcr, [1 Shahauy el a l . (76,77) have 
measured intracsrdiac conduction using His bundle dectrogrcns 
in acutaly and chronically hyp'ortiiyroid rats and defnonotrated 
no effect of l a r g e  doses of propranolol on the atrial - Hio 
time interval nor on the His-ventriculcr activation time.
There was some reduction in heart rate in chronically 
hypsrtfiyruid animals but tho rate did not attain the cuthyrcid 
resting value ; which is in keeping with a direct action of 
thyroid hormone on a thyro'd-horrnone specific adenyl cyclase.
The above studies, in conjunction with the clinical anecdote 
of induction of cardiac failure by -blockade in a thyrotoxic 
patient, arc evidence for a single cardiac site of action of
-blockers - the sympathetic receptor site and a lock of 
sympathetic hyperactivity in thyrotoxicosis. This would 
suggest that the effect of/^-blockade on heart is a reduction in 
rate due to removal of sympathetic tone but not a normalising 
of rate - due to the direct cardiac actions of thyroid hormone.
It raises the possibility that heart rate in hyperthyroidism, 
after ^  -blockade, may give a measure of response of a target 
tissue ~ the heart - to the severity of the thyrotoxicosis®
This data indicates that cardiac protection (important in elderly 
and cardiac patients) by A -blockade will be at best only 
partial and, therefore, treatment with -blockade alone (as 
has been advocated prior to surgery (195) is potentially hazardous,
It is pertinent to observe that while /5-blockade reduces 
pulse rate, tremor, stare and skin conductance (117,175,261), 
tho effects of such therapy in one trial, were not sufficient 
to allow patient preference for ./3-blocker (prcoranolol, practolol) 
over placebo to re cti statistical significance (204). S i i 1 a r 1 y ,
5
patients showed no preference for oxprenolol (98). Another 
study failed to show any reduction in anxiety levels with 
(3 -blockade (229). Propranolol does not reduce the
metabolic rate in hyperthyroidism (223) which further 
emphasj.ses the secondary role o f “blockade in thy rotoxicosi 
namely to alloviatc some of the peripheral manifestations 
of the disordor while definitive therapy is introduced &
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SECTICN D
PHYSIOL Ü n ]■ r: a l a l n f r A o l i c r e l p o n s es to t h y r o t d hcr m c n e s
lo SYSTOLIC TIKE INT E R V A L M E ASUREMENTS: A NEW TEST OF
'fHYRÏÏio'STATUS
INTRODUCTION
The details opposite (Table 25) describe a patient one year 
after a therapy dose of radio-iodine for thyrotoxicosis. She is 
biochemically very toxic but clinically euthyroid.
At the other extreme are found patients with modest 
biochemi cal alterations but a severely thyrotoxic clinical 
présentât.! on.
Discrepancies such ss these point to the need for a means of 
ineasuring the body's response to thyroid hormones, in particular, 
a measure of cardiovascular response would be psrticule.rly 
valuable as this system is tho most frequently compromised 
and most often at risk, particularly, in the dderly thyroid 
patients.
Measurement of basal metabolic rate is a measure of whole 
body response to triyroid hormones; it is, however, a time 
consuming, unwieldy investigation necessitating preparation 
of the patient (wlio has to be in th-- basal state), anc. it is 
disturbed by many factors unrelated to tnyroid status (16). These 
drawbacks have relegates this test to a position of relative 
unimportance.
Likewise, measurement of the Achilles tendon reflex time 
has found a place in assessment of hypothyroidjcm out its value 
in hypertllyroidism is dis;)uted (237,255).
In üüliübor tlnn with D m  3. Hiiiic, Senior Registrar,
D e p a r t m e n t  u f  M e d i c a l  C a r u i n ' o g y ,  t h s  a u t h e r  emb:M'kr-;d o n  
an a s s c G s r n e n t  of s y s t o l i c  t i m e  i n t e r v a l  m o c  s u  r e niants a s  
t h o r n  w a s  s u g o u s  t i v c  c u i d u i  n:\ i n  p u h  oi rl'ii. d w o r k  ttic: t s u c h  
m e a s u r e m u n t  m i g h t  o f f e r  a t o u t  uf s u f f i c i e n t  cei ici I, iv i Ly t c  
p e r m i t  a s s e s s m e n t  o f  c a r d l o v a s c u l n r  r c s p o n c u  t o  c i r c u l a t i n g  
t h y r o i d  i i u r m c n u  I c v c l s .
Significance err / origin of J  -hjg_^ j. e r _ S y s i. o .U c Tirtc_2 nt,; ale ( S ' l_J ' s )
Systolic time interval ref arc to a [j-.r , od uithin the systolic 
part uf the ccrdiac cycle. [mp.hcsis un tnc si gnif icanco of 
the d u r t ion of cy ctola daî ?. e. back to Carrod ( 1074) (97) but i t 
was with the detailed étudiés of Wing ers in 1921 (311,312) that 
the fCl ndctions w-.rc laid for the grcscnt widcs read usa of 
STl’s in clinical c/rdioloqicc 1 practia-:.. host cf tfui present- 
day USB of BTI ' c stems from the work cf ijjcissicr'c gzn.up (299-302).
The h.-xrt may be regarded as two pumps in scries, both of 
variabl. rate, stroi<e and pressure production. T'ney both share 
the same rate. Each pump has two cylindsrs. The- atrium is 
equivalent to a receptor for returning lew pressure fluid and as 
a pump for pumping this fluid into the second cylirider, the 
ventricle, which is tho high pressure pump.
The pressure that this pump is capable of cxertin. on 
the fluid depends on the diastolic or resting muscle fibre 
longtti (F rank-star ling Law) and i:p to a limit the pressure 
exerted increases with increasing fibre length. Thus, the 
greater the v o l u m e  of ths ventricle prior to contraction (end 
diastolic volume), the grec t'^ r the force that can bo produced 
by the fibres. The velocity cf fibre ccntr. ution is related 
to the rests to nee thut tnc blood meets cs it is ejccte.o (tho
1 1 8
af'terload) 5 increasin-j afterload rodacj ng uuio.j.l tv of contrcr.tion. 
This is tha physiological basis of STl's, The pre-ejection 
period, or is subaiuided into the electro-mechanical
delay (EJ-’i.D.) end the isouolurnntric cuntraction time (l.V,C.T,) 
These two intervals arc not divisabie accurately as some 
contract! n of the ventricular muscle will have been initiated 
before the excitation wave spreads throughout the entire 
ventricle, out contract! n is general!y taken as that point ct 
which intravcntricuiar pressure (measured invasively) begins 
to rinse.
The E.M.D. reflects the intraventriculcr cunduction pattc.rn 
and is longthoned, for example, by bundle brancn block or altered 
by biochemicel delay or acceleration of cell to coll excitation.
The I.V.C.T. is relati. o to the rate of rise of left ventricular 
pressure (LI/ ^^/dt ) which is an index of myoccrulal contractility.
Tha contractile state of the mLc.cla is effected by positive 
inotropic agents such as thyroid hern,one, an increase in metabolism 
and by cardiac glycosides and sympathetic venous stimulation ; all 
these factors shorten P.CsP. An increase in end-diar,tolic 
volume will shorten P.E.P. Negative inotropic agents depress 
contractility and cause P.E.P* to lengthen.
I.V.C.T.is affected by the diastolic pressure in the arteries: 
if the pressure is low, the aortic valve opens sooner and thus a 
low diastolic pressure tends to shorty/)!,V.C .T. and hence P.E.P.
An increased velocity of mucle fibre contraction raises the 
systolic blood pressure (and mean aortic pressure). An 
increased aortic pressure lengthsns P.C.f. as the intra-ventricular 
pressure has to be raised to open the aortic valve, orolonging
I.V.CoT, Increases in stroke volume and heart rate increase 
cardiac output which has the same offoct of raising mean 
aortic pressure.
Heart rate is related to P.E.P. Increased sympathetic 
tone increases rate and this also tends to increase the 
contractility ; this increase tends to reduce the IfW.C.T. 
by increasing the velocity of contraction.
Four factors, there'' ■<■.5, primarily affect I.VeC.T,
1) Preload which is t astolic muscle fibre length, or
the end-diastolic jiTiG o
2) Afterload or the resistance to outflow which is determined 
by the aortic diastolic pressure.
3) Myocardial contractility.
4) Ventricular dyssynergy.
LcV.E.T. is affected by the same factors. Heart rate, 
however, appears to be more significant and L.V.E.T. is 
directly related to stroke volume»
An increase in preload means muscle fibres have further to 
contract which tends to take longer and so increase L.V.E.T. and 
stroke volume.
The clinical uses of systolic time interval measurement have 
been thoroughly reviewed by Weissler (302).
This study was intended to assess the sensitivity of systolic 
time interval measurement to thyroid status to determine 
whether such « measure would afford an accurate and sensitive 
measure of cardiovascular response to thyroid hormones*
Syslolfc Iqoctlon Times
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M  G\ 2 3 MEASUREMENT OF SYSTOLIC TIME INTERVALS
M E T H O D S :
Systolic time intervals were measured from simultaneous 
recordings of an sloetrncardiogrcirn, phonoc; rdiogrom and carotid 
arterial pulse tracing (Fig. 23). The piionocL rdiooram was 
taken from a crystal tiiicrophona (Elcme Schonandsr EMT 25c) 
placed over the aorti c valve area. An elccrroc.-rdiogram 
leaii was used which gave a clear QRS complex representing 
ventricular depolarisation. The carotid pulse wave was 
recorded using a plastic tambour connected by an air-fillud 
conducting system to a high speed ink jet recorder (flingograf 34), 
The recording speed w-s 10Ü millimetres per sccoiid, the 
measured intervals were obtained by averaging valuos from 
six beats to the ner root five millise cones.
The frequency response of the Eloma Schononder EliT 510 C 
transducer and its amplifier is greater than BO Herr*
The intervals measured were (1) the total electromechanical
systole (os ) measured from the commencement of ventricular 
2
depolarisation to the first high frequency vibrations of the 
aortic component of the second heart sounds, representing aortic 
valve closure ; (2) the left ventricular ejection time (LVET)
measured from the upstroke of tha arterial pulse to the trough 
of the inciserai notch ; (3) the pre-ejection period (PEP) is
obtained by subtracting the left ventricular ejection time from 
the electro-mechanical systole and represents the interval from 
ventricular depolarisation delay and the isovolumic contraction 
time of the loft ventricle^ (4) the ratio of prc-ejcction period
to loft ventricular ejection time (PEP/LVET) was also calculcMed. 
This ratio encompasses deviations in both basic intervals and 
may reflect abnorf.-ality when neither is clearly abnormal.
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The duration of the QS^j LVET and PEP arc linearly related 
to the heart rate and regression equations have been 
derived Prom observations on normal individuals (Weissler,
301) (Fig»24)„ Results From the present studies were 
expressed as "measured" intervals, measured in absolute 
terms (milliseconds) and were compared with corresponding 
normal values ("calculated" values) calculated From the 
appropriate regression equations. The results were also 
expressed and shown as the systolic time interval indices 
(sufFix 1) calculated as the sum oF the measured interval 
and product oF the heart rate and normal regression slope.
This ofFers a convenient expression for studying serial 
changes and Facilitates comparisons among patients by 
normalising the results For heart rate. The measured 
values of each of the systolic time intervals expressed 
as the systolic time interval indices were compared to 
the calculated values ("calculated" parameters) obtained 
From the regression equations using the Student's T-test.
The results are expressed as the mean and standard 
deviation of the mean for each group.
Systolic time intervals were measured in 20 hyper­
thyroid patients (Table 2b) and 15 hypothyroid subjects
(Table 27). The diagnosis of hyperthyroidism was made
127
on clinical examination and confirmed by PB I estimation
J 31
(values^!670 nmol/l ) and ' I uptake studios (24 hour
13 J
thyroidal uptake^ 60^^, FBI ' at AB hours J) 0,3p' dos?./L 
plasma). The diagnosis of hypothyroidism was suggested 
by clirhca’i exam in -1 ion and confirmed by estimation
(values <1 230 nncl/l) ana serum thyroxine assay(valuus 50 nmol/l
No patients had :igns nor symptoms of concuii i tant carc'iac 
disease, none had conduction defects on r o u t i n e  electro­
cardiography, all were in sinus rhythm emd none was rac-ivlng
15 (T%
therapy which might affect the systolic time intervals.
Five patients from each group (hyper-> and hypothyroid)
had measurements performed after appropriate therapy.
These patients appeared euthyroid on clinical examination
.1 2 7
and this was confirmed by normal PB"" I and serum thyroxins 
estimations (patients number 1 to 5 in Tables 1 and 2)
(Table 28).
m  ths third study, 74 thyroid patients were assessed
without knowledge of their clinical details. Their thyroid
status was predicted from the changes in systolic time
intervals, when compared to normal, as deterfiiined in the
first study. Their thyroid status was also determined
independently by the referring physician from clinical and
routine thyroid investigation. This group included
previously undiagnosed patients, but also others being
125
reviewed folJ owing '"Ï radio-^iodine therapy for thyrotoxicosis,- 
The predicted thyroicj state was then compared with ttie 
independent prediction inferred from systolic time interval 
measuromentso The diagnoses established after full 
investigations were: 36 patients fqperthyroid, 12 of whcm 
had had previous therapy; 11 patients were hypothyroid , 
eight had been previously thyrotoxic; 27 patients were 
euthyroid, 21 had had therapy for hyperthyroidism and six 
presented with signs and ayrptoms of anxiety and were 
referred to exclude thyrotoxicosis (29,30,31,32,33).
RESULTS
The hyperthyroid patients shewed shcrtening of the total 
electro-mechanical systole 51 Tjj 21 (caIcul^hutd value 
549"^ ', l/p 0,001) resulting from a normal left ventricular 
ejection time, 418'^ ’ 20 (calculstad value 417"*^  1,) and
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shortening oP ths pre-ejection period 100^  8 (calculated 
value 132 ;t p2^0,001). The PEP/tUET ratio was
reduced 0.231 0.04 (calculated ratio 0.340 0,40,
P 2/0.001). (Table 26).
The hypothyroid subjects showed prolongation of the 
total electro-mechanical systole 553 14 (calculated
value 548 1, p)> 0.01) which resulted Prom shortening
oP the left ventricular ejection time 402 ^  17 (calculated 
value 416 2, P<0o01) and marked prolongation of the
pre-ejection period 161 j) 10 (calculated value 132 2,p2 O.i
The PEP/LÙET was increased 0.459 ^  0.056 (calculated value 
0.3500 2  0*04; p <  0.001).(Table 27).
in each of the patients studied after therapy, the 
pre-ejection period and PEP/LUET ratio were within the 
normal range (mean plus one standard deviation of calculated 
values). Some variance was found in the duration of the 
QS^ and LVET (Table 28).
The systolic time interval values for each patients in 
the third study are shown (Tables 29,30,31,33). From the 
first two studies the pre-ejection period and PEP/LVET 
showed the most consistent changes and these intervals were 
used to predict the status of the patients. The diagnosis 
of hyperthyroidism was predicted from the association of a 
shortened pre-ejection period and reduced PEP/LVET (the 
normal comparative range was taken as the calculated mean 2 
one standard deviation). In two patients the PEP was 
shortened, but the PEP/LVET was borderline, these patients 
were assessed as hyperthyroid (numbers 1 -r 10, Table 29).
Subjects were designated hypothyroid from lengthening 
of the pre-ejection period and an increased PEP/LVET.
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Two patients with a prolonged PEP, but borderline 
PEP/LVETfwere also designated hypothyroid (numbers 3 
and 1Ü, Table 30).
All patients, euthyroid Following radio-iodine 
therapy, had normal pre-ejection periods and PEP/LV/ET 
ratios. Three patients designated as "anxious" had a 
slightly increased PEP/LUET, but all had normal pre- 
ejection periods'(Table 31).
The predicted diagnoses made, as indicated above, 
agreed with that made by the referring phycician in 
70 of 74 cases, (95"7). Discordant diagnosis occurred 
in four patients (Table 32). No obvious cardiological 
explanation is available to explain the difference in 
these patients. They were of similar age, duration of 
symptoms and therapy as the other patient groups*
'^ 5
DISCUSS I A M
Systolic time interval measurcuients afford a non-invosive, 
repeatable and rapid assessment of cardiac function and have 
been reviewed by Kumar and Spooick, 1970 (154), Weissler,
Harris and Schoenficld J955 (301) and in a textbook by 
Weisslor (302).
This study falls into two parts; in the first, it is 
demonstrated that consistent chanoes in the pre-ejection period 
and PCP/LV/CT ratios occur in unequivocally hypo- and hyperthyroid 
patients. The return to normal of these values in ten patients 
rendered euthyroid supports the belief that measurement of 
such values may be of value in determining the thyroid status 
of an individual.
To confirm this hypothesis, the thyroid status was predicted 
in a mixed group of thyroid clinic patients providing a difficult 
clinical spectrum; which resulted in hyper-, hypo- and euthyroid 
subgroups. Some patients were minimally hypo- or hyperthyroid 
and retained conflicting clinical siigns but, even in this group, 
there was a high degri-e of correlation between predicted diagnosis 
^and that determined independently after full investigation of 
thyroid function. This appears to confirm systolic time interval 
measurements as a sensitive indication of the cardiovascular 
changes induced by tfiyroid disease.
Six patients presented with trc.nor, weight loss and/or 
tachycardia and were found to have interval and thyroid studies 
within the normal ranges; a diagnosis of anxiety state was 
eventually made in these patients by psychiatric assessment and 
exclusion of other possible organic pathologies. Tri-iodotnyromine 
levels were normal in this group, excluding T^ - toxicosis.
Harris et ai (139) reported shortening oP the pre-ejection 
period in subjects with increased endogenous sympatSletic 
activity under emotional tension, anxiety, and with psychosis.
Such p.. Liants may be differontiBted from thyrotoxic patients 
by administration of a beta“adrenoraceptor blocking agent 
which reverses the changes in anxiety, out does not affect 
the pre-ejoction period in thyrotoxic patients (117).
The diagnosis of thyroid diseaso depends in the first 
instance on suspicion followed by adequate clinical examination; 
this is adequate to detect severe examples of thyrotoxicosis 
or myxoodema and diagnosis is confirmed by subsequent investigation,
Problems arise when patients have minimal stigmata of tnyroid 
disorder; this is particularly so in the minimally hypothyroid 
patient who may remain undetected until presenting with angina or 
congestive cardiac failure. Clinical assessment may frequently 
bo mis load i.ng (B5a, 279). Assessment after therapy also poses 
obvious difficulties. The use of biochemical tests as screening 
procedures is also open to error (132); in particular, a large 
number of the general population have spuriously elevated PBI's, 
and the contraceptive pill elevates thyroxine levels. The 
diagnosis of T^ toxicosis requires tha radio immunoassay of 
tri-iodotnyrcmina, an expensive, time-consuming tecnnique not 
generally available. In audition, there is the group of 
patients with "compensated" euthyroidism, i.e. with normal T^ 
and T^ levels, but raised T5H levels, indicative of thyroid 
dusfunction compensated for by pituitary hyper-stimulation. At 
present, no single ideal thyroid test is available and a 
compromise battery of tests may be required covering many aspects 
of thyroid function in the individual patient. In tiie presence
of conflicting tests the clinical assessment of the 
functional status of the patient by the physician often 
decides the management of the patient.
It should bo noted that the patients studied had no 
overt ccrdJac disease on clinical and fCG exami netion and 
fall into discrete "hacmodynamic" groups according to their 
tnyroid status, so that alterations in systolic time intervals 
carry a higher dogroe-; of diaonostic specificity than is the 
case in myocardial infarction or crrdiic failure where many 
variables influence cardiac function.
It would seem that measurement of systolic time intervals 
msy have a place in the assessment of this group of patients 
and may be of more general value where a fully comprehensive 
set of tnyroid function tests is not readily available. Thiese 
studies hove shown such meosurcments to carry a high degree 
of specificity, much more so than the now outmoded measurement 
of basal metabolic rate, Systolic time interval measurements 
offer an accurate measure of the "peripheral" or targat-organ 
effect in thyroid disease ana may well be useful in assessing 
the elderly I'/ho are most sensitive to the cardiac effects of 
thyroid hormoneso
C O N C L U S I O N
The studies described here suggest the following potential 
benefits of STI measurement in thyroid disease,
1) A useful measure of cardiac response to thyroid hormonal 
status that may assist in deciding, for example, 
whether to treat or re-troat apparently mildly thyrotoxic 
patients.
2) A useful measure for sequential studies of 
individual thyroid patients.
3) A potential means of detecting "at risk" patients, 
if it can he shown that shortening or prolongation 
of P.E.Po in hyper- and hypothyroidism is a measure 
of severity of thyroid hormone effect on heart
and indicative of impending cardiac decompensation, 
dysrhythmias etc*
THE RELATIONSHIP BETWEEN SERUM THYROID HORMONE LEVELS 
AND SYSTOLIC TIME INTERVAL MEASUREMENTS,
In an attempt to define a simple relationship between 
the levels of circulating thyroid hormone levels and 
systolic time interval measurement, data from 20 patients 
was analysed for simple mathematical correlations. The 
data covered euthyroid, thyrotoxic and hypothyroid patients 
and the scatter seemed sufficiently wide to obviate selection 
bias. Table 35 lists the raw data.
Using a Wang desk top electronic calculator, with a 
programme for deriving linear regressions, the values of 
T^ and T^ wore separately correlated with each of the 
systolic timo interval parameters in turn and a linear 
relation sought. No significant correlation was obtained.
Next, the T^ and T^ values were run against the 
log values of each of the corresponding STI measurements. 
Again, no significant linear correlation was obtained.
This approach was extended, using a Philip's computer 
and a "Polfit" programme for fitting of variables to a 
polynomial function « i,e,, a relationship of the form
TAB_L^ 2É.
THYROID HORMONE AND SYSTOLIC TIME INTERVALS PARAMETERS IN
20 PATIENTS
I II III IV V VI VII VIII IX X
;jg/iOO
'^3
ml. mg/ml.
HR QSg
msec
QS„
'I
msefc
LVET
msec
LVET^
msec
PEP
msec
PEPj
msec
PEP/LVET
8,04 1.04 73 380 526 285 402 101 124 3333
.16,2 3,50 107 310 524 235 406 75 118 3191
9,8 2.38 81 350 512 275 405 75 107 2727
7.6 1,30 80 395 555 290 418 105 137 3520
18,8 3,70 107 310 524 250 421 60 103 2400
16,0 3,%0 72 400 544 300 415 100 129 3333
4.6
.10.8
1,48
2,24
80
85
380
410
540
580
285
310
413
446
95
100
127
134
3333
3225
11,2 3,80 83 360 , 526 265 398 95 128 3584
20,0 2,60 100 260 460 210 370 50 90 2380
13.4 3,00 74 370 518 280 398 90 120 3214
5,2 1.70 82 350 522 250 381 100 133 4000
12,7 2 c 30 67 375 509 305 412 70 97 2298
10,0 1.39 86 375 547 200 418 95 129 3392
*9c9 1,80 69 405 550 295 412 110 138 3728
15,4 3,12 88 400 515 350 491 50 86 1428
23,7 5,58 93 360 546 280 439 70 107 2413
12,2 0,58 “ - 44 85
12,6 3.25 67 375 509 305 412 70 97 2298
22,5 3.25 93 360 545 290 439 70 107 2413
NOTE; Hormonal 
yjg/lOO ml
data was processed when 
• and triiodothyronine
thyroxine 
as mg/ml.
was assayed as
TABLE 37.
SIGNIFICANT RELATIONSHIPS FOR T., T^ and STI's OF THE FORM,
STI = aT^ 4- bT^ + C
S.T.I RELATIONSHIP ACCURACY OF FIT 
(ASSESSED AS ROOT MEAN 
s q u a r e/m e a n va l u e of STI) 
AND EXPRESSED AS A 
PERCENTAGE.
HcRo HR = 67,5 -f- 1.34 T^ - 0.57 T^ 3.2
P.E.Po PEP = 100.9 " 3.43 T^ -E 6.69 6,3
aSr ASg = 401 - 3.92 + 5.49 T^ 8,7
LOG
PEP = 2,04 " 0,02 T. 4- 0,05 T„ 
PEP ■ 4 3
14.7
fir = 3850 - 83.6 T, . 31.8 T, 17
2 3
Y = aZ H- bz .f cz' 4- etc, where Z is the STI measurement 
under study Y the T^  ^ or T^ value and a^bjC etc, are constant»»
No significant relationship up to 7^ appeared and 
repeat fitting? this time using the log of 2 , was
simj..1,ar 1 y linproducti\/e»
Finally* as neither hormone gave a significant relationship 
when compared repeatedly to the STI value (as estimated by 
the standard error of the estimate for V)? a relationship of 
the form Z - aX -f bY t c ? was sought ^ where Z is the STI 
parameter? X and Y are the T^ and T^ values and a?b?c are 
contrasts. The relationship log Z “ aX -i- by 4» c was also 
evaluated. This approach was performed using a
computer programme for multiple regression*
Accuracy of fit was assessed by the root mean square 
as a fraction of the mean value of Z,
Table 37opposite lists the significant relationships.
Serum hormone levels relate well to heart rate and pre-ejection 
period, loss well to the other parameters.
Such derivations do not, of course, prove that such 
postulated relationships between cardiovascular end hormonal 
parameters actually exist*
11o ZINC HANDLING AND THYROID STATUS
A MEASURE Of SEVERITY Of THYROTOXICOSIS
INTR O D U C T I O N
Certain aspects of the thyrotoxic process such as the 
exophthalmos and pre-tibia! myxoedema, may not necessarily 
refloat the metabolic severity of the disease process? 
but rather relate to the underlying pathological process* 
This may render indices such as the Wayne index misleading 
in individual cases as a measure of the severity of 
thyrotoxicosis»
What is required is a measure of the metabolic 
impact of the disorder* It seemed that degree of weight 
loss might afford a measure of the severity of the 
condition and a metabolic correlate of weight loss was 
sougl'.t. In the light of reports of increased zinc losses 
in malnutrition kwashiorkor (135)? the metabolism of 
this metal was studied in patients with tl'iyrci'J disease.
plasipo zinc levels and 24 hour urinary zinc outputs were 
measured in 24 thyrotoxic and ten hypothyroid patients.
The findings were related to thyroid status, hormonal 
parameters, weight changes and to a scale assessing 
acuteness and severity of the metabolic response to hyper» 
or hypothyroidism,
PATIENTS & METHODS
Thirty»four patients with unequivocal clinical evidence 
and biochemical confirmation of hyper- or hypothyroidism 
were studied* Hyperthyroid patients wero selected on the 
basis of fairly severe symptomatology, particularly of rapid 
weight loss.
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Patients were scored on the Wayne Index (17j56) as a 
first approximation of the clinical severity of thyroid 
malfunction. They were also assessed on a scale designed 
to give a measure of acuteness and severity of the 
metabolic response to thyroid over- or underactiv/ity (fig*. 25).
This rating was composed of rate of weight change (amount 
of weight gain or loss; duration of symptoms)y basal 
(resting) heart rate y fasting plasma cholesterol, serum 
thyroxine level and serum tri-iodothyromine levelb
Plasma levels of zinc and 24 hour urinary zinc 
excretion were measured by the method of Peaston (217).
Zinc clearances (ml/min) were calculated as rate of 
urinary excretion over 24 hours (ml/min) x urinary zinc 
concentration -f- plasma zinc concentration.
Serum thyroxine levels were measured by the Thyopac 4 
(Amersham) method and serum tri^iodothyromine (T^) levels 
by a radio-immunoassay procedure.
Serum cholesterol was measured on samples obtained after 
a 12 hour fast by the automated method of Annan and Isherwood (9)
Twenty-two patients were studied as outpatients and 12 as 
inpatients. All the patients were female, except for four 
thyrotoxic ones. Ten healthy subjects, clinically and 
biochemically euthyroid ,served as controls. The mean age and 
ranges for hyper-, hypo- and euthyroid control groups were 
similar. All subjects studied had normal renal function as 
Judged by plasma urea levels and creatinine clearances 
performed at the time of the zinc clearance studies,
RESULTS
Table 34 lists relevant data for subjects grouped according 
to thyroid status. Zinc clearance, but not plasma zinc levels
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are significantly higher in thyrotoxic patients compared with 
euthyroid or hypothyroid subjects (p 0«001) The measured 
parameters of zinc metabolism do not differ significantly in 
euthyroid and hypothyroid groups.
Table 35 details the degree of correlation between zinc 
clearance and other measures of thyroid status in thyrotoxic: 
patients. Rate of weight loss shows the best correlation 
(r = 0.92). The Wayne Index score correlates rather poorly 
(r ™ 0,61) whereas there is a highly significant correlation 
(r = 0,86) between the score for the index of severity and 
acuteness of metabolic response shown in Fig, 25,
Correlations for hypothyroid patients are not significant.
It proved impossible to assess accurately the duration of 
symptoms as onset was usually insidious and so rate of weight 
gain could not be estimated with any accuracy*
DISCUSSION
It is perhaps surprising that, despite widespread interest 
in zincuria, as an indicator of catabolism (135), few studies 
have been performed in thyrotoxic patients who would seem to 
offer a good model for tissue catabolism. One study did report a 
fall-in red cell zinc concentrations in thyrotoxics and 
considered this a possible specific action of thyroxine on 
red cell zinc metalloenzymes (218).
This present investigation has demonstrated a significantly 
higher zinc output in urine in thyrotoxic patients compared to 
euthyroid or hypothyroid patients. The correlation between 
clearance and Wayne Index score was poor, possibly because 
the Index contains items (e.g. ocular signs) that relate 
more to the underlying pathogenesis of the disorder than to 
the severity of the metabolic changes induced by elevated 
hormone levels. The best correlation was with rate of weight
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c iixyjixy üiyniT leant correlation with the rating 
devised to estimate the acuteness and severity oF the, 
body's metabolic response to thyrotoxicosis.
No significant correlations were found in the ten hypo­
thyroid patients, though five of them had marked weight 
gain ( \ 12,5 K g , ) c  The onset of the disorder was insidious 
and the duration of the disorder uncertain, and this may 
explain the lack of positive findings. It may be that a 
study of zinc metabolism in "acutely” hypothyroid patients 
would show evidence of zinc retention*
Plasma zinc levels were maintained in thyrotoxic 
patients (no significant difference from levels in euthyroid 
controls) despite tho increased urinary losses. Dividing 
zinc clearance by creatinine clearance did not affect the 
significance of the correlations, and suggests that the 
increased urinary zinc loss is not due to a renal effect of 
thyroid hormones.
The data presented here suggests that urinary zinc losses in 
thyrotoxicosis are correlated with catabolic status and not a 
specific effect of thyroid hormones on, say, zinc metalloenzymes.
It has been suggested that tissue catabolism releases amino 
acids and other constituents into the circulation; these compounds 
form stable co-ordination compounds with zinc. Normally, some IDfc 
of total plasma zinc exists in this form in equilibrium with a 
further 60-70% of plasma zinc loosely attached to plasma albumin.
The remaining plasma zinc is largely present in chemical combination 
as part of the metalloprotein ^  ^  macroglobulin (87,100), The 
main excretory pathway for zinc is via the gut. Renal losses are 
in tho form of low molecular weight complexes as those alone 
normally pass the glomerulus. The excessive losses
described in severe thyrotoxicosis in this study indicate an
34
increased loss of tissue breakdown products or an 
alteration in the equilibrium with albumin-bound zinc. 
This point appears worthy of further study.
No clinically significant consequence of increased 
zincuria was noted in the thyrotoxic patients, bub it 
seems likely that the occurrence of thyrotoxicosis in 
patients with malabsorption of zinc, phenylketonuria, 
prolonged parenteral nutrition, or other conditions 
where zinc is deficient (87,100) will exacerbate the 
latter disorders.
This investigation suggests that measurement of 
zinc losses in thyrotoxic patients may offer a measure 
of the "metabolic stress" of the disease process and 
permit grading of thyrotoxic patients in terms of 
severity of the impact of the disease on the body.
CONCLUSION
These two studies, which form Section D of this 
thesis, offer methods of assessment of patients* response 
to thyroid malfunction and may permit selection of "at 
risk*’ patients, sequential measurement of therapy in terms 
of change in severity of the condition and may, particularly, 
offer objective evidence for the physicians*s assessment 
of his patient.
135
SECTION [
THYROID AND HEART
INTRODUCTION
This section consists of 2 parts. It is partly 
speculative but important in that it examines some 
aspects of the relationship between thyroid and heart.
Whereas the typical appearance of the young woman 
with Graves' disease presents little diagnostic difficulty, 
older patients - and such patients formed the bujk of 
those participating in the Trial - often have occult 
thyrotoxicosis until a cardiac problem is precipitated.
The cardiac complications of thyrotoxicosis are a major 
source of the morbidity and mortality that still attends 
this disease.
part 1 examines the evidence for the clinical entity 
of thyrotoxic cardiomyopathy and describes an animal study 
pertinent to the concept*
In part II, the relationship between lipid and lipoprotein 
metabolism and thyroid status is explored with particular 
emphasis on the acceleration of coronary atherosclerosis. 
Studies on patients with compensated euthyroidism and 
subclinical hypothyroidism (see page 75 ) are adduced and 
the possible risks of delaying thyroxine replacement therapy 
argued,
SECTION E
PART I* THYROID AND HEART ; THYROTOXIC CARDIOMYOPATHY
Thyrotoxicosis is an important factor in the production 
of atrial fibrillation - 10% of the patients in the Trial 
were in atrial fibrillation *-,in the production of cardiac
136
enlargement *= 8% of 165 x-rayed had cardiomegaly -, 
and in the production of congestive cardiac failure 
- 6% were in failure at diagnosis. There is still, 
however, considerable uncortainty whether thyrotoxicosis 
per SB is responsible for these manifestations, that 
is, it is still a matter of dispute as to whether there 
is a distinct entity of heart disease caused by 
thyrotoxicosis, a "thyrotoxic cardiomyopathy". Symptoms 
such as dyspnoea or palpitation are common in 
uncomplicated thyrotoxicosis and so the term thyroid 
heart disease is generally restricted to patients with 
thyrotoxicosis and atrial fibrillation or congestive 
cardiac failure.
The vast majority of patients with thyroid heart 
disease have evidence of associated coronary,hypertensive, 
rheumatic or syphilitic heart disease. Kepler end 
Barnes (147) found evidence of organic heart disease in 
67 per cent of 27 cases of fatal thyrotoxicosis where there 
had been congestive cardiac failure. Maher and Sittler (176) 
found organic heart disease in 75% of 180 cases of 
thyrotoxicosis, including all 30 patients with congestive 
failure and 41 out of 42 patients with atrial fibrillation. 
Despite the lack of definite evidence in support of a unique 
thyrotoxic cardiomyopathy, some workers believe in the 
entity and have adduced the occasional case as such an 
entity (60, 132).
However, definite proof of such an entity would require 
vigorous exclusion of other possibilities and the author is 
unaware of any patient with presumed thyrotoxic cardiomyopathy 
who has, for instance, had normal coronary arteries
demonstrated by angiography.
The increasing incidence of thyroid heart disease 
with ago (it is exceptional under the age of 40 years) 
and the reduction in tine usual predominance of females 
in Graves’ disease to around 2-3 to 1 in thyroid heart 
disease may be explained in the terms of the rising 
incidence of significant coronary artery disease with 
age and tho greater predilection for males to be so affected.
Thyrotoxicosis increases body metabolism and lays an 
increased demand on the heart which has to increase output 
and deal with an increased venous return* If the demands 
are outwith tho heart’s capacity to meet them rhythm upsets 
or failure will develop; however, the cardiac reserve is 
such that these events are likely to supervene in a heart 
aIready dis^ e^ ased^ ,
It is, however, established that thyroid hormones 
have direct action on cardiac muscle with augmentation 
of contractility (35) and on the conduction system with 
accelerated A-U nodal conduction (76,117), The possibility, 
therefore, exists that atrial fibrillation, cardiomegaly 
and failure may be the results of a true thyrotoxic cardio­
myopathy.
The possibility was further examined in two ways;
1. CLINICALLY.
Over three years, forty thyrotoxic (including 24 previously 
thyrotoxic) patients under the age of 35 were seen and 
examined for possible thyrotoxic cardiomyopathy. Nine presented 
with atrial fibrillation (2 had cardiomegaly on chest x-ray)
2 with cardiac failure and 7 were noted to have incidental
cardiomegaly on chest x-ray, 12 patients had evidence of
24 were worn on, 16 m c n,
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pre-existing cardiac disease, particularly^ rheumatic 
fever (8 cases), atrial septal defect (1 case) 
hypertension (1 case essential, 2 renal aetiology), 7 patients 
had a history of respiratory or urinary infections 
shortly before tho onset of cardiac complications and 2 
patients had a family history of premature ischaemic 
heart disease (one patirnt had a I la hyparlipoproteinaemia 
and the other manifested a lib pattern subsequent to being 
euthyroid (on tfiyroxine). This group contained all 
thyrotoxic patients with cardiac abnormality except 3 
with radiological evidence of cardiomegaly. in 3 patients 
with cardiac enlargement (all male) no evidence of co­
existent cardiac disease was found and screening for a 
family history of coronary artery disease or cardiomyopathy 
and for hypcrlipcproteinaemia was negative. This offered 
suggestive evidence that cardiomegaly might be induced 
directly by thyrotoxicosis.
2® This possibility was examined further in a laboratory study, 
ANIMALS AND METHODS®
18 male Wister rats were fed 360 yjgm* tri-iodothyronine 
daily in their drinking water for sixteen weeks. 18 controls 
received drinking water with no additive. The rats receiving 
the hormone showed little objective evidence of disability 
initially in the first month but subsequently they became 
sluggish and irritable.
6 rats on T^ were sacrificed at 16 weeks and weighed®
The heart weights and D.N.A. and R.N.A, contents were measured.
6 controls were similarly treated.
6 rats on T^ were sacrificed and samples of left ventricle 
examined by electronmicroscopy for evidence of cellular 
structural disorder, A group of 6 control rats were similarly 
examined.
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ELECTRON MICROSCOPIC VIEWS OF LEFT VENTRICLE FROM 
THYROTOXIC RAT HEARTS®
(a) and (B) are general views of rat left ventricular sections 
after 3 months on 3 6O pg per day. (Magnification x 13,000,).
The apparent mitochondrial disorganisation is probably 
artefact dec to incomplete penetration of the glntaraldehyde 
preservative, There does, however, appear to be a consistent 
tendency to mitochondrial "clumping" in the hyperthyroid 
an i. mal s.
>ïyotibrillar structure and membrane organisation are 
maintained.
(C) and (d) are views of left ventricle from control 
(magnification x 6 ,0 0 0) and hyijerthyroid (magnification x 8,400) 
rate left ventricle respectively.
Mitochondria are well preserved with intact cristae in 
the hyperthyroid specimen. Disorganisation in the control animal 
is probably artefact. The hyperthyroid specimen shows an erythro­
cyte in a capillary.
Ovei’all structure is preserved,
(E) and (f) are further views of control (magnification x  6,000) 
and hyperthyroid (magnification x 1 0 ,7 5 0 ) rate left ventricle. 
Structural order is maintained except for mitochondrial cristae.
To obtain better fixation, several anaesthetised rats were sub­
mitted to thoracotomy and perfused with gluteraldehyde preservative 
via and aortic cannula at a pressure of 100mm.hg. The cerebral vessel 
and distal aorta were ligaîn^d and the great veins sectioned just 
prior to retrograde coronary perfusion.
(g) (magnification x 2 2 ,7 5 0) and (H) (magnification x 
2 2 ,7 5 0 ) arc views from a control and hyperthyroid rat 
( 7 2 0 u^g ly per da,y), respectively. Mitochondrial architecture 
is hotter preserved with this method of fixation.
The presence of an erythrocyte in a capillary suggests 
still incomplete perfusion, and, possibly, p;rioi' administration 
of a vasodilator would enhance perfusion.
The overall appearances offer no evidence for thyroid 
hormone-'induced structural damage. The mitochondrial 
clumping is possibly part of the adaptive changes of left 
ventricular hypertrophy.
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6 rats on For 1G weeks were transferred back to 
normal drinking water and after a further 12 weeks were 
sacrificed with 6 control rats. Hearts and animals 
were weighed and heart DNA and RNA content measured.
Samples of left ventricle from rats on ly and from 
controls were stained with haematoxylin and eosin and 
examined for evidence of myocytic replication.
RESULTS
Treatment with T^ for 15 weeks induced frank left 
ventricular hypertrophy (increase 50%) with
concomitant increases in protein (i.e. weight), D.N.A, 
and R.NaA. content (Table 38), However, the mode of 
hypertrophy is questionable because no light microscopical 
evidence of myocyte replication (mitosis or polyploidy) 
was detected with only one possible multinucl^ate cell 
observed in 18 slides. This raises the possibility that 
hypertrophy is due to cell enlargement rather than division 
though Linzbach has shown fairly convincing evidence of 
cell division in hypertrophy due to hypertension (15Ba), 
However, D,N,A. content ( mg./gm. tissue) is elgrated and 
this suggests that division has occurred, though this may 
be limited to the connective tissue noiety.
Electronmicroscopy failed to demonstrate any structural 
change. In particular, mitochondrial cristae were intact. 
It is known that thyroid hormone has potent effects on the 
mitochondrial respiratory enzyme change but no mitochondrial 
structural damage was observed (Figura 26).
Interestingly, there was evidence of regression of 
hypertrophy (though not to completely normal levels) after
,g A
1 4
cessation of tri-iodothyronine. This would support the 
thesis that thyrotoxic cardiomegaly may be a reversible 
entity and not necessarily an indicator of thyrotoxic 
cardiomyopathy® Further studies such as the use of 
tritiatad thyridine to detect and localise nuclear 
changes would be of interest in this model®
The aetiology of the hypertrophy produced by thyroid
hormone may be multiple, 'It may be due, for example, 
to the circulatory changes induced by the condition, 
with increased volume load, augmented contractility and 
tachycardia playing a part by imposing on the heart a 
demand for more energy output and, in turn, an adaptive 
growth response® Also direct metabolic effects of
thyroid hormone may be involved with activation of D,N®A,
and RoN.A® synthesis, stimulation of mitochondrial respiration 
and activation of membrane ATPase^ all potential inducers 
of adaptive growth changes (50).
Faced with these many potential factors in producing 
cardiac hypertrophy, it is impossible to delineate an 
aetiology for the much rarer (and doubtful) entity of 
thyrotoxic cardiomyopathy* One may speculate that if the 
entity exists its rarity suggests the requirement of a further 
factor in addition to thyrotoxicosis - possibly a latent 
cardiac membrane or enzyme disorder which is activated by 
thyrotoxicosis and only then manifests its presence®.
PART lie. THYROID AND LIPID METABOLISM,
A® LIPID ABNORMALITIES IN THYROTOXICOSIS®
Measurement of total fasting plasma cholesterol levels 
in thyrotoxic patients (see Table 7) confirmed the frequently 
reported finding that cholesterol levels are significantly
lower than in euthyroid patients® These studies were 
extended to an investigation of free fatty acid levels and 
lipoprotein lipase levels in thyrotoxic patients*
PATIENTS AND METHODS
Ten female patients clinically and biochemically 
thyrotoxic in the age range 60-70 years were selected for 
s tudy I.
Fasting venesamples were taken into [*D®T*A. anticoagulated 
tubes, 5000 unit.a of heparin given intravenously and repeat 
blood samples taken exactly 15 minutes later. Samples 
were spun at 3000 r.p .m® immediately and the decanted plasma 
cooled to 4 0 c 0 in an ice bath® The samples were transported 
to the laboratory at 4°C, and processed.
Fasting free fatty acid levels were measured I;y the Dole 
method (64),
Lipoprotein lipase activity was assayed by the method 
of Weir et al, (298), specimens being stored frozen until 
they could be processed together*
Pre- and post-heparin plasma samples were wormed to 37°C. 
in an incubator over 30 minutes and lipase activity measured 
(see page7^ /^ ),
In the light of the findings these studies were repeated 
on 8 thyrotoxic patients in atrial fibrillation, all female, 
in the age group (65“75 years) prone to ischaemic heart 
disease, on digoxin but not on beta-adrenoreceptor blocking 
agents® All these patients were normotensive and had no 
evidence of rheumatic fever*
7 thyrotoxic patients presenting with congestive cardiac 
failure were similarly studied . These patients were on
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diuretics, digoxin (five) and were all female. The age 
range was 64-72 yearso
RESULTSo
Fasting plasma free fatty acids in thyrotoxicosis wore 
found to be elevated above the values of a euthyroid control 
group (same age range and sex) - p <^0o001o Similarly, 
post-heparin lipolytic activity was found to be augmented in 
the thyrotoxic group - p<(^  0,.001,
These findings are detailed in the table opposite (Table 39) 
Patients in fibrillation or failure demonstrated similar 
findings and were not significantly different on measured 
parameters from the thyrotoxic group with no overt cardiac 
pathology,
D I S C U S S I O N :
The possible significance of the increased fatty acid 
levels in thyrotoxicosis was evaluated as follows, fatty 
Bcids are considered by some workers to be important 
dysrhythrnic agents, particularly in the context of myocardial 
infarction, where Oliver et al. (210,155) contend that they 
play a major role in the causation of major dysrhythmias 
following infarction and so predispose to sudden death,
Thare is experimental evidence that very high levels of 
free fatty acids are arrhythmogenic in animals but the 
significance of the levels attained in humans after infarction 
(due to stimulation of lipolysis by catecholamines) is 
uncertain (212,213), as the levels attained are much lower 
than those produced in animals. Moreover, the reserve 
of albumin binding sites for mopping up released fatty acids 
is relatively enormous (266).
The significance oT fatty acid levels in inducing 
atrial fibrillation in thyrotoxic patients was evaluated 
in the light of the preceding remarks.
No significant differences were, in fact, found between 
any of the three groups studied - in particular, patients 
presenting with atrial fibrillotion were not significantly 
different in terms of circulating fatty acid levels or lipase 
activity from thyrotoxic patients with no overt cardiac 
pathology or thyrotoxic patients with cardiac failure.
These findings suggest that elevated fatty acid levels 
probably do not play a significant role in the causation 
of "thyrotoxic fibrillation” . One might speculate that 
they are a relatively harmless aspect of the hypermetabolism 
and weight loss due to thyrotoxicosis,
PART II.
8c THYROID AND ATHEROSCLEROSIS.
It is wellknown that frank hypothyroidism is attended 
by an increased risk of accelerated coronary atherosclerosis. 
This is considered to be due to induced hypercholesterolaemia 
(79, 179, 93) and altered metabolism of potentially atherogenic 
material.
The author's interest in this aspect of thyroid disease 
was stimulated by clinical observations on a 51 year old 
woman. This patient presented in 1972 with angina of effort 
and was found on lipoprotein screening to have a Typa I la 
hyperlipoprotoinaemia. She was treated with Trinitrin for 
angina and with a low cholesterol diet supplemented subsequently 
by the bile séquestrant cholestyramine. There was little 
response to this therapy over a two year period with serum 
lipoprotein parameters remaining persistently abnormal. The
oU J
m
%*
LU
ce
a
o
a
cc
>
:c
L—
C3
Q.
> -
x:
en
LU
Q
XI
V-
cn
LU
(-
a
cc
Q .
eu
Q .
Q
u;
ce
o
a
en
LU
to
<rm
LO o  lO o  LO
co
cr.
eu CM
to r-H to
w co
■cl­eo Lf)
ooc o
LU CO 
U 
> +
a o o
to CMr-i
O
cc û 
LU co 
t-
i n *f
UJ
o en
a
o
aen
o
LOCO
CD
CO
h-
t o
co
o
CM
OO
LO
LO
1- Oa
(O
Lû
C M CO
LO
tu c LU CX
CO
L U WX
O CM
r-t
o
CMtl
lNCM
UT
t/l
co
LU
X
Xce
The patient was seen by the author in 1974 and was 
considered to be possibly hypothyroid, A PBI-127 assay 
performed in 1972 as a routine screen gave a value of 
284 nmol/i. (within normal range). Full hormonal assay 
in 1974 gave frankly hypothyroid results - 21 nmol/ly
0,10 nrriol/Ly TSH 50 mu/t- Thyroxine replacement 
therapy was cautiously instituted^ eventually reaching a 
dose of Oi, 15 mg/day. Serum parameters on this dose are 
T^ - 162 nmo/l_y - 1,6 nmo/b, TSH 10 mu/ml. Over a 
nine month period total serum cholesterol and LDL cholesterol 
fell progressively and are now well within the normal range.
It is probable that rendering the patient virtually euthyroid 
has caused a reduction in her total body cholesterol mass 
with normalisation of serum values. The patient is at present 
being taken off cholestyramine to see if her values stay 
normal,
PATIENTS AMD METHODS
Studies were performed on two groups (all female) of 
patients to characterise the significance of serum thyroid 
hormone levels in hypothyroidism. The first group consisted 
of 20 patients with clinically overt and biochemically confirmed 
hypothyroidism* The second group was composed of 12 patients 
clinically euthyroid but biochemically frankly hypothyroid 
(Table 40). Fasting lipoprotein profiles (Fredrickson 
classification) were performed on all these patients and, 
when abnormal, were repeated on at least one further occasion 
to confirm the findings.
Lipoprotein classification of fasting plasma was performed
by the standard method of ultracentrifugation (92) and assay
of cholesterol in the subtractions by a modification of the
Pearson reaction as described below.
1 /g Æ;
The reagents consist of diluent composed of 25'f acetic 
acid (50 ml.) in acetic anhydride (150 mi,) with 7,5^ 
toluene^p-sulphonic acid as colour stabiliser. The acid 
reagent is 15 t^ sulphuric acid in diluent (4.5 ml, conc..
'Î- 25.5 ml. diluent).
Tho standard cholosterol solution consists of 
209c5 rno* cholesterol in 100 ml. diluent. This allows for 
the final volume after colour development being 4„4 ml. 
for the standard and 4.2 ml. for the sérum. The standard 
cholesterol solution is 200 mg./lOOml.
(The reagent is dangerous and must be pipetted carefully). 
Standards and blank are set up thus:
TES T
0*2 ml,serum 
2 ml. diluent
STANDARD
0.2 ml.standard 
Do 2 ml.water 
2 mlo diluont
BLANK
2 ml.diluent
There is a time lag of several seconds before a reaction 
takes place causing generation of considerable heat ; the 
contents of each tube are mixed by careful shaking and 
allowed to cool to 37^ in a water bath. Add 2 ml. acid 
reagent and again mix contents of the tube.
There is an initial precipitation of protein and this 
redissolves readily. The tubes are all incubated in a 
water bath at 37°C. for 10 minutes, A green colour develops 
which is stable for about 10 minutes and thereafter begins to 
fade slowly. For this reason it has been found best to run
determinations in batches of eight. If more than one 
batch has to bo carried out a standard 8 blank should ba 
included each time. The optical densities are read ago-inst
the blank at 425 mgs. on an SP 60 0.
CALCULATION
mgrn cholssterol/lDO ml. serum = Op Test sol. ^
OD S t a n d a r d  S n l .  ^
Total serum triglyceride was assayed by the method of 
Kessler and Lederer (148)
The intravenous Intralipid tolerance test was performed 
as previously described (p.75 ) in 5 patients from each
group.
These studies were repeated when patients were euthyroid 
on thyroxine replacement therapy (0.15 ■» 0.20 mg./day).
RESULTS
15 of the 20 clinically and biochemically hypothyroid 
patients had hyperlipoproteinaemia results - 8 showed a 
Type lia abnormality, 2 a Ijb pattern and 5 a Type IV pattern. 
All 20 patients had abnormal intralipid results indicating a 
decreased utilisation of triglyceride.
Repeat lipoprotein profiles three montns after full 
replacement therapy had been instituted, showed normal 
profiles for all but two patients - one had a mild Type IV 
abnormality (probably related tocbesity) and one a continuing 
I la pattern. This last patient has a family history of 
ischaemic heart disease and is now on a low cholesterol diet.
Of the 12 patients with biochemical but not overtly
l A J
clinical hypothyroidism, six had abnormal phenotypes - 
two a 11 a pattern, 2 a IJb pattern and 2 a Type 11/ pattern.
The mean levels for total cholestérol and triglyceride 
and subfractions were lower than in Group I paralleling 
the degree of thyroid hormonal abnormality. All these 
abnormalities reverted to normal with adequate replacement 
th(-rapy. Seven patients had abnormal Jntialipid
tests»
Those results emphasise the importance of routine 
hormonal screening to detect subclinical hypothyroidism 
which may be a significant factor in producing clinical heart 
disease by accelerating the atherosclerotic process. Bastenie 
et al, (11,12,57) have emphasised this point and claim to 
have detected a significant incidence of thyroid abnormality 
in patients sustaining myocardial infarctions.
The data presented here is sufficient to emphase the 
dangers of inadequate review of treated thyrotoxic patients.
THE SIGNIFICANCE OF "COMPENSATED EUTHYROIDISM"
There is some dispute as to the significance of an 
elevated TSH value in a clinically euthyroid individual with 
thyroxine and tri-iodothyronine values in the normal range.
One report suggested that, in post-therapy patients, this 
finding could persist for several years and did not indicate an 
increased risk of the patient developing frank hypothyroidism 
(274) - see pageyg o
This, however, was a retrospective study with the potential 
for bias in patient selection. The author’s prospective study 
of a group of these patients carried out over a period of one 
year suggest they do, in fact, develop hypothyroidism at a
greater rate than patients with normal TSH values* This suoQcst
1
that such patients should perhaps be commenced on thyroxine 
replacement therapy at this stage.
As ttiis state of '’compensated euthyroidism" is probably 
an intermediate stage on the way to frank hypothyroidism, 
it is interesting to search for any metabolic abnormalities 
that may indicate a degree of hormonal insufficiency even 
though this condition is termed "compensated",
A significant incidence of abnormality was noted, particularly 
with the intravenous intralipid test (psge75). This supports 
the contention that such patients may be at risk from 
abnormal intermediary metabolism and may run an increased 
risk of atherosclerosis. It would appear wise to commence 
such patients on replacement therapy as soon as TSH levels 
are raised.
Furthermore, it has been claimed that women with elevated 
TSH levels have elevated proXaotih levels (due to TRH 
stimulation) and run an increased risk of promotion of 
carcinoma of the breast(96,197), though this is still an 
unsettled issue (307), This may be another valid argument 
for advocating early replacement therapy in female patients 
with "compensated euthyroidism"*
CONCLUSION TO PART IIB,
These studies indicate that thyroid disorder is a 
continuous spectrum with large parts of the spectrum dependent 
on full hormonal characterisation for detection. These occult 
abnormalities have been demonstrated by the author to carry a 
high incidence of disordered intermediary metabolism. This 
underlines the importance of adequate hormonal assessment of 
patients with possible thyroid disease and the need for prompt 
hormonal replacement therapy where indicated.
TENTATIVE CONClUSinNS TO THIS STUDY
^ I  therapy i.s the potential treatment of choi.ce for the 
majority of thyrotoxic patients by virtue of its efficacy, 
siinplioty of administration and lack of serious side*"Of f nets, 
particularly in regard to carcinogenesis. The major 
drawback to its use is the risk of hypothyroidism. The 
present study has demonstrated fairly conclusively that 
iodine-125 offers no obvious advantage in this regard. The 
question therefore arises ? can we improve the mode of 
usage of iodine-131 ?
Throughout the Trial of iodine-125, the author found 
only onO' patient who, when started on thyroxine replacement 
therapy, failed to take it and this failure was the result 
of the patient's genuine misunderstanding of the lifelong 
nature of such replacement therapy. Similarly, two years' 
attendance at a general thyroid clinic confirmed ttie impression 
that patient non-compliance was very rare. This accords with 
the findings of Safa who found 91.5% of patients treated 
with iodinO"131 and given replacement therapy were still taking 
it, all the others but one having stopped on the advice of 
, their physician(250a). This indicates that thyroxine
replacement therapy is simple and well adhered to* Furthermore, 
with present day assays of T^ ana TSH, it is possible to 
gauge replacement dose accurately so as to give doses in tha 
euthyroid range and avoid subclinical hyper- or hypo- thyroidism, 
Also, the use of zinc clearance measurements or, more so, STI 
measurement permit a measure of the cardiac response to thyroio 
hormone levels and may assist in adjusting replacement therapy. 
It soems an attractive policy to deliberately adopt thyroid 
ablation as the goal of radioiodino therapy and to destroy
the thyroid as soon as feasible with largish dose(s) of 
iodine-1315 so as to permit early institution of replacement 
therapy, prompt discharge of the patient from the clinic and 
reduction of time lost off work, patient inconvenience and 
thyroid clinic load. The potential dangers of subclinical 
hypothyroidism of "comp' nsated euthyroidism" and the author': 
experience in cardiology clinics where there is a steady 
trickle of treated thyrotoxic patients presenting with 
cardiac complications of undetected hypothyroidism,support 
this approach to thyrotoxicosis. Studies arc needed of 
the optimum doses regimes that should be adopted in such on 
approach. Careful monitoring would be required to detect 
any increase in the incidence of carcinoma and leukaemia 
that might result from the increased body irradiation 
(1*7 Rads to the marrow per millicurie) from higher therapy
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